Propionate metabolism in Mycobacterium tuberculosis: characterization of the vitamin B12-dependent methylmalonyl pathway by Savvi, Suzana Anna
 i 
  
 
 
 
Propionate metabolism in Mycobacterium tuberculosis: 
Characterization of the vitamin B12-dependent 
methylmalonyl pathway 
 
A dissertation submitted to the Faculty of Science 
University of theWitwatersrand, Johannesburg, 
for the degree of Doctor of Philosophy 
December 2008. 
 
 
 
 
Suzana Anna Savvi 
 ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
When you are inspired by some great purpose, 
some extraordinary project, all your thoughts 
break their bonds: Your mind transcends 
limitations, your consciousness expands in every 
direction, and you find yourself in a new, great, 
and wonderful world. Dormant forces, faculties 
and talents become alive, and you discover 
yourself to be a greater person by far than you 
ever dreamed yourself to be. 
                                                                                                                                    Patanjali 
 iii 
 
                                            DECLARATION 
I declare that this thesis is my own unaided work. It is being submitted for the degree of 
Doctor of Philosophy at the University of the Witwatersrand, Johannesburg. It has not been 
submitted for any degree or examination at any other university.  
 
 
 
                                                                        10 December 2008 
 
___________________________                                                                _______________ 
Suzana Anna Savvi                                                                                       Date 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iv 
 
                                                ABSTRACT 
 
 
Propionyl-CoA is a three-carbon (C3) short-chain fatty acid (SCFA) derivative of branched- 
chain amino acids, branched- and odd-chain fatty acids and cholesterol.  Degradation of 
propionyl-CoA-generating carbon sources during infection (Pandey and Sassetti, 2008) 
requires the concomitant ability to oxidise this metabolite as a carbon and energy source, so as 
to avoid its cytotoxic effects if accumulated. The methylcitrate cycle in Mycobacterium 
tuberculosis (MTB) has been characterized and is essential for propionate oxidation in vitro, 
although dispensable for growth and persistence in mice (Muñoz-Elias et al., 2006). This 
study reveals that MTB possesses an alternative pathway for propionate metabolism, the 
vitamin B12-dependent methylmalonyl pathway. Specifically, we demonstrate the ability of 
MTB to utilise propionyl-CoA-generating carbon sources in the absence of the methylcitrate 
cycle, provided that vitamin B12 is supplied exogenously. This ability is shown to be 
dependent on methylmalonyl-CoA mutase (MCM; MutAB), which requires the 
adenosylcobalamin derivative of vitamin B12 for activity. The inability of MTB to synthesise 
vitamin B12 (Warner et al., 2007)  is consistent with the essentiality of the methylcitrate cycle 
for growth on propionate (Muñoz-Elias et al., 2006). The demonstrated functionality of the 
methylmalonyl pathway offers an explanation for the dispensability of the methylcitrate cycle 
for survival of the mycobacterium in vivo where access to vitamin B12 may be unrestricted.  
Gene expression analysis was used to interpret flux through the two pathways on propionate 
(C3) and valerate (C5) odd-chain fatty acids. In the presence of a functional methylmalonyl 
pathway, expression of methylcitrate dehydratase (MCD) and methylcitrate lyase (MCL) was 
reduced. Consistent with reduced levels of bifunctional isocitrate lyase (ICL)1/ MCL in MTB 
(Gould et al., 2006; Muñoz-Elias et al., 2006), growth on propionate and valerate was shown 
to by-pass the requirement for carbon anaplerosis by the glyoxylate cycle when propionyl-
CoA was converted to the tricarboxylic acid cycle (TCA) intermediate, succinyl-CoA, through 
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the methylmalonyl pathway. The potential of an autonomous methylmalonyl pathway in MTB 
is demonstrated which underscores the importance of vitamin B12 in MTB physiology.  
Alternately, MTB deficient for the methylcitrate cycle was able to grow on heptadecanoate 
(C17) without vitamin B12 supplementation. In the absence of either propionate oxidizing 
pathway, derivative propionyl-CoA may be used as a  key precursor for the biosynthesis of 
several cell wall virulence lipids (Jain et al., 2007).  
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1 INTRODUCTION 
1.1 Resurgence of tuberculosis  
Tuberculosis (TB) is a chronic disease caused by the etiological agent, Mycobacterium 
tuberculosis (MTB). About one third of the world’s population – an estimated 1.8 billion 
people –is believed to be latently infected with MTB (Dye et al., 1999). The highest incidence 
rates of TB are in sub-Saharan Africa and are associated with the high prevalence of HIV 
infection (Corbett et al., 2003).  The annual risk of TB increases dramatically in 
immunocompromised patients as a result of immune system perturbations by HIV (Wood et 
al., 2000), consistent with coinfection rates of >50% in southern African countries (Dye, 
2006).  The synergy between MTB and HIV (Collins et al., 2002b) makes for a lethal 
combination which, together with the world-wide emergence of drug-resistant strains of MTB 
introduced by the selective pressure imposed by more than 30 years of short-course 
chemotherapy (Anon, 1981, 1982), and the parallel demographic evolution of expanding 
pathogen and patient populations (Wirth et al., 2008), has elevated the magnitude of concern 
about the TB epidemic. Measures for controlling this disease need to be significantly 
improved if the estimated figures for between 2000 and 2020, where 35 million people are 
predicted to die from TB, are to be reduced (www.who.int/tb/strategy/en/).   
Immunization as an efficient and cost-effective strategy against TB is part of the World Health 
Organization’s (WHO) expanded vaccination program. Since the 1920s, an attenuated 
derivative of MTB, bacillus Calmette–Guérin (BCG) (Behr et al., 1999), has been widely used 
as a prophylactic TB vaccine because of its proven efficacy at preventing TB meningitis and 
miliary TB in children (Cohn, 1997). However variable protective efficacy against pulmonary 
disease is displayed in adults and may stem from high diversity among BCG strains (Brosch et 
al., 2007). This translates into BCG having little impact on the global prevalence and 
epidemiology of TB.  
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1.1.1 Disease pathology  
 
The inhalation of mycobacterial-containing droplets and subsequent engulfment by alveolar 
macrophages and dendritic cells in the airways stimulates a robust proinflammatory response 
through the activity of Toll-like receptor agonists abundant on the surface of the bacteria. 
Interaction with these antigen presenting cells (APC) results in the production of 
inflammatory cytokines, including tumor necrosis factor  (TNF) and interleukin (IL)-12 
(Henderson et al., 1997; Hickman et al., 2002). This drives the recruitment of various immune 
cells types to the infection site, which collectively, are responsible for mediating containment 
of infection through the formation of the ‘tubercle’ or granuloma after which the disease is 
named (Bishai, 2000). Specifically, activated dendritic cells traffic to the secondary lymphoid 
organs and prime naïve T cells to initiate the adaptive immune response (Banchereau and 
Steinman, 1998). A strong T cell response is initiated, dominated by  effector CD4+ T cells of 
the Th1 type (Flynn and Chan, 2001; Kaufmann et al., 2005). These secrete IFN-γ and TNF-
α, which in turn induces antimycobacterial mechanisms in macrophages, including the 
production of reactive oxygen and nitrogen intermediates (Ding et al., 1988; Flynn and Chan, 
2001). The markedly enhanced incidence of TB in individuals that are coinfected with HIV 
indicates that the CD4+ T cell defense is clearly a crucial element of the cellular  immune 
response, and correlates with reduced granuloma-forming capacity and dissemination 
throughout the host (Kaufmann and McMichael, 2005).  
 
The mature-phase granulomatous lesion has a central necrotic core surrounded by concentric 
layers of macrophages, epithelioid cells, multinucleated Langhans giant cells and lymphocytes 
enclosed within a fibrotic capsule with surrounding peripheral lymphoid follicular structures 
orchestrating the local immune response (Ulrichs et al., 2004; Ulrichs and Kaufmann, 2006). 
Successful containment of the pathogen results in latent infection. Various models have 
documented the distinct spatio-temporal dynamics of infiltrating leukocytes during the process 
of granuloma formation (Lin et al., 2006a; Segovia-Juarez et al., 2004; Tsai et al., 2006). 
Notably, mice do not develop such highly organised structures to contain infection but rather 
develop chronic multibacillary infection. As a consequence, mice may have less tissue 
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damage and give faster colony forming unit (CFU) clearance during TB drug therapy (Jain et 
al., 2008). Therefore the granuloma is considered to serve as an environmental niche in which 
mycobacteria can survive, effectively screened from active immune surveillance (Grosset, 
2003).  Bacteria persist under the low oxygen tension  (Sherman et al., 2001; Via et al., 2008; 
Voskuil et al., 2003) and lipophilic environment within the granuloma (Honer Zu Bentrup et 
al., 1999; McKinney et al., 2000; Muñoz-Elias and McKinney, 2005) by adjusting their 
metabolism, allowing for transition to dormant-like nonreplicative state.  
Only between 5-10% of individuals who become infected with MTB subsequently develop 
clinical disease (Bishai, 2000; Bloom and Murray, 1992). In the other 90% the interplay 
between adaptive and innate immunity serves to control the infection with no obvious clinical 
symptoms. These individuals are in a state of latent TB infection (LTBI) which may persist 
for many years without ever developing into active disease. Latent infection with MTB is 
estimated to affect at least 2 billion people worldwide (Dye et al., 1999). Several effector 
molecules released by MTB at the infection site promote the survival of viable bacilli during 
latent infection (Russell et al., 2002; Russell, 2007). For instance, interaction of a 
mycobacterial mannose-containing cell wall ligand with DC-specific C-type lectin, DC-SIGN, 
induces the immunosuppressive cytokine IL-10 (Geijtenbeek et al., 2003; Tailleux et al., 
2005),  contributing to the survival of MTB during latent infection. Such mechanisms actively 
deployed by the bacilli to achieve subversion of host immune responsiveness, combined with 
host mechanism to prevent exacerbated immunopathology during chronic infection, where 
regulatory T cells (Treg) are responsible for down-modulating the immune responses (Kursar et 
al., 2007), result in low level persistent infection rather than sterile eradication of this 
pathogen. Therefore, latently infected individuals represent a large reservoir of MTB.  
 
Reactivation occurs when the immunological balance between pathogen and host is disturbed 
as a consequence of several possible host and environmental factors such as TB/HIV 
coinfection (Corbett et al., 2003), the use of immunosuppressive agents (Jacobs et al., 2007) 
possible host genetic factors (Caws et al., 2008) and other factors such as malnutrition, ageing 
and stress. Peptidoglycan hydrolases otherwise known as resuscitation-promoting factors have 
been implicated in reactivation from chronic TB (Biketov et al., 2007; Russell-Goldman et al., 
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2008). The morphological heterogeneity that may exist in human granulomas demonstrates 
the continuum between active and non-progressive lesions (Lin et al., 2006a). A progressive 
lesion is characterised by caseous necrosis that precedes erosion into the bronchus and 
promotes transmission (Reichler et al., 2002; Rodrigo et al., 1997). By coughing, a patient 
with tuberculous lung cavities aerosolises and disseminates the bacilli.  During this active 
stage of disease, TB is highly contagious (Escombe et al., 2008), and can transmit to between 
10 and 15 people a year from a single infected person (Riley et al., 1962; Riley et al., 1995; 
Sultan et al., 1960). Given the high numbers of infected individuals, reducing the incidence of 
TB and the rate of MTB transmission presents enormous challenges. 
 
1.1.2 TB chemotherapy  
 
Since the risk of disease is highly dependent on the immune status of the host, susceptibility to 
reactivation increases dramatically to 5-15% annually in persons coinfected with HIV (Corbett 
et al., 2003; Raviglione et al., 1995). Considering that both pulmonary and disseminated 
forms of disease develop in these individuals, accounting for 25% of AIDS deaths worldwide, 
the WHO and its international partners have formed the TB/HIV Working Group 
(http://www.stoptb.org/wg/tb_hiv/) in response to the challenges presented by the entwined 
epidemics of TB and HIV. This group develops global policy on the control of HIV-related 
TB, and tackles issues such as ‘immune reconstitution inflammatory syndrome’ (IRIS), a 
poorly understood phenomenon that affects those taking drugs for both TB and HIV. In the 
case of IRIS, initiating antiretroviral therapy alone seems to severely aggravate TB in dually 
infected patients, which further compounds the problems associated with co-infection. The 
Stop TB Strategy, launched in 2006 by the WHO, has integrated these challenges as one of the 
six components of its enhanced, core-based directly observed treatment short-course (DOTS) 
programme (http://www.who.int/tb/strategy/en/index.html).  
The DOTS-based service was launched in 1995 to address the operational problem that 
effective TB chemotherapy requires a lengthy 6-9-month  treatment with a combination of the 
first line drugs, rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA) and ethambutanol 
(EMB) (el-Sadr et al., 1998). Despite the global implementation of DOTS-based TB control 
 6 
programmes, the limited effectiveness of current therapy is evidenced by the emergence and 
spread of multi (MDR) and extensively drug-resistant (XDR) strains of MTB, where MDR is 
defined as resistance to the first-line drugs, INH and RIF. This development, which is severely 
compromising TB control efforts, has been driven by the lack of compliance with the lengthy 
and complicated treatment regimen and the use of suboptimal drug concentrations. When 
available, second-line drugs, which include the fluoroquinolones (ciprofloxacin, ofloxacin, 
moxifloxacin, gatifloxicin and levofloxacin), the injectable drugs (amikacin, kanamycin and 
capreomycin) and others, such as ethionamide, D-cycloserine and p-aminosalicylic acid, are 
administered to patients who fail to respond to first-line therapy, albeit often under poorly 
supervised DOTS programmes. Second-line drug treatment is fraught with drawbacks such as 
adverse side effects and prolonged duration of therapy (up to 2 years), further limiting patient 
adherence and fuelling the rise of XDR-TB, which is due to infection with strains that are 
resistant to any fluoroquinolone, and at least one of three injectable second-line drugs 
(capreomycin, kanamycin and amikacin), in addition to INH and RIF 
(http://www.euro.who.int /Document/Mediacentre/fs0107e.pdf). Propagation of these highly 
resistant strains by nosocomial transmission in communities with high HIV prevalence and 
poor TB control practices contributed to the recent and highly publicised outbreak of XDR-TB 
at Tugela Ferry in the KwaZulu-Natal province of South Africa (Gandhi et al., 2006). In this 
study, 53 cases of XDR-TB were identified from 221 MDR-TB cases identified in the area in 
2005. Moreover, XDR strains of MTB were found to be transmitted to HIV co-infected 
patients and were associated with high mortality (Gandhi et al., 2006; Singh et al., 2007b). A 
subsequent molecular epidemiological analysis of this outbreak revealed that the emergence 
and clonal spread of XDR-TB that occurred in this region over this past decade was 
attributable to strains belonging to the F15/LAM4/KZN strain family, with the lack of routine 
drug susceptibility testing as an integral part of DOTS in an ever expanding HIV positive 
society being identified as the major factor underlying this unfortunate outbreak (Pillay and 
Sturm, 2007).  
 
Clearly new treatment-shortening therapies that also are effective against MDR and XDR 
strains of MTB are urgently required. Mathematical modeling of the impact of treatment 
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duration on TB dynamics have suggested that a 2-3 fold increase in rates of decline could be 
achieved should treatment duration be reduced to 2 months (Salomon et al., 2006), 
emphasizing the importance of drug discovery research that is aimed specifically at shortening 
the duration of therapy. A number of promising lead compounds and drug candidates are in 
various stages of clinical development to direct TB therapy closer towards achieving these 
goals.  A novel drug class for TB treatment is exemplified by the diarylquinoline, TMC207,  
which was originally identified by empiric whole cell screening against M. smegmatis (MSM), 
and which has been demonstrated to inhibit the mycobacterial ATP synthase (Andries et al., 
2005; Koul et al., 2007). Another novel class of compounds in the TB drug development 
pipeline is the nitroimidazoles, which includes PA-824 (Manjunatha et al., 2006) and OPC-
67863 (Matsumoto et al., 2006). Both compounds are prodrugs whose nitroreductive 
activation is a prerequisite for bactericidal activity but whose precise mechanism of action has 
not been resolved fully (Manjunatha et al., 2006; Matsumoto et al., 2006; Singh et al., 2008). 
Although these drugs may make significant contributions to future TB therapy, further 
knowledge of the mechanisms of persistence and proliferation of MTB are necessary in order 
to uncover novel essential metabolic targets against which drugs having improved efficacy 
could be designed, thereby simplifying and shortening TB chemotherapy. Specifically, 
discovering and evaluating new compounds depends on the metabolic state of the organism, 
which directly impacts on drug susceptibility as exemplified by resistance to fosfomycin in 
Listeria monocytogenes, largely an in vitro phenotype as expression of a virulence factor 
during mouse infection is responsible for in vivo susceptibility (Scortti et al., 2006). 
 
1.2 Persistence of MTB and its role in defining antitubercular therapy 
A testimony to the resilience of MTB is highlighted by the ability of this pathogen to survive 
for extended periods in the asymptomatic host in a state of clinical latency from which it can 
reactivate and to persist, possibly in a quiescent, physiological state of non-replication during 
active disease in the face of administered chemotherapy. The issue of how the viability of 
MTB can be maintained in the absence of growth is the subject  of intense interest and debate 
(Boshoff and Barry, 2005) although there is little information available on the metabolic status 
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of the organism in a persistence state. When bacteria were cultivated in microfluidic chambers 
and their behavior recorded using time–lapse video microscopy, Escherichia coli persisters 
were identified as a pre-existing subpopulation in an arrested growth state (Balaban et al., 
2004). Studies have suggested that despite the stability in mycobacterial colonization during 
the chronic stage of infection in the mouse model (Muñoz-Elias et al., 2005), the bacilli 
remain metabolically active (Talaat et al., 2007). The slowing down or arrest of bacterial 
replication during the chronic state of infection and in persister organisms is thought to be at 
least partly responsible for increased phenotypic drug tolerance (Paramasivan et al., 2005).  
New drugs will need to overcome this refractoriness, although their development is contingent 
upon greater knowledge of persistence during active disease or latent infection.   
To facilitate research in this area, a number of in vitro models of latency and persistence have 
been established. A model based on the gradual depletion of oxygen which causes MTB to 
shift from active replication into a state of non-replicating persistence that may resemble the 
physiological state of quiescent tubercle bacilli in vivo, was used to explore the lethal effect of 
metronidazole against dormant bacilli under anaerobic conditions (Wayne, 1976; Wayne and 
Sramek, 1994; Wayne and Hayes, 1996). Similarly, the related nitroimidazole antibiotic, PA-
824, possessed activity against static non-replicating MTB in this anaerobic culture model 
(Stover et al., 2000).  Stationary phase cultures have similarly been adopted to model non-
growing persister MTB tolerant to antibiotics (Hu et al., 2000; Hu et al., 2003). Such models 
have been used in whole cell screens of compound libraries and identified candidates with 
significant activity against non-growing bacilli (Bryk et al., 2008; Byrne et al., 2007). For 
example, rhodanines are the most recent class of compounds identified able to kill 
nonreplicating bacteria (Bryk et al., 2008). Further clinical development is contingent on 
suitable pharmaceutical properties and drug-drug compatibility (Balganesh et al., 2008) given 
which, prophylaxis in individuals with latent MTB infection is proposed (Bryk et al., 2008).  
 To validate persistence drug targets, powerful new genetic systems for conditional gene 
silencing have been developed and are being applied (Blokpoel et al., 2005; Ehrt et al., 2005). 
Application of this approach to the MTB 20S proteasome core revealed an unexpected 
requirement of the proteasome for persistence of MTB during the chronic phase of infection in 
mice (Gandotra et al., 2007). An improved understanding of the mechanisms governing 
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persistence, in combination with conditional gene silencing, will increase the number of 
validated persistence targets for drug discovery, which will ultimately shorten and simplify 
therapy.  
1.3 Intraphagosomal survival of MTB 
1.3.1 The phagosome enviroment  
 
Deep within the pulmonary alveoli, inhaled mycobacteria bind and enter resident alveolar 
macrophages, dendritic cells and monocytes by binding to multiple receptors. These myeloid 
cells have a significant role in innate host resistance to infection representing the first line of 
defense. Phagocytosis by the predominant complement receptor type 3 (CR3) (Schlesinger et 
al., 1990) in a cholesterol-dependent manner (Gatfield and Pieters, 2000; Peyron et al., 2000) 
enables entry into macrophages. These membrane-bound organelles termed phagosomes 
become privileged replicative niches of MTB by interference of phagolysosomal biogenesis 
(Goren et al., 1976; Vergne et al., 2005). Through the manipulation of host signal transduction 
pathways, MTB maintains extensive communication with early endosomal traffic (Vergne et 
al., 2004)  promoting access to nutrients for survival and growth (Russell et al., 1996; Sturgill-
Koszycki et al., 1996; Vergne et al., 2004).  The capacity of mycobacteria to block 
phagosome-lysosome fusion is influenced by several virulence factors (Chua et al., 2004; 
Russell et al., 2002). Some recognised mechanisms by which MTB modulates host cell 
trafficking pathways thereby inhibiting phagosomal maturation include the active recruitment 
and retention of coronin-1 on mycobacterial phagosomes (Ferrari et al., 1999; Jayachandran et 
al., 2007), hydrolysis of the membrane trafficking regulatory lipid essential for phagosomal 
acquisition of lysosomal constituents, phosphatidylinositol 3-phosphate (PI3P) by MTB 
secreted lipid phosphotase (Fratti et al., 2001; Vergne et al., 2005) and MTB eukaryotic-like 
protein kinase G (PknG)-directed signal transduction (Walburger et al., 2004). Advances in 
identifying host factors required for mycobacterial survival in the phagosome are lending 
further insights into how mycobacteria manipulate the host cell (Kuijl et al., 2007; Philips et 
al., 2008). The consequence of preventing phagosome-lysosome fusion is a compartment with 
 10 
limited phagosomal acidification and hydrolytic capacity (Mwandumba et al., 2004; Russell et 
al., 2002).  
The macrophage’s antimicrobial defense mechanisms extend beyond fusion of phagosomes 
with lysosomes and include other potent mechanisms such as nutrient limitation (Muñoz-Elias 
and McKinney, 2006), acidic pH (Deretic and Fratti, 1999), the synergistic action of fatty 
acids and host immune effectors such as reactive oxygen and nitrogen intermediates (Akaki et 
al., 2000; Chan et al., 1992; Hemsworth and Kochan, 1978; Saito and Tomioka, 1988) and the 
recently discovered host-derived inhibitory factor, carbon monoxide (CO) (Kumar et al., 
2008; Shiloh et al., 2008). The adaptive metabolic strategies adopted to survive in the hostile 
intraphagosomal environment have been probed using in vitro models (Betts et al., 2002; Dahl 
et al., 2003; Fisher et al., 2002; Hampshire et al., 2004; Manganelli et al., 2001; Voskuil et 
al., 2003; Wayne and Hayes, 1996), showing significant overlap in RNA expression between 
infected macrophage (Fontan et al., 2008; Schnappinger et al., 2003) , murine and human lung 
tissue (Fenhalls et al., 2002; Shi et al., 2005; Talaat et al., 2007; Timm et al., 2003). A 
common feature that has emerged in response to the various intraphagosomal stresses is the 
induction of the DosR regulon (Kendall et al., 2004; Schnappinger et al., 2003), a set of 
approximately 50 genes induced in response to hypoxia, CO and nitric oxide (NO) (Kumar et 
al., 2008; Park et al., 2003; Sherman et al., 2001; Shiloh et al., 2008; Voskuil et al., 2003), 
which is controlled by a two-component regulator system comprising the sensor kinases DosS 
and DosT and the cognate response regulator, DosR (Kumar et al., 2007; Roberts et al., 2004). 
The DosR regulon includes genes of anaerobic respiration and stabilization of vital cellular 
components, and together with the Enduring Hypoxic Response (EHR) is thought to play an 
important role in MTB adopting a quiescent physiological state (Ohno et al., 2003; Roberts et 
al., 2004; Rustad et al., 2008; Voskuil et al., 2003). The generation of NO by IFN-γ-activated 
macrophages induces an environment inhibitory of aerobic respiration (Brown, 2001). 
Hypoxia-mediated bacteriostasis in vitro (Voskuil et al., 2003; Wayne and Hayes, 1996) 
shares similarities to NO induced transition of MTB from active growth to nonreplicating 
persistence in mice (Karakousis et al., 2004; Shi et al., 2005), supporting the notion that NO 
production (together with granuloma formation) by the immune system limits aerobic 
respiration of MTB and impairs growth.  
 11 
 
1.3.2 Metabolic adaptations of MTB within the phagosome  
 
The overall theme that has emerged from such studies is that MTB undergoes a switch to 
microaerophilic and lipid metabolism inside the phagosome. The down-regulation of genes 
encoding subunits of NADH dehydrogenase (NDH)-I, the menaquinol-cytochrome c complex, 
and ATP synthase collectively reflect the reduced need for energy generation as a function of 
adaptation to a low-growth state inside the macrophage (Beste et al., 2007; Schnappinger et 
al., 2003). The concomitant up-regulation of the type II NADH dehydrogenase, NDH-2, 
probably signals the increased need for regenerating reducing equivalents for β-oxidation 
(Schnappinger et al., 2003). In other organisms, NDH-2 acts as the electron donor for the 
electron transport chain (ETC) under anaerobic conditions (Boshoff and Barry, 2005; Rao et 
al., 2008; Shi et al., 2005).  No ATP is generated by substrate level phosphorylation through 
β-oxidation (Boshoff and Barry, 2005; Schnappinger et al., 2003). In this instance, ATP 
synthesis by ATP synthase may be essential for viability, as demonstrated in carbon-limited 
cultures (Koul et al., 2008; Rao et al., 2008). ATP synthase activity is contingent on the NDH-
2-dependent proton motive force (PMF) (Rao et al., 2008), using fumurate reductase and/or 
succinate dehydrogenase with fumurate or nitrate reductase with nitrate as the electron 
acceptors (Boshoff and Barry, 2005; Rao et al., 2008). The NDH-2 therefore has bimodal 
action in  (i) the regeneration of reducing equivalents; and (ii) maintaining the PMF required 
for ATP synthesis. Limiting terminal electron acceptors, fumurate or nitrate, in culture is 
expected to phenocopy inhibition of NDH-2 by similarly restricting the recycling of reducing 
equivalents and disrupting the PMF and therefore, ATP synthesis.  However other enzymes 
such as isocitrate lyase (ICL) with glycine dehydrogenase may contribute to the maintenance 
of NAD+ pools when cultures are grown on fatty acid carbon sources (Wayne and Lin, 1982). 
The redox balance may be maintained by also sinking cellular reducing equivalents into 
triacylglycerol synthesis (Reed et al., 2007). 
Interestingly, the genes predicted to be involved in NAD+ regeneration are not actively 
induced or repressed during the EHR suggesting that in the absence of respiration, other 
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pathways operate during hypoxia to generate energy (Boshoff and Barry, 2005; Rustad et al., 
2008). This may be reflected by the survival of bacilli that are recalcitrant to treatment with 
the ATP synthase inhibitor, R207910, in the hypoxic granulomas that are formed in guinea 
pigs (Lenaerts et al., 2007). In MSM, maintenance of an energised membrane is not dependent 
on the activity of ATP synthase (Koul et al., 2008), suggesting that the sole function of ATP 
synthase is in ATP synthesis. Conceivably, substrate level phosphorylation may function 
instead to meet the cellular demand for ATP. This is exemplified  in other bacteria where loss 
of oxidative phosphorylation is compensated by increased flow through the glycolytic 
pathways and TCA cycle to enhance substrate level phosphorylation on fermentable carbon 
sources (Jensen and Michelsen, 1992; Santana et al., 1994). However, the essentiality of ATP 
synthase in MSM, even on fermentable substrates suggests that substrate level 
phosphorylation is unable to meet the cellular demand for ATP (Tran and Cook, 2005). In 
MTB, ATP synthase may be essential (Sassetti et al., 2003) under the conditions tested either 
due to (i) the insufficient generation of ATP by substrate level phosphorylation, or (ii) the 
obligatory requirement for the oxidation of NADH by providing a sink for translocated 
protons. In the event that the latter is not a prerequisite, it has been proposed that substrate 
level phosphorylation may be enhanced by activating the reversible succinyl-CoA→ 
methylmalonyl-CoA→ propionyl-CoA→ propionate pathway (methylmalonyl pathway), 
(Kana et al., 2009) which could generate 2 ATP molecules per succinyl-CoA, provided the 
coenzyme B12 requirements of the methylmalonyl-CoA mutase (MCM) are met (discussed in 
section 1.5.1).  In MSM, no growth on succinate was observed by a ATP synthase mutant 
(Tran and Cook, 2005), although the relevance of the methylmalonyl pathway for viability of 
this mutant strain was not assessed.  
 
The propensity of MTB to slow down its metabolism (Beste et al., 2007) may contribute to 
the tolerance displayed by the bacterium to adverse conditions although the ability of MTB to 
survive within macrophages is more than merely a passive retreat into dormancy. MTB 
remains metabolically active (Lee et al., 2008; Talaat et al., 2007) displaying active defense  
(Darwin et al., 2003; Davis et al., 2007; Vandal et al., 2008)  and physical properties (Chan et 
al., 1991) against macrophage effector functions, enabling the maintenance of acute and 
persistent infections (Zahrt and Deretic, 2002).  
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1.3.3 The nutrient status within phagosomes   
 
The intraphagosomal environment has been considered nutrient deficient. This has been 
deduced indirectly from various auxotrophic mutants attenuated for growth due to the limited 
availability of nutrients in the phagosomal compartment. Most amino acid auxotrophs of MTB 
are attenuated (Gordhan et al., 2002; Parish, 2003; Sambandamurthy et al., 2005; Sampson et 
al., 2004) suggesting a restriction either in terms of abundance of, or accessibility to amino 
acids (Seth and Connell, 2000). The exception seems to be the methionine auxotroph of M. 
bovis BCG which is not compromised for survival in mice (Wooff et al., 2002). Methionine 
has also been suggested to be the main sulphur source for pathogenic mycobacteria in vivo 
(Wheeler et al., 2005). These finding are analogous to observations in Brucella spp., which 
suggested that although the synthesis of other amino acids is essential for intracellular 
multiplication, a methionine mutant was not found in a screen for growth inhibition in 
macrophages (Kohler et al., 2002). Conflicting studies from other intracellular pathogens such 
as Legionella pneumophila suggest that amino acids constitute the main source of carbon and 
energy (George et al., 1980). However, this may reflect vacuole differences which are subject 
to bacterial manipulation (Muñoz-Elias and McKinney, 2006), or, as in the case of L. 
pneumophila, amino acid auxotrophy may be an in vitro phenomenon since it possesses the 
synthetic gene complement for several amino acids which may account for its ability to persist 
in diverse enviroments (Chien et al., 2004).  
The broad metabolic adjustments mediated by RelMtb-dependent accumulation of ppGpp in 
vitro in response to starvation (Primm et al., 2000) have been likened to long term persistence 
in vivo (Dahl et al., 2003). A mutant of MTB defective for the RelMtb-mediated stringent 
response was not attenuated in macrophages (Primm et al., 2000), but was severely impaired 
in sustaining chronic infection, suggesting that nutrient deprivation is reflective of host 
containment within noncavitating granulomas rather than within the macrophage. 
Concentrations of vacuolar iron are also thought to be higher than previously believed (Fontan 
et al., 2008; Wagner et al., 2005). In general though, the expression signature for 
intraphagosomally residing MTB finds many genes required for the synthesis of amino acids, 
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purines, and pyrimidines up regulated, indicating that bacteria are probably not able to obtain 
these components from the phagosome, where phosphate and sulphate are also considered to 
be limiting (Fontan et al., 2008; Rachman et al., 2006a).  
Genes involved in β-oxidation, the glyoxylate cycle and gluconeogenesis which are reportedly 
upregulated (Fontan et al., 2008; Rachman et al., 2006a; Schnappinger et al., 2003; Timm et 
al., 2003) further underscore the lipid-rich nature of the replicative vacuole of MTB. The 
absence of the phosphotransferase system for carbohydrate uptake and the detection of only 
five sugar permeases further reinforces the notion that the phagosome does not provide an 
environment rich in diverse sugars (Titgemeyer et al., 2007).  
Finally, the induction of a set of genes which are involved in cell wall and cell membrane 
components (Fontan et al., 2008; Rachman et al., 2006a) suggests that perturbation of the cell 
envelope is a major intracellular stress imposed by the macrophage, with lipid metabolism 
allowing for the remodeling and maintenance of this periphery which is actively engaged in 
modulating the immune system. 
 
1.3.4 Cell envelope shedding 
 
After infection of macrophages, MTB undergoes several changes in secretion and expression 
of surface components. In respect of energy consumption, the continual production and 
release of lipidated cell wall constituents is very expensive although justifiably beneficial to 
the bacilli as it manipulates the host response to influence disease progression. These 
biologically active lipid components may play a role in vacuole modulation (Fratti et al., 
2003) or immune modulation  (Brennan, 2003). Included in the latter is the class of methyl-
branched fatty lipids (Kolattukudy et al., 1997; Minnikin et al., 2002)  thought to be important 
for virulence (Cox et al., 1999; Sirakova et al., 2001). The biosynthesis of  the surface- 
exposed lipids, phthiocerol dimycocerosates (PDIMs), and glycosylated phenolphthiocerol 
esters is unique to the virulent strains of mycobacteria (Azad et al., 1997; Reed et al., 2004). 
The complex synthesis and transport of this wax has been characterised in detail. Four of the 
six multifunctional proteins of the modular polyketide synthase (PKS) system show selectivity 
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for methylmalonyl-CoA, allowing the introduction of the characteristic methyl branches into 
the PDIM molecule (Fernandes and Kolattukudy, 1997; Jain and Cox, 2005; Rainwater and 
Kolattukudy, 1985; Trivedi et al., 2005). Several of these biosynthetic genes are significantly 
upregulated  in macrophages (Fontan et al., 2008). PDIM production has been shown to 
modulate the early immune response to infection in a tissue-specific manner (Cox et al., 1999; 
Rousseau et al., 2004). Hepta- and octamethyl phthioceranic acids and hydroxyphthioceranic 
acids are the major acyl constituents of sulfolipids (SL) (Sirakova et al., 2001), where SL-N, a 
precursor of the major sulfatide of MTB, SL-1, is highly immunogenic (Gilleron et al., 2004).  
Of recent interest is the synthesis of the class of related PDIM lipids, phenolic glycolipids, 
which confers on a subset of MTB isolates belonging to the W-Beijing family, the ability to 
inhibit the release of key inflammatory effector molecules by cells of the host’s innate 
immune response (Reed et al., 2004; Tsenova et al., 2005). However, it has recently been 
shown that although PGL production contributes to the regulation of the host cytokine 
response, a global suppressive effect amongst all PGL-producing W-Beijing strains is not 
exhibited, but instead is dependent on the background of the strain in which it is produced 
(Sinsimer et al., 2008). This finding argues against earlier speculation that the associations 
between bacterial lineage and disease phenotype could be explained by the presence or 
absence of a functional PGL producing polyketide synthase, pks1-15 (Caws et al., 2008).  
Anti-inflammatory signals can also be potentiated by TLR-2 dependent signaling of the 19- 
kDa lipoprotein (Noss et al., 2001) and binding of mannose-capped lipoarabinomannan to 
DC-SIGN (Geijtenbeek et al., 2003). Trehalose mycolates, mycolic-acid containing 
glycolipids, positively and negatively influence granulomatous inflammation (Geisel et al., 
2005) based on the stereochemistry of the cyclopropane modification (Rao et al., 2005; Rao et 
al., 2006). These subtle differences in structure fine-tune the immune pathology to a level 
believed to be appropriate to the survival and persistence strategies of the bacteria (Russell, 
2007).  
These reports are all consistent with notion that MTB plays an active part in disease 
progression. Indeed, varying features of the dynamic cell envelope, whose composition is 
controlled to a degree by the intramembrane protease Rv2869c (Makinoshima and Glickman, 
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2005), translates into the differential infection outcomes observed by different strains which 
elicit different immune responses (Manca et al., 2004).   
 
1.4 Carbon metabolism in MTB 
1.4.1 Interpreting carbon usage in vivo through metabolic pathway assessment  
 
MTB is an intracellular pathogen, although this organism shows no obligate parasitism as it is 
a prototroph possessing a flexible metabolic arsenal. Niche-specific adaptation of 
mycobacteria has evolved to allow optimal usage of available nutrients from the surrounding 
environment. The substrates define the metabolic pathways harbored by the bacterium for 
acquisition and assimilation of the respective nutrients. To this end, MTB is capable of 
oxidizing a variety of carbon substrates including carbohydrates, hydrocarbons, alcohols, 
ketones and carboxylic acids (Wheeler, 2005). The diverse pathway infrastructure necessary 
for catabolism of these sugars and fatty acids is evidenced in the gene complement in MTB 
for β-oxidation, glycolytic and pentose phosphate pathways and the TCA and glyoxylate 
cycles (Cole et al., 1998). The genes encoding fatty acid β-oxidation enzymes show a 
remarkable degree of paralogous expansion: for example, there are 36 paralogues each of  
FadD and FadE, involved either in fatty acid degradation or in the biosynthesis of acyl-CoA 
substrates (Cole et al., 1998; Saxena et al., 2003). This functional diversification may be a 
mechanism by which MTB ensures its ability to utilise the variety and quantity of mammalian 
fatty acids available within the host (Hiltunen and Qin, 2000). The topological organization of 
the large MTB metabolic network is also a testimony to the remarkable diversification evident 
within the MTB metabolome (Verkhedkar et al., 2007). A functional consequence is a large 
number of alternate routes, augmenting redundancy and flux plasticity (Almaas et al., 2005). 
In effect, the more reactions a metabolic network possesses, the stronger the network-induced 
redundancy, and the smaller the core of essential reactions. In this way, MTB maintains the 
integrity and robustness of its network, allowing for increased adaptive versatility required for 
occupancy of the organism within the differing host environments.  
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The observed abundance of lipolytic genes, in conjunction with the earlier studies which 
found mycobacteria isolated from infected  mouse lung can readily metabolise both odd- and 
even-chain fatty acids (Bloch and Segal, 1956; Wheeler and Ratledge, 1988), support the 
proposition that these may be the dominant substrates during MTB infection. However, this 
may be subject to tissue (niche)-specific variation (Neyrolles et al., 2006; van der Wel et al., 
2007) defined by the stage of infection (Boshoff and Barry, 2005). Various studies have 
revealed unique transcriptome signatures of MTB in human granulomas depending on the site 
of sample isolation (Fenhalls et al., 2002; Rachman et al., 2006b; Timm et al., 2003). These 
findings caution against using information of this type to make broad generalizations 
regarding the in vivo physiology of MTB.  
Consistent with a dependence of MTB on lipid metabolism, however, is the fact that ICL, 
which catalyzes the first step of glyoxylate cycle, is essential for growth and persistence of 
this organism in macrophages and mice (Muñoz-Elias and McKinney, 2005). However, the 
murine model does not mimic the environmental heterogeneity displayed in humans which is  
highlighted by relatively little overlap in gene expression profiles between the two (Boshoff 
and Barry, 2005; Rachman et al., 2006b). Specifically icl gene transcript detection is 
extremely variable, and furthermore, icl transcript appears to be entirely absent from the 
central necrotic area and transition zones of human necrotic granulomas (Fenhalls et al., 
2002).  
Although prevalent, lipids, in all likelihood, are not the exclusive carbon source for MTB in 
vivo. During the acute stage of infection, a putative high affinity disaccharide transporter (lpgY 
sugABC) is essential for virulence of MTB in mice (Sassetti and Rubin, 2003) and in chronic 
infection, metabolically active bacilli transcribe genes for carbohydrate and lipid utilization 
(Talaat et al., 2007), suggesting that MTB may utilise both carbon sources. In other 
organisms, species-specific differences in this regard have been observed. For example, in 
Azotobacter vinelandii, acetate induces fatty acid dependent inhibition of glucose uptake and 
glycolysis (Tauchert et al., 1990), E. coli preferentially uses glucose which represses the 
glyoxylate shunt (Walsh and Koshland, 1985), whereas Corynebacterium glutamicum can 
grow on a mixture of glucose and fatty acids with the glyoxylate shunt predominantly 
fulfilling the anaplerotic functions (Wendisch et al., 2000). The impact of substrate affinity 
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and regulatory control would need to be assessed for MTB grown on a mixture of lipids and 
carbohydrates. It has been suggested that the dispensability of key glycolytic enzymes for in 
vivo growth (Sassetti and Rubin, 2003) is due to carbohydrate intermediates, such as glucose-
6-phosphate, serving as precursors for biosyntheses (Muñoz-Elias and McKinney, 2006). This 
view is supported by the essentiality of pyruvate kinase (pykA), which catalyzes the last step 
in glycolysis, in vitro (glucose carbon source) but not in vivo (Sassetti et al., 2003; Sassetti 
and Rubin, 2003). A single nucleotide polymorphism (SNP) in this gene that renders pyruvate 
kinase inactive is present in the some members of the MTB complex, further substantiating 
the importance of lipids for growth  in vivo (Keating et al., 2005). Consistent with this notion 
is the induction of pckA, which encodes the gluconeogenic rate-limiting enzyme, 
phosphoenolpyruvate carboxykinase, which converts fatty acids into sugars (Schnappinger et 
al., 2003). The avirulent nature of a mycobacterial  mutant defective for this gene (Collins et 
al., 2002a; Liu et al., 2003) reinforces the concept that carbohydrates are used for biosynthetic 
rather than catabolic purposes, since glucose-induced pckA downregulation (Liu et al., 2003) 
would afford a pyruvate carboxylase (PCA) bypass in the presence of carbohydrates (Fig. 1). 
Upregulation of icl and pckA (Schnappinger et al., 2003; Timm et al., 2003) might not only 
signal fatty acid metabolism but also the possible oxidation of acetyl-CoA to CO2 by the PEP-
glyoxylate cycle, active under glucose limitation, possibly compensating for higher NADPH 
formation on alternative substrates (Fischer and Sauer, 2003; Muñoz-Elias and McKinney, 
2006). The detection of the competing enzyme, isocitrate dehydrogenase (Fischer and Sauer, 
2003), indicates that the TCA’s biosynthetic role would be provisionally functional. Indeed, it 
has been proposed that MTB operates in the half cyclic mode leading to α-ketoglutarate 
(2KG) via the oxidative branch and succinate via the reductive branch (Muñoz-Elias and 
McKinney, 2006; Tian et al., 2005a) quenching the bacterium’s biosynthetic demands rather 
than providing metabolic energy. This may be a consequence of the disjunction at the level of 
conversion of 2KG to succinyl-CoA (Fig. 1)(Tian et al., 2005a; Tian et al., 2005b) – a  
characteristic feature of some microbes that are adapted to low oxygen conditions (Pitson et 
al., 1999). These two branches in MTB are metabolically linked by either the glyoxylate shunt 
or a novel, variant bypass pathway via α-ketoglutarate decarboxylase and succinic 
semialdehyde dehydrogenase (Tian et al., 2005a). However, the existence of other bypass 
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pathways acting under niche- specific conditions such as the γ-aminobutyric acid (GABA) 
shunt or a α-ketoglutarate oxidoreductase cannot be excluded and needs investigation. 
Importantly, only this latter option would generate succinyl-CoA as an intermediate in the 
canonical TCA cycle, in an energy efficient manner. Alternatively, pools of succinyl-CoA for 
methionine, diaminopimelate  and heme biosynthesis would need to be derived from succinyl-
CoA synthetase in an energy-dependent manner (Carrillo-Castaneda and Ortega, 1970) or 
from propionyl-CoA via the methylmalonyl-CoA pathway (described in section 1.5.1). The 
described bypass pathway in MTB (Tian et al., 2005a) is energetically unfavorable with 
respect to succinyl-CoA generation, with the favored selection for the alternate routes to 
succinyl-CoA and their contribution to in vivo metabolism largely unknown.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MDH/
MQO
FUM
KGD
ACN
CIT
ICDSDH
SCS
ICL
pyruvate
PEP
PPC
PYK
PCK
PPS
MEZ
PCA
MLS
oxaloacetate
acetyl-CoA 
citrate
isocitrate
α-ketoglutaratesuccinate
fumurate
glyoxylate
acetyl-CoA
malate
PDHC
FA β-oxidation
propionyl-CoA
succinyl-CoA
Methylcitrate 
cycle
M
et
hy
lm
a
lo
n
yl
 
pa
th
w
a
y
TCA cycle
Glyoxylate cycle
M
et
hy
lm
a
lo
n
yl
 
pa
th
w
a
y
M
et
hy
lm
a
lo
n
yl
 
pa
th
w
a
y
 21 
 
Fig. 1  Anaplerotic pathways in MTB. 
 Pathways feeding into the TCA cycle which are present in MTB are denoted by solid arrows 
and pathways not present in MTB are denoted by dashed arrows, namely 
phosphoenolpyruvate (PEP) synthase (PPS) and PEP carboxylase (PPC). Pyruvate is produced 
from malate by malic enzyme (MEZ) or from oxaloacetate by the sequential action of PEP 
carboxykinase (PCK) and pyruvate kinase (PYK); coupled decarboxylation of pyruvate by the 
pyruvate dehydrogenase complex (PDHC) yields acetyl-CoA. Anaplerosis during 
carbohydrate catabolism is by carboxylation of pyruvate to oxaloacetate by pyruvate 
carboxylase (PCA). Previous studies have established the importance of the glyoxylate cycle 
for anaplerosis during fatty acid (FA) catabolism by MTB (Muñoz-Elias and McKinney, 
2005). Glyoxylate cycle enzymes are the isocitrate lyases (ICL1/ICL2) and malate synthase 
(MLS). Anaplerosis during odd-chain FA β-oxidation by the methylmalonyl pathway occurs 
at the succinate dehydrogenase (SDH) branch point of the tricarboxylic acid (TCA) cycle 
adapted from Tian et al (2005). CIT, citrate synthase; ACN, aconitase; ICD, isocitrate 
dehydrogenase; KGD, α-ketoglutarate decarboxylase; SSADH, succinic semialdehyde 
dehydrogenase; SDH, succinate dehydrogenase; FUM, fumarase; MDH, malate 
dehydrogenase; MQO, malate:quinine oxidoreductase; SCS, succinate synthase.    
 
 
 
1.4.2 Regulation of carbon metabolism in MTB 
 
MTB’s regulatory repertoire includes 190 transcriptional regulators (Cole et al., 1998), which 
collectively coordinate gene expression necessary for pathogenesis. Partial characterization of 
a few two-component regulatory systems such as DosR/S/T (Malhotra et al., 2004), RegX3-
SenX3 (Parish et al., 2003), MprA-MrpB (Zahrt and Deretic, 2001) and PhoP-PhoQ (Walters 
et al., 2006) and a few selective sigma factors (Ando et al., 2003; Sun et al., 2004) have 
implicated these systems in virulence. However, the molecular mechanisms of how MTB 
senses environmental stresses and induces metabolic adaptation remain largely unknown. 
Recent studies indicate that in the absence of SoxR regulatory protein and FNR (fumurate 
nitrate regulator), MTB possesses an Fe-S cluster transcription factor, WhiB3, and heme 
proteins DosS and DosT, sensors which detect environmental redox signals such as O2, NO 
and fluctuations in the intracellular redox state to promote bacterial persistence (Kumar et al., 
2007; Singh et al., 2007a). The induction of the DosR regulon in palmitate (Boshoff et al., 
2004) and the essentiality of WhiB3 for growth on various carbon sources, including TCA 
intermediates and acetate (Singh et al., 2007a), stresses the coupling of the intracellular redox 
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environment to central and fatty acid metabolism. For instance, in glucose limited cultures of 
E. coli, the regulation of key enzymes of the TCA cycle is mediated by FNR and ArcA, O2-
sensing regulators (Shalel-Levanon et al., 2005).   
Contribution to the global control of carbon metabolism in MTB in response to the many 
extracellular and intracellular signals through a second messenger system based on cyclic 
nucleotide monophosphates (cNMP) has been reported (McCue et al., 2000). In E. coli, the 
role of cAMP signal transduction in mediating catabolite repression has been well 
characterised with the adenylate cyclase catalysing the synthesis of cAMP, which then 
transduces the signal by binding cAMP receptor protein (CRP) and activating it as a 
transcription factor (de Crombrugghe et al., 1984; Kolb et al., 1993).  MTB has 15 putative 
nucleotide cyclases and eight orthologues of cAMP receptor protein (CRP)-like transcriptional 
regulators (Dass et al., 2008; McCue et al., 2000). Rv3676 is one such CRP-like 
transcriptional regulator described in MTB (Bai et al., 2005). Deletion of this gene leads to 
attenuation in macrophage infections and in the mouse model of TB (Rickman et al., 2005). 
The lack of Rv3676 function in M. bovis BCG has also been suggested to be one of the 
additional reasons for its attenuation (Brosch et al., 2007; Spreadbury et al., 2005). Together, 
these observations suggest that several important genes are under cAMP regulation.  
 
In a recent study, the relative distribution of flux through central metabolism under glucose 
limitation was dominated by cAMP-dependent catabolite repression (Nanchen et al., 2008). 
Importantly, flux through the PEP-glyoxylate cycle is controlled by intracellular cAMP levels, 
actively induced by the cAMP-CRP complex. In C. glutamicum, the ICL-encoding gene, 
aceB, is under the control of the CRP homologue, GlxR (glyoxylate bypass regulator) (Kim et 
al., 2004), which is highly homologous to Rv3676 (75% amino acid identity). A potential 
CRP binding site was identified 279 bp upstream of the MTB glyoxylate cycle gene, icl 
(Spreadbury et al., 2005), although the cognate regulatory factor remains undefined since 
computational methods for identifying potential regulon members of the Rv3676 did not 
include icl as a candidate (Bai et al., 2005). An alternative theory stems from the observation 
that malate dehydrogenase (mdh) expression levels were increased by cAMP in shaking low 
oxygen cultures (Gazdik and McDonough, 2005). MDH converts malate to oxaloacetate and it 
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is speculated that increased levels are necessary to drive the forward reactions of the 
glyoxylate cycle and thereby, indirect regulation of glyoxylate cycle metabolism by cAMP is 
achieved. In E. coli, glyoxylate cycle gene expression is controlled by the IclR repressor 
which regulates the aceBAK operon (Sunnarborg et al., 1990), encoding isocitrate 
dehydrogenase (ICD) kinase (aceK), and both glyoxylate cycle enzymes, ICL (aceA) and 
MLS (aceB). At the branch-point of the TCA cycle and the glyoxylate cycle, flux is 
predominantly controlled through the reversible inactivation of ICD by phosphorylation, 
catalysed by ICD kinase (LaPorte et al., 1984; Walsh and Koshland, 1985). A bioinformatics 
search of the MTB proteome revealed that Rv1719 contains an N-terminal helix-turn-helix 
DNA binding motif followed by an IclR-type effector binding domain (Pfam PF01614), and 
along with reports that MTB possesses an ICD kinase (Singh and Ghosh, 2006) suggest that 
MTB may have a similar mechanism of control.  Metabolic control analysis (MCA) predicted 
that reducing  kinase activity by 30% would increase the amount of dephosphorylated (active) 
ICD sufficiently to diminish flux through the glyoxylate cycle (Singh and Ghosh, 2006), 
consistent with the low affinity of ICL for the competing isocitrate substrate (Km=188 µM) 
(Gould et al., 2006) relative to ICD-1 (Km=10µM) and ICD-2 (Km=20µM) (Banerjee et al., 
2005). The mechanisms employed to regulate gene expression are varied and complex and 
defining the precise mechanisms for directing carbon flux in MTB requires further 
investigation. Recent work identified a TetR-type regulator, KstR (ketosteroid regulator) 
which is  induced in response to growth on  palmitate, which was proposed to regulate the 
uptake and utilization of a variety of lipids, including cholesterol; however, it also influences 
genes of the pentose phosphate pathway and glycerol metabolism (Kendall et al., 2007a; Van 
der Geize et al., 2007).  
  
1.4.3 The sources and types of nutrients in vivo 
 
Discrete microanatomical niches exist within the human host and sources of nutrients are 
likely to be varied and vast. Proliferation of MTB either within the extracellular caseous 
matter of cavities (Grosset, 2003; Lenaerts et al., 2007) or within permissive phagocytes such 
as that witnessed at the margins of liquefied lesions in lungs (Kaplan et al., 2003) and in 
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follicular structures in the peripheral rim of closed necrotic noncavitating granulomas (Ulrichs 
et al., 2004), attests to the bacilli’s exquisite ability to actively harness intracellular carbon 
sources, so much so that they have been described as ‘fat’ (Garton et al., 2008) and to 
mobilise these extracellular sources into internal reserves of storage lipids, known as 
triacylglycerols (TAG). These lipids are thought to provide a carbon and energy source during 
periods of latency and transmission when stored TAG is hydrolysed following, for instance, 
PE30 lipase induction (Schnappinger et al., 2003). The high global prevalence of strains of 
MTB of the W-Beijing lineage and their apparent advantage over other lineages (Barczak et 
al., 2005; Reed et al., 2007) has been attributed in part to the striking accumulation of TAG in 
these strains as a result of a diacylglycerol acyltransferase (TAG synthase;  Rv3130c), a 
member of the DosR regulon which is constitutively expressed in these strains (Reed et al., 
2007). TAG  accumulation has been found in bacteria obtained from organ lesions (Garton et 
al., 2002; Garton et al., 2008) which might represent TAG stored during dormancy or 
produced in the expanding granuloma from the fatty acids released from the degrading host 
tissue (Daniel et al., 2004). The exogenous fatty acids may form TAG by direct incorporation 
or elongation using de novo synthesised fatty acids from the C2 units generated by β-oxidation 
of host  fatty acids (Garton et al., 2002; Sirakova et al., 2006).  Fifteen TAG synthases have 
been identified in the MTB genome. Many are co-transcribed with lipases that are actively 
involved in making fatty acids available from several sources, including: (i) host cellular or 
membrane lipids (Jackson et al., 1989; Mason et al., 1972); (ii) bacterial phospholipid 
turnover (Garton et al., 2002),; (iii) release of  long fatty acid chains from polyketide 
synthases (Asselineau et al., 2002); (iv) accumulated C24 and C26 fatty acids due to possible 
FASII down-regulation in macrophages in response to acidic pH (Daniel et al., 2004; Fisher et 
al., 2002).  Therefore, most TAG synthases are likely to display broad substrate specificity 
induced under the influence of different host factors (Alvarez and Steinbuchel, 2002). The rich 
source of energy that TAG, sourced either from the host or synthesized by the bacilli, may  
provide to bacteria in a predominantly low metabolic state, in combination with the essential 
ICL requirement for persistence, strongly implicates TAGs as a necessary component of the 
physiology of MTB for long-term survival. This is marvelously exemplified by the finding 
that MTB gravitates to extra-pulmonary fatty deposits, where it sequesters host fatty acids into 
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dense TAG droplets and persists for years undetected by immune surveillance (Neyrolles et 
al., 2006). Similarly lipid-rich foamy macrophages may constitute a reservoir for persisting 
mycobacteria which display intracytoplasmic lipid inclusions when freed from the phagosome 
into lipid droplets, favouring internalization of cellular host lipids (Peyron et al., 2008).  
Lung surfactant ingested by alveolar macrophages (Grabner and Meerbach, 1991) also 
contains other complex lipids such as dipalmitoyl phosphatidylcholine, a membrane 
phospholipid,  which MTB is capable of metabolizing (Muñoz-Elias and McKinney, 2005) 
using phospholipase C (plc) to produce phosphorylcholine and diacylglycerol (DAG) 
(Johansen et al., 1996), with the latter potentially undergoing further acylation to TAG.  In 
addition, phospholipases C are required for releasing fatty acids from the host phospholipids, 
which may then be used as a carbon source through β-oxidation and the glyoxylate cycle, with 
the joint cooperation between plc and icl evident in their combined requirement for virulence 
(Muñoz-Elias and McKinney, 2005; Raynaud et al., 2002).  
Other intraphagosomal lipid metabolizing pathogens include Rhodococcus equi (Wall et al., 
2005), Candida albicans (Lorenz and Fink, 2002) and Salmonella enterica serovar 
typhimurium (Fang et al., 2005), which rely on a functional glyoxylate cycle like MTB for 
catabolising the concentrated lipid source in this compartment. The induction of fatty acid β-
oxidation in E. coli has recently been shown to be dependent on the RelA-mediated stringent 
response as part of the expanded repertoire of metabolic genes induced by ppGpp to remediate 
nutrient stress (Traxler et al., 2008). This finding further informs the complex composition of 
the phagosome environment which is in stark contrast to the improved nutritional status of the 
cytosol, reportedly abundant in glycogen (Ripio et al., 1997), oligopeptides, aminosugars and 
amino acids (Chatterjee et al., 2006). Consistent with this, cytosolic pathogens such as 
Shigella flexneri (Lucchini et al., 2005) and Listeria monocytogenes (Chatterjee et al., 2006; 
Chico-Calero et al., 2002) are icl-deficient. Intracellular Legionella pneumophilia scavanges 
host amino acids and potentially carbohydrates from the host  (Bruggemann et al., 2006). 
Escape into the energy-rich cytosolic environment is documented for MTB where the bacilli 
multiply more rapidly than their vacuolar counterparts (van der Wel et al., 2007). As observed 
in Candida albicans, progression to systemic disease may be dependent on glycolysis (Barelle 
et al., 2006). 
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The usage of available nutrient sources is clearly dependent upon the location of MTB. It is 
conceivable, for instance, that bacteria escaping the granuloma and persisting in healthy lung 
tissue (Hernandez-Pando et al., 2000; Opie, 1927) may use the rich source of cholesterol in 
pulmonary exudates, a conclusion consistent with the metabolic pattern that emerged from in 
vivo non-replicating persistent type bacilli in sputum (Garton et al., 2008). Mounting evidence 
that cholesterol is an important carbon source for MTB has emerged in recent years. Uptake 
and catabolism of this complex sterol has been demonstrated and accessing this unique carbon 
source has been shown to be essential to the survival success of MTB (Joshi et al., 2006; 
Pandey and Sassetti, 2008; Van der Geize et al., 2007). Gaining entry into host cells by 
promiscuous binding to multiple surface receptors laden in cholesterol-rich domains of the 
plasma membrane (Gatfield and Pieters, 2000) ensures a higher cholesterol fraction within 
vesicles (Mason et al., 1972). Together with cholesterol-rich glycosphingolipid fusion to 
mycobacterial vacuoles (Russell et al., 1996) , this ‘carbon collateral’ may provide a distinct 
advantage to MTB.  
An interesting alternative is that mycobacteria may have evolved to utilise lipids in order to 
neutralise the free fatty acids produced by macrophages in antimicrobial defense (Akaki et al., 
2000; Coonrod et al., 1989), in addition to their use as an energy source. In support of this 
hypothesis, free fatty acids are reportedly inhibitory to lipogenesis (Ferdinandus and Clark, 
1969), and toxic free fatty acids can be incorporated into non-toxic triglyceride (McCarthy, 
1971). This raises fundamental questions as to the established reasons for essentiality of 
certain genes involved in this process. 
 
1.5 Propionate metabolism   
The broad selection of substrates available to MTB and the respective complementing 
biochemical pathways for breakdown thereof have not been fully elucidated and are the focus 
of much ongoing research. For example, the established importance of β-oxidation and the 
glyoxylate cycle in virulence of several pathogenic microorganisms, including MTB, is a 
prerequisite for appreciating the degree of reliance on lipids as a carbon source in vivo. 
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Similarly, the attenuation observed for MTB defective in cholesterol uptake places into 
context the importance of this sterol as a carbon source. This leads to the actualization of a 
common thread between these essential converging pathways, namely, the potential 
precursors of propionyl-CoA. Metabolism of this intermediate is an aspect of MTB 
physiology which remains to be fully characterised.  
Cellular generation of propionyl-CoA can stem from several different processes including 
thioesterification of propionate, catabolism of the branched-chain amino acids isoleucine, 
valine and methionine, decarboxylation of succinate and catabolism of odd- and branched- 
chain fatty acids. The cytotoxic effects of propionyl-CoA accumulation is associated largely 
with interference of pyruvate oxidation, competitive with coenzyme A (CoASH) (Brock et al., 
2000; Brock and Buckel, 2004; Maerker et al., 2005; Maruyama and Kitamura, 1985). These 
effects encourage efficient clearance of this metabolite by channeling it as a carbon and 
energy source.    
In mammalian tissue, propionate is physiologically derived from intestinal fermentation 
(Bergman, 1990) or from methyl-branched fatty acids, phytanic acid  and the pristanic acid 
derivative, both present in the human diet (Verhoeven and Jakobs, 2001). Corynebacterium 
species (McKenna and Kallio, 1971) and mycobacterial species (Cox et al., 1972; Sakai et al., 
2004) are capable of oxidizing such branched isoprenoid alkanes, where pristane is oxidised to 
pristanic acid which is then esterfied with CoA, and after several successive cycles of β-
oxidation, releasing three molecules of propionyl-CoA. The presence of pristane in human 
tissue (Avigan et al., 1967) might make this a relevant source of propionyl-CoA in MTB. 
Cholesterol is another potentially important source of propionyl-CoA in vivo yielding two 
molecules of propionyl-CoA per molecule of cholesterol catabolised by β-oxidation of the 
branched side chain at C17, and the catabolism of rings A and B (Van der Geize et al., 2007). 
Potentially, breakdown of these host derived lipids, and utilization of free fatty acids, C5 
ketone bodies and host protein (Ibrahim-Granet et al., 2008), along with intracellular recycling 
of select MTB cellular components, may yield propionyl-CoA levels which demand its 
metabolism to be a pivotal facet of MTB physiology.  
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1.5.1  Characterised pathways for propionyl-CoA catabolism 
 
 
 There are several pathways characterised for the oxidation of propionate. All of the described 
pathways start with propionyl-CoA, which is synthesised by a tightly regulated ATP- 
dependent acyl-CoA synthase, in keeping with CoA homeostasis (Garrity et al., 2007; 
Palacios et al., 2003). Propionyl-CoA may undergo α-oxidation in the acryloyl-CoA pathway, 
β-oxidation by the 3-hydroxypropionate pathway, α-carboxylation via the methylmalonyl-
CoA pathway, reductive carboxylation by the crotonyl-CoA pathway or Claisen condensation 
by the 2-methylcitrate, 2-hydroxyglutarate and citramalate pathways (Textor et al., 1997; 
Wegener et al., 1968b). The ultimate fate of activated propionyl-CoA is the production of 
either acetyl-CoA (non-randomising) or succinyl-CoA (randomising) as end-products of these 
catabolic pathways, entering the TCA cycle at the citrate synthase or succinate dehydrogenase 
steps, respectively (Fig. 1).  
The best studied pathway is the route for propionate metabolism in higher eukaryotes via 
methylmalonyl in which propionyl-CoA is carboxylated to (S)-methylmalonyl-CoA, which is 
racemised to the (R)-enantiomer. The carboxylation of propionyl-CoA can be catalysed by 
distinct biotin-dependent enzymes, the propionyl-CoA:oxaloacetate transcarboxylase which 
functions in the reversible decarboxylation of propionyl-CoA in Propionibacterium shermanii 
(Hall et al., 2004), and propionyl-CoA carboxylases (PCC) which catalyse only the 
irreversible carboxylation between propionyl-CoA and (S)-methylmalonyl-CoA (Buckel et 
al., 2005). A biotin-independent methylmalonyl-CoA decarboxylase has also been identified 
(Haller et al., 2000). Isomerisation is mediated by the coenzyme B12-dependent MCM to 
succinyl-CoA.  
In animals and humans, propionate is oxidised by the methylmalonyl pathway which provides 
energy and removes toxic propionyl-CoA (Brock and Buckel, 2004). This pathway has been 
described in a number of bacteria, including Pseudomonas butanovora (Doughty et al., 2006), 
Sulfolobus solfataricus (Chong et al., 2007), Pelotomaculum thermopropionicum (Kosaka et 
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al., 2006), Streptomyces cinnamonensis (Vrijbloed et al., 1999), MSM (Stjernholm et al., 
1962) and M.  vaccae (Vestal and Perry, 1969).  
The mutase enzyme also catalyses the  reverse metabolic direction in a number of organisms 
(Haller et al., 2000), which may link succinate to  polyketide synthesis (Hunaiti and 
Kolattukudy, 1984; Valentin and Dennis, 1996; Vrijbloed et al., 1999). P. shermanii employs 
the pathway for propionate formation in order to dispose of reducing equivalents in glucose or 
glycerol fermentations (Allen et al., 1964). In Saccharopolyspora erythraea the MCM 
provides methylmalonyl-CoA subunits for erythromycin production in oil-based 
fermentations, although it acts in the reverse direction in carbohydrate-based fermentations 
(Reeves et al., 2006, 2007).   
 
1.5.2 The adenosylcobalamin-dependent methylmalonyl-CoA mutase reaction 
 
The MCM enzyme catalyses a 1,2-intramolecular rearrangement of the thioester moiety (X= 
COSCoA) using adenosylcobalamin (AdoCbl; coenzyme B12) specifically as a cofactor.  
 
A highly reactive free deoxyadenosyl radical species and cob(II)-alamin are generated by 
hemolytic cleavage of a C-Co bond of the coenzyme that is weakened by steric repulsion due 
to a protein conformation change induced by substrate binding (Garcia-Viloca et al., 2004; 
Mancia et al., 1999). The crystal structure of MCM in complex with its substrate shows the 
active site is deeply buried inside a TIM barrel structure, which shields the biradical 
intermediates from solvent and oxidative interception (Mancia and Evans, 1998; Thoma et al., 
2000). The rate of Co-C bond homeolysis is accelerated by a factor of 1011 in the ternary 
complex of enzyme, AdoCbl and substrate relative to the uncatalysed rate in solution, 
effectively lowering the activation free energy (transition state barrier) by 71.1 kJ/mol 
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(Chowdhury and Banerjee, 2000). The deoxyadenosyl carbon radical abstracts a hydrogen 
atom from the methyl group of the substrate to initiate a free radical mechanism for a carbon 
skeletal isomerisation, followed by re-abstraction of the hydrogen atom from deoxyadenosine 
to form the product and regenerate the cofactor (Banerjee and Vlasie, 2002; Vlasie and 
Banerjee, 2004). The hydrogen transfer proceeds by a highly quantal tunneling mechanism 
(Dybala-Defratyka et al., 2007; Garcia-Viloca et al., 2004), and together with the lowering of 
the activation barrier, contributes to the dramatic rate acceleration of the MCM reaction 
(Chowdhury and Banerjee, 2000; Garcia-Viloca et al., 2004). In the case of the MCM from P. 
shermanii, the overall equilibrium for the rearrangement reaction favors succinyl-CoA 
formation by a factor of 3 (Meier et al., 1996; Thoma and Leadlay, 1998) in agreement with 
the methylene radical (methylmalonyl-CoA) having a slightly higher energy state than the 
more stable secondary methine radical (succinyl-CoA) (Chowdhury and Banerjee, 2000). 
Stabilization of the methylene radical by cob(II)alamin (Buckel et al., 2005) and partial proton 
transfer to activate the migrating thioester group (Smith et al., 1999) are proposed 
mechanisms thought to facilitate the MCM-catalyzed reaction by lowering the transition states 
that interconvert these radicals.    
The central catalytic role of coenzyme B12 is therefore essential for the mutase reaction. 
Availability of the adenosylated form of cobalamin is ensured by the protein 
adenosyltransferase (ATR), which participates in the de novo synthesis of AdoCbl or on 
precursor cobinamide (incomplete corrinoid) salvaged from the environment (Escalante-
Semerena, 2007). For an obligate pathogen such as MTB which possesses three vitamin B12-
dependent enzymes (Cole et al., 1998; Dawes et al., 2003; Warner et al., 2007) accessing the 
‘escorted’ cobalamin (Yamanishi et al., 2005) from mammalian tissues where the 
concentration is quite low (30-700nM with >95% of B12 bound ; (Hsu et al., 1966; Shevell 
and Rosenblatt, 1992) is probably limited. However, it is important to note that the obligate 
pathogen, M. leprae, has retained the genes encoding two vitamin B12–dependent enzymes 
(MetH, MCM) despite having lost most of the cobalamin synthesizing genes through 
reductive evolution (Cole et al., 2001). Alternately in silico analysis by Rodniov et al (2003)  
classified MTB as having a complete adenosylcobalamin biosynthetic pathway although no 
evidence of de novo synthesis exists. Therfore, an energy saving alternative to de novo 
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synthesis is that exogenous corrinoids (molecules containing the cobalt-containing cyclic 
tetrapyrrole known as the corrin ring) may be salvaged and transported into the bacterial cell 
where AdoCbl, or potentially adenosylcobinamide (AdoCba; the coenzymatic form whose 
lower axial ligand is not dimethylbenzimidazole (DMB)) is formed (Anderson et al., 2008).   
ATR catalyses the reductive adenosylation of cobalamin and transfers adenosylcobalamin to 
MCM (Padovani et al., 2008). Binding of the cofactor is accompanied by a significant 
conformational change in which the lower axial ligand, DMB, is coordinated to the cobalt 
atom (a mode of attachment that is called ‘base-on’), is displaced from the cobalt, and then 
replaced by the histidine residue in the conserved DXHXXG motif of the mutase family 
(Marsh and Holloway, 1992), with this base exchange being named ‘base-off, His-on’ 
(Chowdhury et al., 2001). Impairments in the ATR-dependent conversion of apo- to holo-
MCM result in no mutase activity, which, in humans, leads to methylmalonic aciduria (Leal et 
al., 2003), and in Methylobacterium extorquens lacking the glyoxylate cycle, inhibits growth 
on C2 compounds since the alternate anaplerotic pathway is dependent on MCM (Korotkova 
and Lidstrom, 2004; Korotkova et al., 2005). Significantly, MCM is a crucial component of 
alternate pathways to the glyoxylate cycle for acetate assimilation in various organisms, such 
as the glyoxylate regeneration cycle of M. extorquens  (Korotkova et al., 2002), the 
ethymalonyl-CoA pathway described for Streptomyces collinus (Han and Reynolds, 1997), 
Rhodobacter sphaeroides (Alber et al., 2006; Erb et al., 2007) and Rhodobacter capsulatus 
(Meister et al., 2005), and the citramalate cycle of Rhodospirillum rubrum (Berg et al., 2002), 
highlighting the importance of vitamin B12 for growth of these organisms on acetate.  
 
1.5.3 Anaplerosis by the methylmalonyl pathway 
 
Anaplerois is of Greek origin meaning ‘to fill up’, and refers to pathways that form 
intermediates that replenish the TCA cycle. Several organisms lacking the vitamin B12-
dependent MCM (Ledley et al., 1991) or only the coenzyme B12 (Huser et al., 2003; London 
et al., 1999), may use the methylcitrate cycle for the assimilation of propionate (Brock et al., 
2001; Claes et al., 2002). This cycle was first discovered in alkane- and lipid metabolizing 
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yeasts (Tabuchi and Serisawa, 1975). The simple α-oxidation of propionate to pyruvate is 
achieved by the condensation of propionyl-CoA with oxaloacetate to yield (2S,3S)-
methylcitrate, followed by isomerisation of this tricarboxylic acid to form (2R,3S)-2-
methylisocitrate, which is cleaved to succinate and pyruvate. Studies with 13C-labeled 
propionate indicate that in E. coli, the pyruvate is further oxidised to acetyl- CoA and 
channeled into the anaplerotic glyoxylate cycle (Textor et al., 1997). In this system, the PEP 
synthase and the PEP carboxylase were unable to support growth in the absence of ICL 
(Textor et al., 1997; Wegener et al., 1969). A distinguishing feature between propionate 
oxidizing pathways has emerged in that E. coli, which cannot synthesise vitamin B12 de novo 
but possesses a functional MCM (Roth et al., 1996; Roy and Leadlay, 1992), when 
supplemented with vitamin B12, appeared to have a near zero glyoxylate flux when this 
pathway was used for propionate oxidation (Evans et al., 1993). In addition, blocking the 
methylmalonyl pathway at the succinate dehydrogenase level resulted in an absence of labeled 
glutamate as observed in control wild type cultures, strongly suggesting that this may be the 
result of glyoxylate cycle that is now induced as described by Textor et al., shifting the flux 
away from isocitrate dehydrogenase in the absence of succinyl-CoA anaplerosis and 
minimizing the incorporation of label into α-oxoglutarate (Fig. 1). This raises the intriguing 
question as to whether the anaplerotic flux from succinyl-CoA from the methylmalonyl 
pathway is sufficient to support growth of E. coli in the absence of ICL if provided with 
exogenous vitamin B12. Significantly, similar findings have been reported in Pseudomonas 
and mycobacterial strains (Blevins and Perry, 1972). In this study, no ICL activity was 
detected for growth on propylamine (a propionyl-CoA precursor) or propionate. Furthermore, 
incorporation of 14CO2 into pyruvate confirmed the presence of the anaplerotic propionyl-CoA 
carboxylase–methylmalonyl-CoA pathway of propionate utilization. Interestingly, inhibition 
of the pyruvate dehydrogenase enzyme complex altered the amount of labeled pyruvate as 
compared to the uninhibited control, suggesting that flux through the methylcitrate cycle is 
disrupted by this manipulation, increasing flux through the methylmalonyl pathway. Indeed, 
much speculation may be made regarding pathway preference, given evidence that they may 
operate simultaneously (Evans et al., 1993). The greater incorporation of 14CO2 into pyruvate 
during propylamine oxidation relative to growth on propionate (Blevins and Perry, 1972) 
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suggests that metabolism by one pathway is preferred in respect to carbon source, or more 
specifically, ambient propionate concentration. This is illustrated in Burkholderia sacchari 
where disruption of the methylcitrate cycle is only relevant in terms of increasing poly-3-
hydroxybutyrate-3-hydroxyvalerate (3HV) production (i.e. a mutation in the methylcitrate 
cycle results in more propionate availability for 3HV) at lower propionate concentrations 
(0.02%), whereas at increased propionate concentrations, oxidation by an as yet unidentified 
contributor pathway becomes significant (Bramer et al., 2002).  MSM does not require the 
methylcitrate cycle for growth on propionate media (Upton and McKinney, 2007) and 
although MTB relies on the methycitrate cycle for growth in vitro (outside the living host) , it 
is dispensable for survival in vivo (Muñoz-Elias et al., 2006). These findings indicate the 
existence of alternate pathways for propionate metabolism in these mycobacterial species, 
consistent with the presence of orthologues specific to the methylmalonyl pathway in both 
MSM (Muñoz-Elias et al., 2006) and MTB (Cole et al., 1998; Fleischmann et al., 2002).  
 
Clearly, one notable difference between the methylmalonyl pathway and the alternate 2-
methylcitrate cycle is the ability of the former to substitute for the glyoxylate cycle of the 
TCA cycle through the net generation of succinate rather than pyruvate (Fig. 1). This 
anaplerotic role of the MCM pathway seems to be exploited in several instances by organisms 
deficient for ICL, supporting growth on propionyl-CoA precursors such as C3-C9 
monocarboxylic acids (Nieder and Shapiro, 1975). A mycobacterial sp. defective for the 
glyoxylate cycle due to a mutated MLS gene could grow on pristanic acid (Sakai et al., 2004). 
Similarly deletion of the glcB gene encoding MLS in MSM did not affect growth on 
propionate as the sole carbon source (Upton and McKinney, 2007). However, in these cases 
little is known about the identity of all the propionate metabolizing pathways. It is possible 
that growth on propionate or propionyl-CoA derivative carbon sources in the absence of the 
glyoxylate cycle may be dependent on MCM although has not been established empirically. In 
humans, stimulating anaplerosis through the methylmalonyl pathway as a remedy for fatty 
acid oxidation disorders is widely acknowledged (Reszko et al., 2003; Roe et al., 2002b).  
Alternately, other propionate oxidation pathways which instead yield acetyl -CoA may be 
operating. In the absence of the glyoxylate cycle, the acetyl-CoA is channeled by pyruvate 
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carboxylase or PEP synthase / PEP carboxylase into the TCA cycle (Fig. 1) to support growth 
(Horswill and Escalante-Semerena, 1999). Further studies need to be done in order to 
elucidate the degree of importance that anaplerosis from these multiple donor pathways has in 
supporting growth on propionate-generating carbon sources in mycobacteria and other 
microorganisms. 
The methylcitrate cycle is analogous to the first few steps of the TCA cycle utilizing the 
common enzymes, SDH, FUM, MQO and/or MDH to regenerate oxaloacetate from succinate 
in the methycitrate cycle. Aconitase, also common to the methylcitrate and TCA cycles, 
mediates only the rehydration of 2-methyl-cis-aconitate to (2R,3S)-2-methylisocitrate 
following dehydration of (2S,3S)-2-methylcitrate by MCD in the methylcitrate cycle. 
Furthermore, intermediates of the methylcitrate cycle inhibit isocitrate dehydrogenase of the 
TCA cycle (Brock, 2005; Cheema-Dhadli et al., 1975; Horswill et al., 2001; Plaut et al., 
1975). Such interferences with the TCA cycle are proposed to diminish the rate of ATP 
synthesis providing a strong selective advantage for the autonomous methylmalonyl pathway 
in any organism intent on preserving energy (Buckel et al., 2005). This notion is strongly 
reinforced by the preservation of the component genes for the methylmalonyl pathway in M.  
leprae, an organism which has undergone large-scale reductive evolution (Cole et al., 2001).  
  
1.6 The anabolic role of MCM in polyketide synthesis  
 
In MTB, the lipid profile is influenced by the available carbon source (Brown et al., 2008; 
Jain et al., 2007; Pandey and Sassetti, 2008). Similarly the mycolic acid pattern of the 
actinomycete Rhodococcus erythropolis is affected by growth on various carbon sources. 
Specifically, no odd-numbered carbon chains were found in the cell unless grown on odd- or 
branched-chain carbon sources such as propionate, valerate, nonane, undecane or pristane 
suggesting that the availability of propionyl-CoA precursor derived from these carbon sources 
is paramount in determining the mycolic acid pattern (Sokolovska et al., 2003). Conceivably, 
a similar reliance on available propionyl-CoA generating carbon sources for conversion to 
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methylmalonyl-CoA for use in methyl-branched chain fatty acid synthesis may be displayed 
in MTB (Fernandes and Kolattukudy, 1997; Jain and Cox, 2005; Rainwater and Kolattukudy, 
1985; Trivedi et al., 2005). However in other organisms, using the citric acid cycle 
intermediate succinyl-CoA, MCM is a major source of methylmalonyl-CoA precursor for 
polyketide products (Dayem et al., 2002; Hunaiti and Kolattukudy, 1984; Reeves et al., 2007; 
Valentin and Dennis, 1996; Zhang et al., 1999). Significantly, disruption of this pathway has 
been shown to have an  influence on  secondary polyketide biosynthesis in other 
actinomycetes (Reeves et al., 2004; Valentin and Dennis, 1996; Vrijbloed et al., 1999).  
In S. cinnamonensis, four routes to methylmalonyl-CoA have been described (Li et al., 2004; 
Vrijbloed et al., 1999; Zhang and Reynolds, 2001), two of which are proposed to function in 
MTB, namely isomerisation of succinyl-CoA catalysed by MCM and carboxylation of 
propionyl-CoA catalysed by PCC. Notably endogenous biotinylated proteins such as PCC are 
sensitive to reactive nitrogen intermediates released by activated macrophages which induce 
intermolecular disulphide formation and interfere with the proper assembly and function of 
the PCC oligomeric protein (Rhee et al., 2005).  
Therefore, it is reasonable to speculate that in MTB, should methylmalonyl-CoA extender 
subunits necessary for methyl-branched fatty acid synthesis become limiting as a result of 
PCC inhibition or failure to derive sufficient precursor propionyl-CoA from niche-specific 
carbon sources in vivo, compensation by the anabolic succinyl-CoA→methylmalonyl-CoA 
reaction of MCM would maintain the methylmalonyl-CoA metabolite pool. This may be 
relevant to the survival of MTB as the methyl-branched lipid fraction of its cell wall may 
influence MTB physiology with respect to permeability, antigenic properties and 
susceptibility to bactericidal compounds (Camacho et al., 2001; Rousseau et al., 2004; Zuber 
et al., 2008). An increase in the contribution of MCM to methylmalonyl-CoA metabolite 
maintenance, concomitant with a decrease in  flow of propionyl-CoA to methylmalonyl-CoA 
by PCC has been reported (Reszko et al., 2003). In effect, redistributing flux in response to 
such perturbations encountered in activated macrophages would achieve a higher order of 
cellular robustness, shown to be critical in maintaining  steady-states of essential metabolites 
(Kim et al., 2007). In MTB, constant methylmalonyl-CoA levels may be maintained by 
regulatory modules associated with low degree metabolites resulting in functional clusters of 
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highly correlated reactions (Samal et al., 2006), in the absence of a MCM regulator, mutR in 
MTB (Reeves et al., 2007). Notably, a strain overexpressing mutAB was associated with a 
90% loss of the episomal construct carrying mutAB in vivo which argues that perturbations of 
methylmalonyl-CoA metabolism are not well tolerated (Jain et al., 2007).   
Potentially, PEP oxidation through the catabolic PEP-glyoxylate cycle (Fischer and Sauer, 
2003) or oxidation of even-chain fatty acids to acetyl-CoA, which is assimilated through the 
glyoxylate cycle, may act to elevate endogenous succinate levels which may be used for 
anabolic polyketide synthesis through the MCM arm. Consistent with this, high pools of 
succinate are found in acetate grown cultures (Plassmeier et al., 2007; Wendisch et al., 2000). 
This would extend the importance of ICL beyond its classical role in the glyoxylate cycle to 
the provision of precursor succinate for methyl-branched fatty acid synthesis.  
An inverse association between propionate catabolism through the methylmalonyl pathway 
and fumurate respiration has been proposed (Kosaka et al., 2006; Thompson and Zeikus, 
1988). Fumurate respiration contributes to the generation of the PMF necessary for energy 
production in hypoxic nongrowing MTB (Rao et al., 2008). As a consequence, intracellular 
levels of succinate may be raised.  It is therefore reasonable to postulate a co-regulation of 
fumurate respiration with methylmalonyl-CoA synthesis by MCM in MTB. Indeed, 
anaerobically induced fumurate reductase was found to produce succinyl-CoA required for 
methionine biosynthesis in the absence of α-ketoglutarate dehydrogenase (Carrillo-Castaneda 
and Ortega, 1970). In MTB, the absence of α-ketoglutarate dehydrogenase and the reductive 
TCA half-cycle (Tian et al., 2005a; Tian et al., 2005b) may similarly result in enhanced 
succinate and succinyl-CoA formation under conditions where fumurate reductase is 
derepressed, as in Heliobacter pylori (Pitson et al., 1999).  
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2 AIMS and OBJECTIVES 
 Propionyl-CoA is an important intermediary high-energy metabolite, whose toxic 
accumulation may be defused through one of several routes. The main objectives of this study 
were to characterise the propionate oxidation pathways in MTB for growth on a variety of 
propionyl-CoA-generating carbon sources and to determine the functional relationship 
between these pathways in vitro, in order to gain a greater understanding of the contributions 
of each pathway to MTB pathogenesis in vivo.  
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3 MATERIALS and METHODS 
3.1 Bacterial strains and culture conditions 
The bacterial strains and plasmids used in this study are detailed in Table S. 1. Wild type 
MTB (strain H37Rv, ATCC 25618) and derivatives were grown standing at 37○C in 
Middlebrook 7H9 media (Merck) supplemented with 0.2% glycerol, oleic acid-albumin-
dextrose-catalase (OADC) enrichment (Merck) and 0.05% Tween 80. Sodium acetate, sodium 
propionate, valeric acid and heptadecanoic acid were purchased from Sigma. Bacteria grown 
on fatty acids were cultured in 7H9 media containing 0.5% albumin, 0.085% NaCl, 0.05% 
Tween-80 and sodium acetate, sodium propionate or valeric acid at a concentration of 0.1% 
(10 mM in all cases). Sodium propionate was also added to a final concentration of 0.2%. The 
pH of the valeric acid-containing medium was adjusted to 6.8 with 10M NaOH prior to use. In 
the case of heptadecanoic acid, a pre-warmed 0.2% stock solution of heptadecanoic acid was 
added to the media at a final concentration of 0.007% (0.25 mM). The poor solubility of 
heptadecanoic acid in water accounted for the lower final concentration of this carbon source. 
Unless otherwise indicated, vitamin B12 supplement (cyanocobalamin (CNCbl)), Sigma) was 
included at a concentration of 10 µg/ml. Hygromycin (Hyg) and kanamycin (Km) and 
streptomycin were used in MTB cultures at final concentrations of 50, 25 and 20µg/ml 
respectively. 3-Nitropropionate (3NP, Sigma) was used at a concentration of 0.1 mM (Muñoz-
Elias and McKinney, 2005). Growth curves were monitored by measuring the optical density 
(OD600) of cultures using at least three independent biological replicates. 
 
3.2 Construction and complementation of mutant strains of MTB 
The DNA sequences of the genes under investigation and their flanking regions were obtained 
from http://genolist.pasteur.fr/TubercuList/. MTB genomic DNA containing the mutAB genes 
and flanking sequences was obtained from the BAC library (BAC Rv58 spanning region 
1640681 to 172735) (Brosch et al., 1998) and digested with EcoRI to obtain a 7760bp 
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template which was cloned into p2NIL (Parish and Stoker, 2000) to form p2mutAB. An 
internal, 2342-bp region of mutAB was deleted from p2mutAB by digestion with AscI and 
BglII, with 1762bp of the full length 4101bp gene remaining. The fragment was blunt-ended 
with Klenow fragment (Roche) and re-ligated to create p2∆mutAB. The ∆mutAB mutation 
created an out-of-frame fusion at the AscI/ BglII junction and eliminated 213 amino acids 
from the C-terminus of the 615-amino-acid mutA and 566 amino acids from the N-terminus of 
the 750-amino-acid mutB (Fig. 5a). The remainder of the operonic genes and their 
corresponding ribosomal binding site (RBS) were intact. The PAg85-lacZ, Phsp60-sacB cassette 
marker gene cassette from pGOAL17 (Parish and Stoker, 2000) was inserted into the PacI 
sites of p2NIL to complete construction of the suicide delivery vector, p2∆mutAB17 (Fig.S. 
1.i). The mutAB deletion mutant of MTB H37Rv, ∆mutAB, was constructed by two-step allelic 
exchange mutagenesis using previously described methods (Gordhan et al., 1996; Parish and 
Stoker, 2000). 
Genetic reversion of the mutAB mutation in the ∆mutAB mutant strain to generate the 
∆mutAB::mutAB derivative was carried out by knock-in allelic exchange mutagenesis using 
the suicide plasmid, p2mutAB17, which contains the full-length mutAB genes plus 1431 bp of 
3’- and 2228 bp of 5’-flanking chromosomal sequence (Fig.S. 1.ii). This vector was 
constructed by cloning the lacZ-sacB cassette from pGOAL17 in the PacI site of p2mutAB. 
The ∆prpDC, ∆mutAB ∆prpDC and ∆mutAB::mutAB ∆prpDC mutants were constructed by 
deletion of the prpDC gene in the H37Rv, ∆mutAB and ∆mutAB::mutAB backgrounds, 
respectively, using the previously described suicide plasmid, pAU100 (Muñoz-Elias et al., 
2006). The ∆prpDC mutant was complemented genetically by integration of the previously 
described complementation vector, pPRPDC (Muñoz-Elias et al., 2006), at the attB locus. The 
∆ic1l::hyg mutant was constructed by deletion of icl1 in H37Rv, using the knockout vector 
pJM056-1, previously described by McKinney et al. (McKinney et al., 2000). The episomal 
vector harboring icl1, pICL1, was used for complementation of ∆ic1l::hyg (Muñoz-Elias and 
McKinney, 2005). The plasmids pAU100, pPRPDC, pJM056-1 and pICL1 were all obtained 
as a kind gift from Prof. J. McKinney (EPFL, Switzerland). All mutant strains were 
genotypically confirmed by Southern blot analysis (Fig. 5a and Fig.S. 2 ), as previously 
described (Gordhan et al., 1996).  
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MTB genomic DNA containing the Rv1998c gene and flanking sequences was obtained from 
the BAC library (BAC Rv175 spanning region 2238065 to 2310745) (Brosch et al., 1998)  
and digested with SphI to obtain a 3640bp template which was cloned into pGEM3Z(+)f  
(Promega) to form pGEMRv1998c. This vector was digested with BamHI and HindIII and the 
3670bp fragment containing Rv1998c was cloned into p2NIL (Parish and Stoker, 2000) to 
form p2Rv1998c. An internal, 312-bp region of Rv1998c was deleted from p2Rv1998c by 
digestion with NarI, with 464bp of the full length 777bp gene remaining. The vector was re-
ligated to create p2∆Rv1998c and confirmed by PCR (see Table S. 2 for a description of the 
primers and amplicon properties). The PAg85-lacZ, Phsp60-sacB cassette marker gene cassette 
from pGOAL17  (Parish and Stoker, 2000) was inserted into the PacI sites of p2NIL to 
complete construction of the suicide delivery vector, p2∆Rv1998c17. 
 
3.3 Heterologous over-production of a His-tagged recombinant form of 
Rv1998c in E. coli 
The Rv1998c ORF was amplified by PCR with the Expand High Fidelity PCR System (Roche 
Molecular Biochemicals) from genomic MTB DNA. To facilitate cloning, the PCR primers 
used to generate the ORF were designed to contain BamHI and HindIII, respectively, as 
described in Table S. 2. The PCR product and pQE30xa (Qiagen) vector were both restricted 
with these two enzymes, and the PCR product was cloned into pQE30xa for over-expression 
of Rv1998c with an N-terminal His-tag. The sequence of the insert of the resulting vector, 
pQE30xa::Rv1998c, was confirmed. Chemically competent E. coli cells (XL-1 Blue, 
Stratagene) were transformed with the plasmid and maintained in Luria-Broth (LB) with 0.2% 
glucose to efficiently block transcription of Rv1998c. Overproduction of the His-tagged 
recombinant form of Rv1998c was performed by growing cells at 30○C in LB to an OD600 of 
0.6- 0.8 and equilibrating at room temperature (~18○C) for 1 h. Following induction of gene 
expression with 0.05 mM isopropyl thio-β-D-galactoside (IPTG), 1.5-ml samples were taken 
from cultures stirred at ~18○C over a 2-h time course of subsequent growth. As a positive 
control, the MCL from E. coli was over-expressed with an N-terminal His-tag in parallel using 
the pQE30::prpB expression vector (Brock et al., 2001) that was kindly provided by Dr. M. 
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Brock (Hans-Knöll-Institut, Germany). The cells were pelleted and resuspended in 300µl of 
ice-cold phosphate buffered saline (PBS). The cells were disrupted by sonication and the 
sample centrifuged at 4○C (15000 x g for 5 min) to separate fractions. Sample aliquots (15 µl) 
were fractionated by SDS-PAGE (12% acrylamide) using PageRuler prestained protein ladder 
(Fermentas) as a protein size marker. Overproduction of soluble E. coli MCL (PrpB) (32kDa) 
from room temperature induction was confirmed by SDS-PAGE. In contrast, the His-tagged 
Rv1998c recombinant protein (30 kDa) was localised exclusively in the insoluble fraction 
(Fig. 8). Induction conditions were adjusted in subsequent experiments to optimise for the 
production of small amounts of recombinant Rv1998c protein in the soluble fraction. Fifty ml 
cultures were induced at ~18°C at a lower cell density (OD600=0.4) with 0.01mM IPTG 
overnight in flasks with a large surface area for improved aeration, before harvesting by 
centrifugation and resuspension in 1ml of lysis / column buffer (50mM Tris-HCl pH7.4, 0.3M 
NaCl, 5mM imidazole). Chromotographic enrichment of the His-tagged proteins was 
perfomed using His-Bind resin (Novagen). Briefly, after disruption by sonication, 500µl of 
cell lysate was loaded onto Ni-nitrilotriacetic acid (Ni-NTA) agarose (Novagen) with a bed 
volume of 200ul. The column was washed with lysis/column buffer to remove unspecifically 
bound proteins. MTB Rv1998c and E. coli MCL (PrpB) were each eluted with 1ml of elution 
buffer (50mM Tris-HCl pH 7.4, 250mM imidazole). The eluant was supplemented 
immediately with 2mM dithiothreitol (DTT) to prevent oxidation of any sensitive cysteine 
residues. To concentrate proteins for analysis by SDS-PAGE, ice-cold trichloroacetic acid 
(TCA) protein precipitation was done on the 1ml eluant. The protein pellet was resuspended in 
100 µl sample buffer (10 × concentrate).   
3.4 Tetracycline-inducible expression of Rv1998c in MTB  
The Rv1998c open reading frame (ORF) was amplified by PCR in an Eppendorf 
MasterCycler Gradient using High Fidelity Phusion Polymerase (New England Biolabs) using 
the primers detailed in Table S. 2. The amplicon, which contains the entire Rv1998c ORF and 
its native ribosome binding site (RBS) was cloned downstream of the tetracycline (Tet) 
regulated mycobacerial promoter, Pmyc1tetO, carried on the episomal plasmid, pSE100 (Ehrt et 
al., 2005) by insertion between the BamHI and SphI sites of the vector. The resulting 
 42 
construct, pSE100::Rv1998c, was confirmed by DNA sequencing of the region spanning the 
upstream tet-promoter to several bases after the end of the Rv1998c ORF. pSE100::Rv1998c 
(Fig.S. 1.iii and Table S. 1) and was co-electroporated into wild type H37Rv together with the 
integrative vector, pMC1s, which carries the Tet repressor (TetR) under the control of a strong 
mycobacterial promoter and directs integration of the Psmyc-tetR fusion at the attB site of the 
chromosome. Recombinants were selected on 7H10 agar plates that contained 50µg/ml Hyg, 
25µg/ml Km without anhydrotetracycline (AHTc) inducer. To assess the possible MCL 
function of Rv1998c in a background devoid of MCL function attributable to ICL (Gould et 
al., 2006), a construct driving Tet-regulated expression of Rv1998c was also introduced into 
the ICL-deficient mutant of H37Rv (∆icl::hyg). However, since the ∆icl1::hyg mutant carries a 
hyg resistance marker which precluded the use of pSE100::Rv1998c, an alternative expression 
strategy was employed in which the integrative vector, pMC1m (Ehrt et al., 2005), which 
carries tetR under the control of a mycobacterial promoter of intermediate strength was 
modified to carry both tetR and Pmyc1tetO. An SpeI (blunted with Klenow) /ClaI digest of 
pSE100::1998c was used to excise the 1306-bp fragment containing the Pmyc1tetO::Rv1998c 
transcriptional fusion. This fragment was cloned into ClaI / PvuII digested pMC1m and the 
final construct, pMC1m::PmyctetO::Rv1998c (Fig.S. 1.iv and Table S. 1) was electroporated 
into the ∆icl1::hyg mutant strain. Confirmation of the transformants harbouring the integrated 
and / or episomal plasmids was done by PCR (see Table S. 2 for a description of the primers 
and amplicon properties).  
3.5 Preparation of MTB cell-free extracts 
Bacteria were grown to late log phase (OD600=0.7-1.0) in 7H9 broth or propionate-containing 
media. Twenty ml of cultures were induced with AHTc at a concentration of 100ng/ml for 20 
h for maximal expression (Ehrt et al., 2005), and collected by centrifugation  (1100 × g for 20 
min). The pellet was washed three times with phosphate-buffered saline containing 0.05% 
Tween-80 (PBST) and resuspended in 2ml of assay buffer. Cells were disrupted by bead 
beating (Savant Fastprep FP120) with 0.1mm zirconia-silica beads (Bio101 lysing matrix B) 
for 3 × 60s, and cooled on ice between bursts. Extracts were clarified by centrifugation (15000 
x g for 15 min) and the aqueous solution filtered through a 0.45µm PVDF membrane filter 
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(Millex). Protein concentrations were determined using the Biorad Protein Assay based on the 
method of Bradford (Bradford, 1976).  A standard curve was generated with bovine serum 
albumin (Sigma). Cell extracts were used immediately for enzymatic assay.  
 
3.6 2- Methylcitrate lyase assays  
Lyophilised threo-2-methylisocitrate, the racemic mixture of (2R,3S)- and (2S,3R)-2-
methylisocitrate, received as a kind gift from Dr. M. Brock (Hans-Knöll-Institut, Germany) 
was dissolved in 0.5M NaOH and heated at 95○C for 20 min to saponify the lactone ring. 
Saponified 2-MIC was diluted into 1M KH2PO4 at pH 7.0, before use in assays. MCL activity 
was measured by following the lactate dehydrogenase (LDH)-mediated reduction of pyruvate 
to lactate with concomitant oxidation of NADH (Warren, 1970). The 1-ml reaction mixture 
contained 50mM KH2PO4 at pH 7.0, 5mM MgCl2, 0.1mM NADH , 7U LDH (Roche), 2mM 
DTT and and cell free extract (5-100µg in 5-100µl). Reactions were preincubated for 5 min 
and started by addition of 2mM 2-MIC (effectively half the concentration of the biologically 
active isomer (2R,3S)-2-methylisocitrate (Darley, 2003)). 2-MIC-stimulated NADH oxidation 
was measured spectrophotometrically at 340nm using the standard extinction coefficient 
6.22mM-1 for a 1cm path length.  Background was measured and subtracted by carrying out 
mock reactions without addition of 2-MIC. Calculations were done using the equation A=εcl, 
where A is the change in absorbanc/min, ε is the molar extinction coefficient, c is the change 
in concentration (moles/litre) and l is the pathlength.  
 
3.7 Gene expression analysis by real-time quantitative reverse 
transcription-PCR (qRT-PCR) 
The level of expression of the prpD (Rv1130), icl (Rv0467) and mutB (Rv1493) genes in 
H37Rv cultured on 7H9, propionate with and without vitamin B12 and valerate with vitamin 
B12 was determined by qRT-PCR. Cultures were grown to mid-log phase (OD600 = 0.4), 
bacteria were harvested and RNA extracted using TRIzol (Sigma), as previously described 
 44 
(Downing et al., 2004). The cell suspensions were transferred to tubes containing Lysing 
Matrix B (Q Biogene) and lysed in a ribolyser (Savant Fastprep FP120) for three cycles (20 
seconds at speed 6) with cooling on ice for 1 min between pulses. Samples were then 
centrifuged (15000 x g for 45 seconds), and the solution above the beads and cellular debris 
removed to a tube containing 300µl of chloroform/isoamyl alcohol (24:1 v/v) and PhaseLock 
gel (Heavy; Sigma). Samples were mixed by rapid inversion for 15 s and then periodically for 
2 min before centrifugation (15000 x g for 5 min). The top aqueous layer was transferred to a 
fresh tube and an equal volume of isopropanol added and samples incubated overnight at 4○C. 
Precipitated nucleic acids were collected by centrifugation (15000 x g  for 20 min at 4○C), and 
pellets washed with 70% ethanol and air dried. Crude RNA samples were treated with DNase 
I (Ambion) by incubation at 37oC for 60 min and purified further using an RNeasy kit 
(Qiagen) according to the manufacturer’s instructions. The concentration of RNA was 
estimated using A260/A280 spectrophotometric readings and the quality of purified total RNA 
was assessed by gel electrophoresis (2% agarose; 0.1% SDS). Samples were then subjected to 
a final DNase I treatment using the Ambion DNA-freeTM kit, according to manufacturer’s 
instructions. Synthesis of cDNA was carried out at 60°C for 30 min using 500 ng of RNA in a 
20 µl reaction mixture containing 1× PCR buffer without MgCl2 (Roche), 12.5 nM reverse 
primers, 4 mM MgCl2, 0.8 mM dNTPs, 3% DMSO and 1 µl of Enhanced Avian Reverse 
Transcriptase (Sigma), in an Eppendorf MasterCycler. Control reactions containing no reverse 
transcriptase were established in parallel to assess levels of contaminating DNA. For qRT-
PCR, 2 µl of cDNA was used for amplification with LightCycler FastStart DNA Master 
SYBR Green I kit in the Roche LightCycler (version 1.5). Absolute quantifications of 
transcript levels using standard curves were performed with the LightCycler software (version 
4.0). Absolute numbers of transcript were normalised to the number of sigA transcripts in the 
same sample and the normalised data were compared with normalised transcript levels in the 
7H9 control. The analysis was performed in triplicate biological samples, each in duplicate. 
Primers used were designed using the Primer3 design programme (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi) and are detailed in Table S. 2. The primers used to determine 
sigA transcript levels for normalization were as described by Dawes et al (Dawes et al., 2003). 
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The paired t-test was used to assess statistical significance of pair-wise comparisons using 
GraphPad Prism software (http://www.graphpad.com/ quickcalcs /ttest1 .cfm). 
Tet-regulated expression of Rv1998c under the control of the Pmyc1tetO promoter-operator was 
analyzed by semi-quantitative RT-PCR using the primers described in Table S. 2. cDNA 
synthesis was carried out as described above and 2µl of cDNA or genomic DNA standard was 
used for PCR amplification in an Eppendorf Mastercycler. Products were visualised on a 2% 
agarose gel.  
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4 RESULTS 
4.1 Pathways for propionate metabolism in MTB deduced from 
bioinformatic analysis 
Early evidence for odd-chain fatty acid metabolism in MTB stems from studies in which 
respiration on heptadecanoic acid (C17) was observed  (Bloch and Segal, 1956). At the outset 
of this study, preliminary experiments that were aimed at assessing the ability of the H37Rv 
strain of MTB to grow on propionate revealed that propionate did indeed support growth of 
H37Rv as an odd-chain fatty acid carbon source (data not shown). Similar findings were 
independently observed and subsequently published by other groups (Chang et al., 2007; 
Muñoz-Elias and McKinney, 2005; Muñoz-Elias et al., 2006). However, at the time of these 
initial investigations, no propionate oxidation pathways in MTB had been functionally 
characterised, prompting a detailed bioinformatic analysis of potential propionate oxidation 
pathways in MTB to be undertaken based on its complete genome sequence (Cole et al., 
1998). Using search terms and sequences selected according to information obtained from the 
KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway database 
(www.genome.jp/kegg/pathway.html), keyword and BLAST searches 
(http://genolist.pasteur.fr/TubercuList/) against the MTB genome (Cole et al., 1998) revealed 
the presence of two putative pathways for propionate metabolism, namely the methylmalonyl 
pathway and the methylcitrate cycle (Fig. 2).  
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Fig. 2 Predicted pathways of propionate metabolism in MTB  
Catabolism of alternative carbon sources including odd- and branched-chain FA, branched-
chain amino acids (BCAA), and cholesterol generates propionyl-CoA as a three-carbon (C3) 
terminal product. Propionyl-CoA can be oxidised to succinate through either the methylcitrate 
and glyoxylate cycles or the methylmalonyl pathway. Methylcitrate cycle enzymes include 
methylcitrate synthase (MCS), MCD and MCL. Glyoxylate cycle enzymes are ICL1, which 
also provides the methylisocitrate lyase (MCL) activity in MTB (Gould et al., 2006; Muñoz-
Elias et al., 2006), and MLS. Methylmalonyl pathway enzymes are propionyl-CoA 
carboxylase (PCC), methylmalonyl-CoA epimerase (MMCE) and methylmalonyl-CoA 
mutase (MCM).  
 
 
4.2 Constituents of the methylmalonyl pathway 
The first step of the methylmalonyl-CoA pathway is catalyzed by a propionyl-CoA 
carboxylase (PCC; Fig. 2). The PCC from Streptomyces coelicolor has been characterised in 
detail and shown to consist of three different components: a larger subunit (α chain) with the 
ability to carboxylate its covalently bound biotin group (AccA2), a smaller subunit (β chain) 
bearing the carboxyltransferase activity (PccB), and the third ε subunit essential for maximal 
activity of the complex (Pccε) (Diacovich et al., 2002; Rodriguez and Gramajo, 1999). Two 
separate reactions are catalysed by this enzyme: 
HCO3- +Mg-ATP + enzyme-biotin ↔ enzyme-biotin-CO2- + Mg-ADP + Pi 
Enzyme-biotin-CO2- + propionyl -CoA ↔ enzyme-biotin + methylmalonyl-CoA 
Several complexes have been purified from a number of other actinomycetes (Erfle, 1973; 
Haase et al., 1982; Hunaiti and Kolattukudy, 1982). These complexes are referred to as acyl-
CoA carboxylases (ACC) as they are able to carboxylate acetyl- propionyl-, or butyryl-CoA. 
The MTB genome contains several genes encoding either the α (accA1, accA2 and accA3) or 
β (accD1-6) subunits, which together form at least three distinct multi-functional ACC 
complexes. These presumably serve distinct biological roles in providing malonyl-, 
methylmalonyl-, or ethylmalonyl-CoA extender units for the biosynthesis of different 
polyketides and fatty acids (Cole et al., 1998). Of the six β subunits encoded by MTB, 
BLAST analysis identified AccD5 as having the highest homology (65% sequence identity) to 
the β subunit of the characterised PCC complex of S. coelicolor (PccB). However, the aspartic 
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residue (D422) believed to be responsible for substrate selectivity in PccB is replaced by a 
cysteine (C437) in the AccD5 of MTB (Diacovich et al., 2004). However Gago et al. found 
that replacing the aspartic residue of PccB with a cysteine did not alter specificity for 
propionyl-CoA (Gago et al., 2006). The protein sequences of the carboxytransferases found in 
MTB and other actinomycetes were analysed using ClustalW (Version 2; 
www.ebi.ac.uk/Tools/) and used to construct a phylogenetic tree (Fig. 3).  
 
Fig. 3 Phylogenetic analysis of β subunits of ACCase complexes found in actinomycetes 
The phylogenetic tree was generated using Clustal W2 . The organism abbreviations are MTB, 
M. tuberculosis; Pa, Propionibacterium acnes; Sc, S. coelicolor; Cg, C. glutamicum.  
 
 
Consistent with the clustering of AccD5 with PCCase from other actinomycetes, the PCC 
complex in MTB, which was biochemically characterised by others during the course of this 
study, was found to comprise α, β and  ε subunits encoded by accA3 (Rv3285) and accD5 
(Rv3280) cotranscribed with accE5 (Rv3281), respectively (Gago et al., 2006; Oh et al., 
2006).  
PCC stereospecifically synthesises (S)-methylmalonyl-CoA. Either the (R) or (S) enantiomer 
of methylmalonyl-CoA can be used as the chain extending substrate by mycoserosic acid 
synthase-like enzymes for multimethyl-branched fatty acid biosynthesis (Rainwater and 
Kolattukudy, 1985). This is contrary to the MCM which recognises only the R-stereoisomer of 
methylmalonyl-CoA mutase (Retey and Lynen, 1964), as the methyl group of the S-isomer 
would sterically clash with Tyr-89 (see below), thus excluding it from the active site (Banerjee 
and Vlasie, 2002). This diversion is rectified by  methylmalonyl-CoA epimerase (MMCE) 
which catalyses the conversion of the (S)-methylmalonyl-CoA to the (R)-methylmalonyl-CoA 
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configuration, keeping the methylmalonyl-CoA enantiomers in isotopic equilibrium (Reszko 
et al., 2003). Based on BLAST analysis, Rv1332A was assigned as the putative MMCE in 
MTB with approximately 60% similarity to characterised MMCE from other bacteria (Bobik 
and Rasche, 2004; Leadlay, 1981). 
The MTB genome was analyzed further for a MCM responsible for the catalysis of the carbon 
skeleton rearrangement of (R)–methylmalonyl-CoA to succinyl-CoA in a vitamin B12 
dependent manner (Fig. 2). MTB contains orthologues of the MCM genes (Cole et al., 1998; 
Fleischmann et al., 2002), with Rv1492 (mutA) and Rv1493 (mutB) annotated as the β 
(65kDa)and α (80kDa) subunits, respectively, of the MCM heterodimer. Cluster analysis 
grouped the MTB α subunit with mutB from P. shermanii (Fig. 4). These branched separately 
from the MeaA from S. cinnamonensis, a B12-dependent MCM-like protein (Smith et al., 
1996; Zhang and Reynolds, 2001) and the homodimeric MCM, sleeping beauty mutase (Sbm) 
from E. coli  (Fig. 4) (Froese et al., 2008; Haller et al., 2000). 
 
Fig. 4 Phylogram of MutB orthologues 
The phylogram was generated by ClustaW2 and shows clustering of Methylobacterium 
extorquens AM1 (ME) MeaA; Genbank accession number AAC44087, Streptomyces 
cinnamonensis (SC) MeaA; Genbank accession number AAG40840, M. tuberculosis  (MTB) 
MutB; Genbank accession number CAB02043, Propionibacterium shermanii (PS) MutB; 
Genbank accession number P11653, E. coli (EC) Sbm; Genbank accession number P27253 
and Streptomyces cinnamonensis (SC) MutB; Genbank accession number Q05065.   
  
 
Key prerequisites including putative RBS sequences and lack of stop codon interruptions 
within the ORFs of interest were noted. Each ORF was further analysed for the conservation 
of signature motifs and important amino acids. Only the larger α subunit has a C-terminal 
coenzyme B12 binding domain characterised by the presence of the conserved DXHXXG 
motif (Marsh and Holloway, 1992), and presumably binds a single molecule of cofactor per 
 51 
heterodimer. The entire constellation of  conserved active site residues, Y243 (Y259), H244 
(H260), Y89 (Y105) and R207 (R223) are present in the α subunit (using the MCM from P. 
shermanii as reference numbering (Banerjee and Vlasie, 2002) with the corresponding MTB 
numbering shown in brackets). These active site residues form an aromatic corridor for 
substrate placement and play critical roles in controlling radical reactivity and protect against 
inactivating side reactions such as electron transfer from cob(II)alamin to the substrate leading 
to hydroxycobalamin (OHCbl) formation (Thoma et al., 2000; Vlasie and Banerjee, 2004). 
Further stabilization by an auxiliary protein which complexes to MCM, known as MeaB, is 
thought to protect against this suicidal inactivation during the course of turnover (Korotkova 
and Lidstrom, 2004; Padovani and Banerjee, 2006), promoting an extended enzyme half-life 
(~170 min for P. shermanii MCM; (Thoma et al., 2000)). Rv1496 was assigned as the 
putative meaB orthologue, showing high homology (40-70% similarity) to meaB from other 
organisms. 
 Notably, the MTB genome encodes three B12-dependent enzymes (Cole et al., 1998), and 
while polymorphisms in the ribonucleotide reductase (Dawes et al., 2003; Tsolaki et al., 2004)  
and the methionine synthase (Fleischmann et al., 2002; Warner et al., 2007) have been 
reported in clinical strains, the MCM is highly conserved. Importantly, close inspection of this 
locus in clinical strains F11, CDC1551, Haarlem and C clinical strains showed no allelic 
variation. 
 Interestingly, bioinformatic analysis of the mutAB operon revealed a predicted mazEF-type 
toxin-antitoxin (TA) module encoded by Rv1494 and Rv1495, respectively, embedded 
between mutAB and the putative meaB. Toxin-antitoxin (TA) systems were originally found 
associated with low copy number plasmids, increasing the effective stability by selectively 
eliminating plasmid-free progeny (post segregational killing; (Yarmolinsky, 1995)). The 
molecular basis underlying this ‘addiction’ is based on the rapid degradation of an unstable 
antitoxin protein, releasing stable toxin from the TA complex to exert its lethal activity in 
plasmid free daughter cells. In this way maintenance of the plasmid is ensured. Although their 
function is the subject of intense interest and debate, it has been proposed that chromosomally 
encoded TA modules may function in genome stabilization by limiting the loss of flanking 
DNA (Szekeres et al., 2007). Therefore, it is conceivable that the mazEF-type TA module 
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may stabilise the mutAB-meaB locus through a TA-dependent mechanism (Szekeres et al., 
2007).  
4.3 Vitamin B12 supplementation enables a functional methylmalonyl 
pathway 
Since it appeared that MTB possessed the complete complement of genes for the 
methylmalonyl pathway, the mutAB gene predicted in the bioinformatics search to form part 
of the methylmalonyl pathway in H37Rv was in part deleted by allelic exchange mutagenesis 
(Fig. 5a) and the mutant strain assessed for propionate utilisation. Surprisingly, growth of 
∆mutAB on 0.1% propionate was indistinguishable from wild type (Fig. 5b.i). These 
observations established that the methylmalonyl pathway was not essential for growth on 
0.1% propionate. Furthermore these results indicate the functionality of the alternate 
propionate oxidizing pathway in MTB, the methylcitrate cycle.  
During work probing the functionality of the B12-dependent methionine synthase, MetH, in 
MTB, it was discovered that it was necessary to supplement growth media with vitamin B12 to 
facilitate operation of this enzyme (Warner et al., 2007). Since MCM also requires a vitamin 
B12-derived coenzyme for functionality, the propionate-containing culture medium was 
supplemented with vitamin B12 to ensure that this coenzyme was not deficient. Growth on 
0.1% propionate was enhanced in the presence of vitamin B12 supplement (Fig. 5b.ii). This 
suggested that MTB may not synthesise the coenzyme necessary for MCM activity under 
these conditions. Since MTB possesses two other vitamin B12-dependent enzymes, it was 
important to determine if the growth advantage afforded by vitamin B12 supplementation was 
specifically mutAB-dependent. ∆mutAB was grown in 0.1% propionate media supplemented 
with vitamin B12 (Fig. 5b.ii). Growth of ∆mutAB with vitamin B12 was similar to H37Rv 
without vitamin B12. This indicates that this growth advantage is mediated specifically by 
MCM (Fig. 5b.ii) and that exogenous vitamin B12 exerts no observable pleiotropic effects on 
propionate metabolism. As growth of ∆mutAB was not abolished under conditions of vitamin 
B12 supplement, it was evident that vitamin B12 did not negatively regulate the alternative 
propionate metabolic pathway. Since the methylcitrate pathway appears not to be negatively 
regulated by vitamin B12 the activity of the methylmalonyl pathway is unlikely to be soley 
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responsible for the improved growth on vitamin B12-supplemented propionate. The growth of 
the complemented ∆mutAB mutant in the presence of vitamin B12 was similar to that of wild 
type with vitamin B12 (data not shown).  
It was considered that higher concentrations of propionate may demand the synergistic 
operation of two or more propionate oxidizing pathways. Therfore, 0.2% propionate was 
subsequently used to further dissect out any possible contribution to growth by the 
methylmalonyl pathway. Growth of ∆mutAB was retarded relative to H37Rv (Fig. 5b.iii). This 
observation was contingent on vitamin B12 supplementation as growth of H37Rv on 0.2% 
propionate without vitamin B12 supplement is similar to ∆mutAB (results not shown). 
Therefore, in summary, the observations displayed in Fig. 5 established the following: (i) 
MTB does not synthesise the necessary coenzyme required for MCM activity in vitro under 
the conditions tested; (ii) the growth stimulatory effect of vitamin B12 is strictly dependent on, 
and mediated by mutAB as improved growth is restored in the reversion mutant, 
∆mutAB::mutAB; (iii) the methylmalonyl pathway enzymes, namely PCC, MMCE and 
vitamin B12-dependent MCM are functional, and; (iv) more than one propionate oxidizing 
pathway  may be required for optimal growth of MTB on 0.1 and 0.2% propionate. 
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Fig. 5 Construction and characterisation of the ∆mutAB mutant of MTB H37Rv  
a. Construction and genotypic characterization of ∆mutAB and its reverted (knock-in) 
derivative (∆mutAB::mutAB)  
The mutAB and flanking genes are shown as solid arrows (not to scale). The line drawing 
above shows the 2342-bp segment internal to mutAB that was deleted in the ∆mutAB mutant 
strain (hatched box). For the Southern blot analysis (right), genomic DNA from the wild type, 
∆mutAB and reverted (∆mutAB::mutAB) strains was digested with SphI which cuts on either 
side of the deleted region to produce a 5870-bp fragment from H37Rv and ∆mutAB::mutAB 
and a 3528-bp fragment from ∆mutAB which were detected using the PCR-generated probe 
denoted by a grey box. 
b. Growth of ∆mutAB on propionate 
(i) Growth of H37Rv () and ∆mutAB () on 0.1% propionate. 
(ii) Improved growth of MTB on 0.1% propionate supplemented with vitamin B12 is mutAB-
dependent. H37Rv with () and without () vitamin B12; ∆mutAB with () and without () 
vitamin B12. 
(iii) Improved growth on 0.2% propionate supplemented with vitamin B12 is mutAB-
dependent. (), ∆mutAB; (), ∆mutAB containing the reverted mutAB allele 
(∆mutAB::mutAB) ; (), H37Rv. 
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4.4 Constituents of the methylcitrate cycle 
The MTB genome encodes homologues of MCS (prpC; Rv1131) and MCD (prpD; Rv1130) 
which are part of the same operon (Fig. 2). Significantly, no MCL-encoding homologue 
(prpB) was immediately evident, despite the presence of prpB homologues in other 
mycobacteria in an operonic arrangement with prpD and prpC (Claes et al., 2002; Upton and 
McKinney, 2007). This suggested that a non-orthologous enzyme may have taken over the 
role of the classical MCL (PrpB) enzyme in MTB. The MCL (PrpB) enzyme catalyses the 
cleavage of 2-methylisocitrate to succinate and pyruvate, analogous to the reaction catalysed 
by ICL in the glyoxylate cycle (Fig. 2). Although, E. coli ICL has no activity on 2-
methylisocitrate (Liu et al., 2005), some activity for 2-methylisocitrate, albeit 5-50-fold lower 
than the activity for the cognate substrate, isocitrate, has been reported for the ICL enzymes 
from Neurospora crassa, Pseudomonas indigofera, Chlorella vulgaris (McFadden et al., 
1972) and Saccharomyces cerevisae (Luttik et al., 2000). At the time of this bioinformatic 
analysis, it had been proposed that the substrate selectivity of these two enzymes could be 
attributed to steric restrictions: the methyl group (C2-CH3) present in pyruvate, but not in 
glyoxylate, could be accommodated by a hydrophobic depression in PrpB formed by F186, 
L234 and P236 (using the E. coli PrpB numbering) that is not present in ICL (Grimm et al., 
2003). W283, F345 and T347 are the equivalent conserved residues in ICL1 of MTB. In 
MTB, modeling predicted that addition of the methyl group to the glyoxylate bound in the 
ICL enzyme would form short van der Waals contact with T347 thereby precluding 2-
methylisocitrate from being accommodated in the hydrophobic pocket of ICL (Grimm et al., 
2003; Liu et al., 2005; Simanshu et al., 2003). A T347A substitution in ICL1 (reducing the 
size of the side chain) was proposed as a way to achieve reversal of substrate specificity (Liu 
et al., 2005). However, since all characterised ICLs have the identical binding pocket triad to 
MTB ICL1 (Grimm et al., 2003; Liu et al., 2005), these predictions were inconsistent with 
reported activity of ICLs on 2-methylisocitrate, as mentioned above. Therefore, ICL could not 
be absolutely excluded as a candidate PrpB in MTB.  Importantly, however, the ICLs with 
minimal MCL activity from Aspergillus nidulans and S. typhimurium are unable to support 
growth of these organisms on propionate as a sole carbon source (Brock, 2005; Horswill and 
Escalante-Semerena, 1999; Pronk et al., 1994). Further differences in the enzyme active site 
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may account for the minimal MCL activity observed in these ICLs. It has been proposed that 
for substrate binding and catalysis a drastic conformational change of a loop spanning 10-11 
amino acid residues containing the signature sequence KKCGH in all ICLs and KRCGH in all 
MCLs, including the active cysteine, is necessary. Importantly, mutation of KKCGH to 
KRCGH in the ICL from E. coli led to an 89% loss of activity (Rehman and McFadden, 
1997). Overall, the evidence suggested very little overlap in function, with MCLs possessing 
no ICL activity (Brock et al., 2001; Grimek et al., 2003; Liu et al., 2005) and ICLs possessing 
minimal MCL activity. This provided the rationale for postulating that an enzyme other than 
ICL may perform the MCL function necessary for growth of MTB on propionate.  
 
4.4.1 Identification of Rv1998c as a putative MCL  
 
Bioinformatic analysis identified a single MCL candidate in the MTB proteome, namely, the 
conserved hypothetical protein (CHP), Rv1998c, which belongs to the Cluster of Orthologous 
Groups (COG) 2513 (Tatusov et al., 1997). Members of COG 2513 are part of the (α/β)8  
ICL/ PEPM enzyme superfamily and include, amongst others, phosphoenolpyruvate mutase 
(PEPM) and MCL.  
PEPMs are involved in the formation of C-P bonds in the biosynthesis of  phosphonate 
secondary metabolites (Hidaka et al., 1990; Pollack et al., 1992). Interestingly, MCL shares 
greater sequence similarity with PEPM enzymes (30-37%) than with ICL (23-32%)  (Jia et al., 
1999). Structure-function analyses have shown that the mutases catalyse very different 
reactions to the lyases (Britton et al., 2001; Liu et al., 2002; Sharma et al., 2000), but despite 
this divergent chemistry, the same catalytic scaffold is conserved (Huang et al., 1999; Liu et 
al., 2004), which accounts for high structural similarity/conservation. The core residues 
characteristic of the ICL/PEPM family members are conserved as they bind the common 
substrate α-C(=O)COO unit and the Mg2+ cofactor (Lu et al., 2005) (Fig. 6). The core 
chemistry involves the stabilization of an oxyanion intermediate.  
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Fig. 6 Amino acid alignment of representatives of the ICL/PEPM superfamily  
Multiple sequence alignment using Clustal Version 2.0.5. PrpB from E. coli, CPEP 
(carboxyPEP mutase) from Streptomyces hygroscopicus, PDP (petal death protein) from D. 
caryophyllus, PEPM from Mytilus edulis and Rv1998c from MTB. The core residues are 
highlighted in yellow and the key diversification residues (glutamic acid and cysteine) shown 
to be essential for isocitrate and methylisocitrate lyase activity are denoted in red italics.  
 
 
 
PrpB            ---------------------MSLHSPGKAFRAALTKENPLQIVGTINANHALLAQRAGY 39 
CPEP            ----------------------MAVTKARTFRELMNAPEILVVPSAYDALSAKVIQQAGF 38 
PDP             MAPPNGTTNGETEVATQGSYTAVSTGRKTTMHRLIEEHGSVLMPGVQDALSAAVVEKTGF 60 
PEPM            --------------------MSTKVKKTTQLKQMLNSKDLEFIMEAHNGLSARIVQEAGF 40 
Rv1998c         ----------------------------MSFHDLHHQGVPFVLPNAWDVPSALAYLAEGF 32 
                                              ::          :  . :   *      *: 
  
PrpB            QAIYLSGGGVAAGSLGLPDLGISTLDDVLTDIRRITDVCS-LPLLVDADIGFGSSAFNVA 98 
CPEP            PAVHMTGSGTSASMLGLPDLGFTSVSEQAINLKNIVLTVD-VPVIMDADAGYG-NAMSVW 96 
PDP             HAAFVSGYSVSAAMLGLPDFGLLTTTEVVEATRRITAAAPNLCVVVDGDTGGG-GPLNVQ 119 
PEPM            KGIWGSGLSVSA-QLGVRDSNEASWTQVVEVLEFMSDASD-VPILLDADTGYG-NFNNAR 97 
Rv1998c         TAIGTTSFGVSS-SGGHPDGHRATRGANIALAAALAPLQC--YVSVDIEDGYSDEPDAIA 89 
                 .   :. ..::   *  *    :          :        : :* : * .        
 
PrpB            RTVKSMIKAGAAGLHIEDQVGAKRCGHRPN--KAIVSKEEMVDRIRAAVDAKTDPDFVIM 156 
CPEP            RATREFERVGIVGYHLEDQVNPKRCGHLEG--KRLISTEEMTGKIEAAVEAREDEDFTII 154 
PDP             RFIRELISAGAKGVFLEDQVWPKKCGHMRG--KAVVPAEEHALKIAAAREAIGDSDFFLV 177 
PEPM            RLVRKLEDRGVAGACLEDKLFPKTNSLHDGRAQPLADIEEFALKIKACKDSQTDPDFCIV 157 
Rv1998c         DYVAQLSTAGIN---IEDSSAEK-----------LIDPALAAAKIVAIKQ--RNPEVFVN 133 
                    .:   *     :**.   *           :      . :* *  :   : :. :  
 
PrpB            ARTDALAV-EGLDAA--IERAQAYVEAGAEMLFPEAITELAMYRQFADAVQVPILANITE 213 
CPEP            ARTDARES-FGLDEA--IRRSREYVAAGADCIFLEAMLDVEEMKRVRDEIDAPLLANMVE 211 
PDP             ARTDARAP-HGLEEG--IRRANLYKEAGADATFVEAPANVDELKEVSAKTKGLRIANMIE 234 
PEPM            ARVEAFIAGWGLDEA--LKRAEAYRNAGADAILMHSKKADPSDIEAFMKAWNNQGPVVIV 215 
Rv1998c         ARVDTYWLRQHADTTSTIQRALRYVDAGADGVFVPLANDPDELAELTRNIPCPVNTLPVP 193 
                **.::       :    :.*:  *  ***:  :           .          .     
 
PrpB            FGATPLFTTDELRSAHVAMALYPLSAFRAMNRAAEHVYNVLRQEGTQKSVIDTMQTRNEL 273 
CPEP            GGKTPWLTTKELESIGYNLAIYPLSGWMAAASVLRKLFTELREAGTTQKFWDDMGLKMSF 271 
PDP             GGKTPLHTPEEFKEMGFHLIAHSLTAVYATARALVNIMKILKEKGTTRDDLDQMATFSEF 294 
PEPM            PTKYYKTPTDHFRDMGVSMVIWANHNLRASVSAIQQTTKQIYDD---QSLVNVEDKIVSV 272 
Rv1998c         G-----LTIADLGELGVARVSTGSVPYSAGLYAAAHAARAVSDG-------EQLPRSVPY 241 
                       .  .: .              *   .  :    : :        :         
 
PrpB            YESINYYQY--EAKLDDLFARSQVK 296 
CPEP            AELFEVFEYSKISELEARFVRDQD- 295 
PDP             NELISLESWYEMESKFKNFTPKAT- 318 
PEPM            KEIFRLQRDDELVQAEDKYLPKN-- 295 
Rv1998c         AELQARLVDYENRTSTT-------- 258 
                 *                        
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Overall this family of proteins comprises an evolutionarily diverse group of enzymes, which 
include oxaloacetate acetylhydrolase (OXAHYD), phosphonopyruvate hydrolases (PPYRH), 
and ketopantonoate hydroxymethyl transferase (PANB). These all catalyze different reactions 
by binding substrate differently inside the barrel (Liu et al., 2005). This diverse functional 
specialization from the members of this family may lead to different undiscovered functions 
for the remaining CHPs which fall within this superfamily. 
Consistent with inclusion of Rv1998c in the ICL/PEPM family, Modbase 
(http://modbase.compbio.ucsf.edu/), a three-dimensional protein structure database, threaded 
the Rv1998c protein sequence most closely with two other members of this family, namely 
PrpB of E. coli Template Protein Data Bank (PDB) code: 1mumA , 21% sequence identity 
(Psi-Blast e-value 8e-36); and with another protein also having MCL activity (Lu et al., 2005; 
Teplyakov et al., 2005) called petal death protein (PDP) of Dianthus caryophyllus PDB code: 
1zlpA,  22% sequence identity (Psi-Blast e-value 4e-27). In addition, homology modeling of 
Rv1998c  was carried out by the Robetta server (http://www.robetta.org/), using E. coli PrpB 
(Fig. 7).  
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Fig. 7 Model of Rv1998c fitted to PrpB of E. coli 
Superimposition of in silico-modeled Rv1998c (blue) and the X-ray crystal structure of E. coli 
PrpB (turquoise). Spdb viewer was used to generate the superimposed image. Rv1998c is 
merged with PrpB where the trace of the polypeptide chain is similar. The open conformation 
of the active site loop which is the conserved catalytic scaffold regulating solvent access in the 
apo structure is marked in black and contains the lyase signature motif KRC*GH (absent from 
Rv1998c) highlighted in red. In Rv1998c, this active site capping loop is truncated. The amino 
acids (using E. coli PrpB numbering) around the active residue C123 of the KR C*GH motif 
and the catalytic E188 residue are drawn with the side chains in red. The amino acid residues 
F186, L234 and P236 that form the hydrophobic pocket are colored in green. Mg2+ is shown 
as a pink sphere.  
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Notably, a cysteinyl residue that is the active site residue for the C-C lyases, surrounded by 
the scaffold residues, KRCGH, which form the active site gating loop, is not conserved in the 
PEPMs (Grimek et al., 2003; Nimmo et al., 1989) and is similarly absent in Rv1998c (Fig. 6 
and Fig. 7). However, since Rv1998c was the only candidate enzyme identified as part of 
COG 2513 in MTB, the possibility that Rv1998c has residual MCL activity by virtue of a 
novel nonorthologous catalytic mechanism, was investigated. 
 
4.4.2 Analysis of the MCL function of Rv1998c 
 
4.4.2.1 Over-expression of Rv1998c in E. coli     
 
Recombinant His-tagged Rv1998c was over-expressed in E. coli in order to assess whether 
this protein possesses detectable MCL activity. Unlike the recombinant E. coli PrpB control, 
which was highly soluble, the His-tagged Rv1998c recombinant was found to be highly 
insoluble under the conditions tested (Fig. 8). 
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Fig. 8 Expression of recombinant Rv1998c in E. coli  
a. Schematic representation of expression vector pQE30xa::Rv1998c  
Rv1998c was fused in-frame to an N-terminal His-tag under the control of the lac operator.  
b. SDS-PAGE analysis of expression of recombinant, His-tagged forms of MTB Rv1998c 
and E. coli PrpB in E. coli  
Samples taken 30, 60 and 120 min after IPTG induction were fractionated by SDS-PAGE on 
12% polyacrylamide gel. The soluble and insoluble fractions from the various samples were 
loaded on separate gels for analysis of recombinant forms of PrpB from E. coli and Rv1998c 
from MTB. 
 
 
 
 
 
Conditions were therefore varied by changing the temperature and length of induction (refer to 
section 3.3) in order to identify conditions that would allow the expression of a soluble form 
of recombinant His-tagged Rv1998c in E. coli. To detect possible trace amounts of 
recombinant Rv1998c in the soluble fraction, this fraction was concentrated by passage 
through a Ni-Sepharose column followed by a TCA precipitation. The protein pellet was 
resuspended in sample buffer and assessed by SDS-PAGE (Fig. 9). However, no protein band 
corresponding to His-tagged Rv1998c was visible. In contrast, as reported by Brock et al., 
soluble recombinant PrpB from E. coli was readily detected as a band migrating at 32kDa in 
the soluble fraction of the E. coli host strain harboring the pQE30::prpB expression vector 
(Brock et al., 2001).   
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Fig. 9  SDS-PAGE of soluble cell extract after affinity chromatography on Ni-Sepharose 
column  
Aliquots of 5, 15 or 20µl were run on 12% SDS-PAGE after affinity chromatography and 
TCA precipitation of soluble cell extract (10× concentrated). Vector only (pQE30xa) and 
soluble E.  coli PrpB were run as negative and positive controls, respectively.  
 
 
 
 
4.4.2.2 Induction of Rv1998c expression in MTB and MCL assay of MTB cell extracts.  
 
Given the insolubility of this recombinant protein in E. coli, possible MCL activity of 
Rv1998c in its natural host was investigated. Semi-quantitative RT-PCR was used to assess 
the expression of Rv1998c in MTB cultured under standard aerobic growth conditions in 7H9 
media (Table 1, column 4). However, no Rv1998c transcript was detected under these 
conditions. This gene has been identified as a member of the DosR regulon (Voskuil et al., 
2003) which is induced by hypoxia and treatment with low-dose NO  (Shi et al., 2005). This 
gene was thus conditionally expressed by placing it under the control of a Tet-inducible 
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promoter (Ehrt et al., 2005) as described in section 3.4. To facilitate detection of MCL 
contributions from Rv1998c, MTB harbouring the recombinant construct was grown in 7H9 
medium to an OD600 of 0.8-1.0, where levels of ICL1 are low ((Wayne and Lin, 1982); Anna 
Upton, personal communication) and induced for Rv1998c expression.  
During the course of this study,  biochemical and structural evidence that ICL1 plays a dual 
role in the glyoxylate and methylcitrate cycles was published by Gould et al. (2006) who 
reported some recovery of  MCL activity from recombinant ICL1 (kcat / Km  of 1.74 ×103 M-1 
s-1; a measure of catalytic efficiency), although notably 367 fold less than E. coli PrpB , 3678 
fold less than A. nidulans PrpB (using the pure enantiomer of MIC) (Brock et al., 2001) and 
2413 fold lower than S. enterica PrpB (Grimek et al., 2003). The crystal structure of ICL1 
revealed that the active site could indeed accommodate the additional methyl group of 2-
methylisocitrate. Clearly, the substrate specificity of  ICL1 does not arise from a single 
determinant, consistent with other findings which suggest that the size of the hydrophobic 
pocket depends to a large extent on the backbone placement of the triad residues (Teplyakov 
et al., 2005). Therfore to eliminate any MCL contribution from ICL1, an icl1 mutant of 
H37Rv was constructed using a knock-out vector obtained as a kind gift from Prof. J. 
McKinney (EPFL, Switzerland). The ∆icl1 mutant was transformed with the vector carrying 
R1998c under control of the Tet-regulated promoter and induced similarly. Growth on 
propionate of the ∆icl1 mutant overexpressing Rv1998c was not assessed due to the absence 
of ICL1 activity necessary to support the function of the glyoxylate cycle which may be 
required in conjunction with the methylcitrate cycle for growth on this carbon source (Textor 
et al., 1997; Wang et al., 2003; Wegener et al., 1969).  
Induction of Rv1998c expression was monitored by detecting Rv1998c transcript levels by 
semi-quantitative PCR (Table 1). Rv1998c was successfully over-expressed in a AHTc-
dependent manner in both wild type H37Rv and the ∆icl1 mutant. MCL activity assays were 
performed using crude cell extract (Table 1). MTB grown on propionate (which has been 
shown to induce ICL1; (Muñoz-Elias et al., 2006)) was used as a positive control for MCL 
activity. The results from one representative experiment are shown in Table 1 using the assay 
conditions described under in section 3.6 (Brock et al., 2001; Muñoz-Elias et al., 2006). The 
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MCL activity for H37Rv grown in propionate (positive control) was comparable with that 
observed by Muñoz-Elías et al. (2006) and served as a positive control. 
 
 
 
Fig. 10 Schematic of construct used for Tet-regulated expression of Rv1998c in MTB 
Using the episomal plasmid, pSE100 (Ehrt et al., 2005) the region upstream of the start codon 
of Rv1998c is replaced with Pmyc1tetO. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 Conditional expression of Rv1998c in MTB  
Semi-quantitative RT for Rv1998c and sigA was done on strains harboring episomal Rv1998c 
under the control of Pmyc1tetO. Column1, H37Rv::Pmyc1tetO1998c with pMC1s induced; 
Column2, H37Rv::Pmyc1tetO1998c::pMC1s uninduced; Column3, 
∆icl1::hyg::Pmyc1tetO1998c::pMC1m induced; Column4, H37Rv::pSE100::pMC1s induced. 
Control reactions without reverse transcriptase revealed no contaminating DNA (not shown).  
MCL enzyme activity in cell free extracts of MTB: *Units are defined as nanomoles of 2-
methylisocitrate-stimulated  NADH consumption min -1 (mg  protein) -1  in the cell free extract. 
The detection limit was 2 nmol min-1 mg-1. Representative data from one experiment of two 
are shown. 
Pmyc1tetO Rv1998cpSE100::Rv1998c
27.22.6< 23.42.2
MCL
activity*
sigA
N/A
Rv1998c
N/A++-+AHTc
0.1 % 
propionate7H97H97H97H9Media
H37RvH37Rv::pSE100
with pMC1s
∆icl1::hyg::
Pmyc1tetO 
1998c::pMC1m
H37Rv::Pmyc1tetO
1998c ::pMC1s 
H37Rv::Pmyc1tetO
1998c ::pMC1s 
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No increase in MCL activity was detected in cell extracts from any of the cultures in which 
Tet-induced Rv1998c transcript was detected. Further, a complete loss of detectable MCL 
activity was found in cell extracts induced for Rv1998c, but lacking ICL1. This experiment 
was repeated with cultures induced for 6 h to minimise the potential toxicity of high protein 
expression levels, but similar findings were obtained (data not shown). (Muñoz-Elias et al., 
2006). The absence of MCL activity in the ∆icl1 strain of H37Rv grown in 7H9 is consistent 
with the undetectable levels of MCL activity subsequently reported for the ∆icl1 ∆icl2 strain 
of Erdman grown in 0.2% glucose (Muñoz-Elias et al., 2006). Together, these results 
indicated that Rv1998c does not provide detectable MCL activity in MTB under the 
conditions tested. 
 
4.4.3 Deletion of Rv1998c in the ∆icl1 mutant of MTB Erdman  
 
In terms of ICL function, an important difference exists between the H37Rv and Erdman 
strains of MTB. Erdman has two distinct ICL-encoding genes, icl1 and icl2 (Honer Zu 
Bentrup et al., 1999). The icl2 (or aceA) gene encodes a functional ICL enzyme, although no 
MCL activity was detected for this protein (kcat < 1×10-3 s-1). In H37Rv and other strains 
belonging to the Euro-American lineage, the aceA gene is split into two open reading frames, 
aceAa (Rv1915) and aceAb (Rv1916) which precludes the formation of ICL2 in H37Rv either 
as a single protein or through the association of the separate aceAa and aceAb modules. 
Consequently, in H37Rv, both ICL and MCL activity is provided exclusively by ICL1.  
Despite the evidence that ICL1 provides MCL activity in MTB, an icl1 mutant of the Erdman 
strain was still able to grow (albeit poorly) on propionate (Muñoz-Elias and McKinney, 2005). 
Since recombinant ICL2 possesses no detectable MCL activity, the poor growth of this mutant 
on propionate (Lin et al., 2008; Muñoz-Elias and McKinney, 2005), combined with the 
residual MCL activity detected in cell extracts of this strain (2.62 ± 0.45 units; (Muñoz-Elias 
et al., 2006)) and the 190-fold lower MCL activity in ∆icl1∆icl2 complemented with ICL2 
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(4.03 ± 0.90 units) as compared to ICL1 (771.36 ± 83.00 units) (Muñoz-Elias et al., 2006) 
supports the existence of another enzyme with MCL activity in this organism.  
To determine whether Rv1998c was accountable for growth of ∆icl1 Erdman MTB in 
propionate, a knock-out vector for Rv1998c was constructed (section 3.2) and electroporated 
into the ∆icl1 Erdman strain. Several attempts were made to obtain single cross-over 
homologous recombinants in the icl1 mutant of this Erdman strain although these were 
unsuccessful. However, parallel electroporations into the MTB H37Rv strain alternately 
resulted in several transformants. However, owing to time constraints, these experiments were 
suspended.   
 
4.5 Growth of MTB H37Rv on propionate is attributable to the 
methylcitrate cycle 
 During the course of this study, evidence for the functionality of the methylcitrate cycle in the 
Erdman strain of MTB was reported (Muñoz-Elias et al., 2006). To assess the functionality of 
this pathway in MTB H37Rv, and to establish its role in supporting the growth of this strain 
on propionate, a mutant of H37Rv with the prpDC genes deleted was generated using the 
same suicide plasmid as was used to create a ∆prpDC mutant of the Erdman strain of MTB 
(Muñoz-Elias et al., 2006). As shown in Fig. 11, the prpDC mutant of H37Rv could not grow 
on propionate whereas its complemented counterpart grew as well as the wild type. These 
results confirmed the essentiality of the methylcitrate cycle for growth of H37Rv on this 
carbon source, as established previously by Muñoz-Elías et al. for the Erdman strain (Muñoz-
Elias et al., 2006).  
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Fig. 11  The methylcitrate cycle is required for growth of H37Rv on propionate 
The effect of loss of prpDC function on growth of H37Rv. , H37Rv; , ∆prpDC; , 
complemented ∆prpDC mutant (∆prpDC::prpDC).  
 
 
4.6 Vitamin B12 supplementation enables growth of a prpDC mutant  
The results of section 4.3 established that supplementation of propionate-containing medium 
with vitamin B12 enabled the activity of MCM, thereby facilitating growth of MTB on this 
carbon source. The ability of the methylmalonyl pathway to support growth of ∆prpDC on 
propionate when the media was supplemented with vitamin B12 was therefore investigated. 
The results shown in Fig. 12 demonstrate that the ∆prpDC mutant can indeed grow in vitamin 
B12-supplemented propionate media. Therefore, the methylcitrate cycle is conditionally 
essential in the absence of vitamin B12 supplement.  This finding reinforces the operation of 
the methylmalonyl pathway subject to the availability of vitamin B12, consistent with our 
earlier observations of improved growth on vitamin B12 supplemented propionate (Fig. 5b. ii 
and iii). These findings also contribute to validating the existence of a pathway for 
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cyanocobalamin uptake into MTB and conversion to the active adenosylcobalamin form by a 
functional ATR.  
To confirm that growth on propionate supplemented by vitamin B12 was mediated solely by 
MCM, a ∆mutAB ∆prpDC double mutant was made. This mutant was unable to metabolise 
propionate as indicated by its inability to grow on this carbon source (Fig. 13). However, 
reversion of the ∆mutAB mutation to mutAB+ in this mutant background (∆mutAB::mutAB 
∆prpDC) restored growth in the presence of vitamin B12 (Fig. 13) showing unequivocally that 
mutAB encodes a functional apoenzyme which must be reconstituted with adenosylcobalamin 
obtained from cyanocobalamin supplement. However, the reversion mutant did not grow as 
well as the ∆prpDC comparator strain (Fig. 13). The reasons for this difference are unclear, 
but one possibility is that during the three rounds of allelic exchange mutagenesis required for 
its construction, the reversion mutant may have inadvertently acquired a second site 
mutation(s) that adversely affected its growth on propionate.  
Growth dependent only on the methylmalonyl pathway (∆prpDC with vitamin B12; Fig. 12) 
was notably poorer than growth dependent only on the methylcitrate cycle (H37Rv without 
vitamin B12; Fig. 11). As addition of vitamin B12 did not enable the equivalent growth of 
∆prpDC (Fig. 12) to that of wild type growth without vitamin B12 (Fig. 11), the effect of 
increasing concentrations of vitamin B12 supplement on growth was assessed. Vitamin B12 
was titrated from 1 to 20µg/ml and found to be saturating for growth at 7.5µg/ml (Fig. 14). 
Therefore, the observed growth kinetics of ∆prpDC in propionate supplemented with 10µg/ml 
vitamin B12 (Fig. 12) established that supplementation with vitamin B12 was not growth 
limiting.  
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Fig. 12 Growth on propionate supplemented with 10 µg/ml vitamin B12.  
, H37Rv; , ∆prpDC; , complemented ∆prpDC mutant (∆prpDC::prpDC). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13 Vitamin B12 supplementation enables mutAB-dependent growth of a prpDC-
deficient mutant of H37Rv on propionate 
 , ∆prpDC; , ∆mutAB ∆prpDC; , ∆mutAB ∆prpDC double mutant containing the 
reverted mutAB allele (∆mutAB::mutAB ∆prpDC). 
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Fig. 14 Effect of vitamin B12 (cyanocobalamin) concentration on growth of the ∆prpDC 
mutant on propionate. 
The concentration of vitamin B12 was varied between 1 - 20µg/ml and the corresponding 
growth rate was plotted as a function of OD600 / time 
 
4.7 Determining propionyl-CoA partitioning through the methylcitrate 
cycle and methylmalonyl-CoA pathway by gene expression analysis 
The results from sections 4.3, 4.5 and 4.6 confirmed that both the methylcitrate cycle and the 
methylmalonyl pathway are functional in MTB. The individual operation of either pathway 
allows for growth on propionate (Fig. 5b and Fig. 12). However the relative contribution of 
either pathway to growth on vitamin B12-supplemented propionate was not known. In order to 
ascertain if the enhanced growth on vitamin B12 supplemented propionate relative to 
propionate (Fig. 5b ii and iii) was ascribed to the activity of both pathways, quantitative gene 
expression analysis by qRT-PCR was performed on selected genes from the two pathways 
(Fig. 15a). Levels of prpD, icl and mutB transcript were determined for bacteria cultured in 
propionate by real-time qRT-PCR and normalised against the values obtained from bacteria 
grown in Middlebrook 7H9 medium supplemented with 0.2% glycerol, OADC enrichment 
and 0.05% Tween 80 to assess any differential regulation of these genes in propionate vs 7H9. 
Further the effects of vitamin B12 on expression levels of these genes in propionate was 
evaluated. The methylcitrate cycle (prpD, icl) was transcriptionally responsive to a functional 
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methylmalonyl pathway as significantly different transcript profiles in the presence and 
absence of vitamin B12 were obtained (Fig. 15). A significant reduction in prpD (P < 0.0001) 
and icl (P < 0.0005) expression levels was observed concomitant with vitamin B12 
supplementation of the propionate-containing medium (Fig. 15b). Using transcript levels as a 
proxy for flux, the inference that significantly lower transcript levels of prpD in propionate 
with vitamin B12 (Fig. 15) corresponds to reduced flux through the methylcitrate cycle may be 
made. 
Paradoxically, mutB transcript is more abundant in propionate media relative to propionate 
supplemented with vitamin B12 (Fig. 15). The standard deviation for fold induction for mutB 
(Fig. 15) may reflect a high degree of heterogeneity in the sample population. It is also 
possible that raised expression of mutB in propionate in the absence of vitamin B12 is a 
compensatory  response illustrating the bacterium’s efforts for achieving optimal growth on 
this fatty acid. 
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Fig. 15 Quantitative expression analysis of methylcitrate cycle and methylmalonyl 
pathway genes in MTB 
a. Expression of prpD, icl and mutB genes of H37Rv cultured in propionate compared to 
7H9. 
H37Rv with () and without () vitamin B12. Insets denote expression of prpD, icl and mutB 
genes of H37Rv grown on propionate in the presence or absence of vitamin B12 compared to 
7H9. Significant differences in expression of prpD and icl in fatty acid carbon sources relative 
to the 7H9 control are denoted by a double asterisk (P < 0.0005) or single asterisk (P < 0.005). 
b. Using the data represented in insets from a. the fold induction of prpD, icl and mutB 
genes of H37Rv cultured in propionate compared to propionate supplemented with 
vitamin B12  is quantified. 
Comparative analysis in expression of prpD, icl and mutB transcript of H37Rv grown in 
propionate media in the presence and absence of vitamin B12. Significant differences in 
expression of prpD and icl  in propionate relative to propionate with vitamin B12 are denoted 
by a double asterisk (P < 0.0001) or single asterisk (P < 0.0005). 
 
 
 
4.8 Growth of MTB on propionate in the absence of the glyoxylate cycle 
Some microbes that metabolise propionate via the methylcitrate cycle require the glyoxylate 
cycle for carbon anaplerosis (Textor et al., 1997; Wang et al., 2003; Wegener et al., 1969). By 
definition, anaplerotic reactions are those that form intermediates of the TCA cycle. For 
example, pyruvate, the end product of the methylcitrate cycle, could be channeled into the 
TCA cycle metabolite pool by other compensatory anaplerotic enzymes which use pyruvate as 
a substrate, such as pyruvate carboxylase (pca) and malic enzyme (mez) (Fig. 1). Alternately 
conversion to acetyl-CoA by pyruvate dehydrogenase (PDH) would depend on anaplerosis by 
the glyoxylate route, contingent on ICL (Fig. 1). TCA cycle intermediates could also be 
replenished by the activities of glutamate dehydrogenase and methylmalonyl-CoA mutase. In 
MSM, the anaplerotic enzyme, PCA, is part of the same operon as the methylcitrate cycle 
genes, which may allow for growth on propionate in the absence of the glyoxylate cycle, i.e. a 
∆icl1∆icl2 mutant of MSM can grow on propionate (Upton and McKinney, 2007). In S. 
typhimurium, which similarly does not require the glyoxylate cycle for growth on propionate, 
pyruvate is converted to oxaloacetate by the sequential activity of PEP synthase and PEP 
carboxylase (Horswill and Escalante-Semerena, 1999). As MTB possesses a bifunctional ICL, 
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it is unknown whether this enzyme acts only in its capacity as a MCL for growth on 
propionate in conjunction with anaplerotic enzymes, pca and mez (Fig. 1).   
The advantages of having a propionate oxidizing pathway operate autonomously and 
independently from these other recognised anaplerotic enzyme was considered. Presumably, 
given that propionyl-CoA is converted to the TCA cycle intermediate, succinyl-CoA, by the 
methylmalonyl pathway, the activities of the other intact anaplerotic enzymes would be 
negligible.  
The question of whether the methylmalonyl pathway was able to support growth in the 
absence of the bifunctional ICL/MCL enzyme was therefore investigated. This line of 
investigation was prompted by significant downregulation of not only prpD but also icl 
transcript in the presence of vitamin B12. Having established that vitamin B12 supplementation 
could complement growth of the ∆prpDC mutant of H37Rv, the same remained to be 
demonstrated for ∆icl1. The lack of a complete methylcitrate and glyoxylate cycle in an ICL1 
mutant was proposed not to have any consequence in the presence of vitamin B12, given the 
above mentioned rationale. Surprisingly, however, MCM-mediated growth of the ∆icl1 
mutant on propionate with vitamin B12 supplement did not phenocopy that of the ∆prpDC 
mutant (Fig. 16). A two week lag phase was observed prior to the initiation of logarithmic 
growth. In other organisms,  growth inhibition on propionate in MCL mutants was shown to 
be due to the accumulation of 2-methylcitrate and/or 2-methylisocitrate, earlier intermediates 
in the methylcitrate cycle, which competitively inhibit the NADP-dependent isocitrate 
dehydrogenase (Brock, 2005; Cheema-Dhadli et al., 1975; Horswill et al., 2001; Plaut et al., 
1975). Similarly, it was speculated that in the absence of MCL activity, the buildup of 
intermediates from the methylcitrate cycle might account for the differences in growth of the 
∆icl1 and ∆prpDC mutants on vitamin B12-supplemented propionate. To test this idea , growth 
of ~∆prpDC∆icl1 (∆prpDC grown in the presence of 3NP as described below) , ∆icl1 and 
∆prpDC were compared on vitamin B12-supplemented propionate.  
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Fig. 16 The methylmalonyl pathway enables bypass of the glyoxylate cycle allowing 
growth of ∆icl1 on propionate supplemented with vitamin B12.  
Growth of ∆icl1 on propionate supplemented with vitamin B12 was compared to ∆prpDC and 
H37Rv. , ∆icl1; , ∆prpDC; , H37Rv; , ∆icl1::icl1  
 
3NP is a structural analog of succinate and a potent inhibitor of ICL (Honer Zu Bentrup et al., 
1999; Schloss and Cleland, 1982). As such, 3NP was found to be inhibitory to growth of MTB 
Erdman on acetate and propionate but not on glucose (Muñoz-Elias and McKinney, 2005; 
Sharma et al., 2000). Consistent with the findings in MTB Erdman, (Muñoz-Elias and 
McKinney, 2005) H37Rv was similarly unable to metabolise propionate in the presence of 
3NP (Fig. 17a). The growth of H37Rv with 3NP and vitamin B12 (Fig. 17a) correlated with 
growth of ∆icl1 (Fig. 16), displaying a consistent two-week growth delay in propionate with 
vitamin B12. This observation supported the specific inhibition of ICL by 3NP. Significantly, 
growth of ∆prpDC with vitamin B12 in the presence of 3NP was indistinguishable from 
growth of ∆prpDC with vitamin B12 supplement in the absence of 3NP (Fig. 17a). Since 
inactivation of  prpDC precluded flux of propionyl-CoA through the methylcitrate cycle, the 
differential response of wild-type and ∆prpDC to 3NP-mediated inhibition of ICL (MCL), 
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implicated the accumulation of toxic, growth inhibitory methylcitrate cycle intermediates in 
3NP-treated wildtype but not ∆prpDC strains, accounting for the lag observed in the former. 
Similar growth rates during log phase growth on propionate with vitamin B12 and 3NP were 
displayed by ∆prpDC and H37Rv (synonymous with the ∆icl1 mutant) (Fig. 16 and Fig. 17a). 
This confirms the theory that the anaplerotic methylmalonyl pathway alone is sufficient for 
growth of MTB on propionate with vitamin B12. Abrogation of MCM activity in the ∆mutAB 
mutant eliminated growth on propionate with vitamin B12 in the presence of 3NP (Fig. 17b) 
confirming that the effects of vitamin B12 supplementation were specifically mediated through 
MCM activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 17 The methylmalonyl pathway enables bypass of the glyoxylate cycle during 
growth of MTB on propionate.  
a. Growth of H37Rv on propionate in the presence of 3NP with () or without () vitamin 
B12 supplementation vs. ∆prpDC on vitamin B12-supplemented propionate with (∆) or without 
() 3NP. 
b. Growth of the ∆mutAB mutant on vitamin B12-supplemented propionate with () or without 
() 3NP 
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4.9 Emergence of suppressor mutants in response to metabolite stress 
To examine whether the growth that was observed following the two-week lag was due to that 
of a suppressor mutant, a ‘reconstruction’ experiment was performed (Rosenberg, 2001). 
Cultures of H37Rv grown on propionate with vitamin B12 and 3NP (Fig. 17a) and those of 
∆icl1 grown on propionate with vitamin B12 (Fig. 16) were passaged several times in 7H9 
media to eliminate residual traces of vitamin B12. These cultures were then used as inoculum 
into media where the conditions of the original experiment where reconstructed i.e. an aliquot 
of the passaged culture was used to inoculate vitamin B12-supplemented propionate with 
0.1mM 3NP. In the case of ∆icl, no 3NP was added. In both instances, growth rates after 
subculturing were comparable to that of H37Rv in vitamin B12-supplemented propionate 
without 3NP (Fig. 18 and data not shown), indicating that the growth observed in the original 
experiment was due to the presence of a suppressor mutant. Importantly, the two-week growth 
delay was eliminated and growth remained strictly vitamin B12 dependent. These observations 
suggested that a functional methylmalonyl pathway had allowed suppressor mutants to arise 
from 3NP inhibited cultures of H37Rv (and from ∆icl1; data not shown) possibly as a result of 
toxic metabolite accumulation imposing stress-induced mutagenesis.   
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Fig. 18 Vitamin B12-dependent growth in propionate of a suppressor mutant after serial 
passage in 7H9 
H37Rv suppressor mutants isolated from vitamin B12 supplemented  propionate with 3NP 
were serially passaged in 7H9 media and reintroduced into vitamin B12 supplemented 
propionate with () and without ()3NP. No growth of H37Rv suppressor mutants was 
observed in propionate with 3NP only ().  
 
 
Since the two-week delay was reproducible and observed independently with both the H37Rv 
and ∆icl1 strains, this suggested that mutants were not preexisting in the population as this 
would have been expected to result in variable growth kinetics. Assuming ~6 × 105 CFU/ml 
(as determined from cultures seeded at OD=0.01, results not shown) and a spontaneous 
mutation frequency of 10-6 -10-8, the emergence of mutants after 2 weeks would be feasible.  
To determine the molecular basis of this heritable genotypic adaptation, the prpDC locus of 
suppressor mutants which arose from cultures of H37Rv grown in propionate with 3NP and 
vitamin B12 (Fig. 17a) as well as ∆icl1 suppressor mutants grown in propionate with vitamin 
B12 (Fig. 16), was sequenced to identify any mutations, as mutations in the prpDC operon 
and/or its promoter region might be expected to recapitulate the ∆prpDC growth phenotype on 
vitamin B12 supplemented propionate with or without 3NP (Fig. 17a). However, no mutations 
were found in the prpDC genes or in the intergenic region between Rv1129c and Rv1130 
(sequenced ~500bp upstream of the Rv1130 ATG start codon spanning one third of Rv1129c). 
As a result,  the mechanism for bypass of ICL1 essentiality in the wild type strain during 
growth on propionate and vitamin B12 has yet to be identified.  
Damage-induced mutagenesis is mediated in MTB by the actions of specialised DNA 
polymerases, such as DnaE2 (Boshoff et al., 2003). In addition, DinB1 and DinB2 are MTB 
homologues of E. coli polIV (DinB) which has been implicated in ‘adaptive’ or stress-induced 
mutagenesis in that organism (Goodman, 2002). Therefore, to investigate the role, if any, of 
specialised DNA polymerases in the emergence of the suppressor mutants described above, 
the ability of strains deficient in these DNA polymerases to overcome the growth impairment 
on propionate supplemented with vitamin B12 and 3NP was tested. However, no differences in 
growth on propionate with vitamin B12 and 3NP were observed between wild type, dnaE2-
deficient and dinB1/dinB2-deficient strains were observed. A consistent, two-week growth 
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delay was observed in all strains (results not shown) further supporting the notion of a lack of 
pre-existing mutants in the starting culture and excluding a role for any of the specialised 
polymerases in induced mutagenesis by toxic methylcitrate cycle metabolite accumulation. 
 
4.10 Growth on C5 and C17 carboxylic acids 
Oxidation of longer odd-chain fatty acids releases derivative acetyl-CoA as well as propionyl-
CoA subunits. In this scenario, the potential of an active methylmalonyl pathway was 
considered. Should propionyl-CoA be diverted into the methylmalonyl pathway, ICL would 
be relieved of its role as a MCL, improving efficiency of the glyoxylate cycle. This ‘division 
of labor’ was proposed to enable the optimal use of such carbon sources. Therefore growth on 
longer odd-chain fatty acids was assessed.  
 
4.10.1 Growth on valerate 
 
Growth on valerate (C5) yields a 1:1 ratio of acetyl-CoA:propionyl-CoA.  H37Rv was found 
to grow poorly on valerate in the absence of vitamin B12 (Fig. 19a).  
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Fig. 19 Growth of MTB on valerate as a propionyl-CoA precursor 
a. Stimulatory effect of vitamin B12 on the growth of H37Rv and the ∆prpDC mutant on 
valerate (C5). H37Rv with () or without () vitamin B12; ∆prpDC with () or without () 
vitamin B12. 
b. Improved growth of H37Rv on vitamin B12-supplemented valerate is mutAB-dependent.  
∆mutAB with vitamin B12  (∆); ∆mutAB containing the reverted mutAB allele with vitamin B12  
(∆mutAB::mutAB)  ();  H37Rv with () or without () vitamin B12 
 
 
In the absence of propionyl-CoA metabolism through the methylmalonyl pathway, catabolism 
of both propionyl-CoA and acetyl-CoA through the methylcitrate and glyoxylate routes 
respectively, may result in a ‘bottleneck effect’, where a degree of toxic intermediate buildup 
as a result of inefficient streaming of these metabolites may possibly account for the retarded 
growth. This observation together with the significant downregulation of methylcitrate cycle 
genes in the presence of a functional methylmalonyl pathway on propionate (Fig. 15) strongly 
implied that partitioning of propionyl-CoA through the methylmalonyl pathway might avoid 
cytotoxic effects by methylcitrate cycle intermediates on valerate supplemented with vitamin 
B12. Indeed, growth was markedly improved on valerate supplemented with vitamin B12 
supporting this theory (Fig. 19a).  
The prpDC mutant of H37Rv could not grow on valerate, as established previously by 
Muñoz-Elías et al. for the Erdman strain (Muñoz-Elias et al., 2006). However, 
supplementation with vitamin B12 restored growth of ∆prpDC (Fig. 19a) presumably 
alleviating propionate toxicity resulting from the absence of both the methylcitrate cycle and 
methylmalonyl pathway. It was shown that the vitamin B12-dependent growth on valerate is 
mediated by mutAB and furthermore, that ∆mutAB with vitamin B12 on valerate grows as 
poorly as H37Rv without vitamin B12, which again confirms that vitamin B12 itself is not a 
regulator of the dynamic between these two propionate oxidizing pathways (Fig. 19b).  
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4.10.2 Comparative analyses of prpD, icl and mutB expression on different carbon 
sources 
 
Inspection of prpD, icl and mutB transcript levels during logarithmic growth on valerate with 
vitamin B12 indicated that levels of prpD and icl were further repressed than on propionate 
with vitamin B12 (Fig. 20)  
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 20 Expression of prpD , icl and mutB genes of H37Rv cultured on propionate or 
valerate in the presence of vitamin B12  
Levels of prpD, icl and mutB transcript were determined by real-time qRT-PCR and 
normalised against the values obtained from bacteria grown in Middlebrook 7H9 medium 
supplemented with 0.2% glycerol, OADC enrichment and 0.05% Tween 80 (7H9) to assess 
any differential regulation of these genes as a function of carbon source. Significant 
differences in expression of prpD and icl in fatty acid carbon sources relative to the 7H9 
control are denoted by a single asterisk (P < 0.0001) or a double asterisk (P < 0.005). 
 
 
This indicated that not only was propionyl-CoA catabolism being regulated largely by 
methylmalonyl pathway, as interpreted by low prpD levels, but also that the glyoxylate cycle 
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may not be active given the low icl levels. To test this, the growth of cultures on valerate in 
the presence of 3NP with and without vitamin B12 was assessed (Fig. 21a). This experiment 
showed that the effects of addition of 3NP to cultures grown on valerate were negligible in the 
presence of vitamin B12 supplement and again confirmed that vitamin B12-dependent growth 
on valerate in the presence of 3NP is mediated by mutAB (Fig. 21b). 
Whereas H37Rv was unable to grow (even partially) on valerate in the presence of the ICL 
inhibitor 3NP, growth of H37Rv with 3NP and vitamin B12 supplement was identical to that of 
∆prpDC with 3NP and vitamin B12 (Fig. 21a). The absence of differential growth between 
(H37Rv + vitamin B12 + 3NP) and (∆prpDC+ vitamin B12 + 3NP) was in stark contrast to the 
differential response on propionate (Fig. 17a).  
 
 
 
 
 
 
 
 
 
 
Fig. 21 Anaplerotic role for MCM revealed by growth of MTB on valerate with 3NP and 
vitamin B12 supplementation.  
a. Growth of H37Rv on valerate in the presence of 3NP with () or without () vitamin B12 
supplementation vs. ∆prpDC on vitamin B12-supplemented valerate with (∆) or without () 
3NP.  
b. Growth of ∆mutAB (∆) and ∆mutAB::mutAB  () on vitamin B12-supplemented valerate    
with 3NP. 
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This firstly implied that there was virtually no flux through the methylcitrate cycle which 
would presumably result in toxic intermediate buildup in the absence of ICL activity. The 
significant difference (P < 0.0001) in prpD levels between cultures grown on propionate with 
vitamin B12 relative to valerate with vitamin B12 (Fig. 20) coupled with the difference in 
growth phenotype of H37Rv with 3NP on vitamin B12 supplemented propionate vs. valerate 
suggested that transcript levels were reflective of flux.  Notably, the expression level of prpD 
in valerate supplemented with vitamin B12 was not significantly different from that observed 
in 7H9 broth (Fig. 20). Secondly, it implied the capacity of the methylmalonyl pathway to 
perform an anaplerotic function for assimilation of acetyl-CoA in the absence of the 
glyoxylate cycle. The apparent dispensability of ICL for growth of MTB on valerate was 
confirmed by identical growths of ∆prpDC in the presence or absence of 3NP (Fig. 21a). This 
was reinforced by the observation that the addition of 3NP had no effect on growth of H37Rv 
in the presence of vitamin B12 supplement (Fig. 22). 
 
 
 
 
 
 
 
 
 
 
Fig. 22 The operation of an autonomous methylmalonyl pathway bypasses the 
requirement for the glyoxylate cycle during growth of MTB on valerate 
Growth of H37Rv on vitamin B12-supplemented valerate with () or without () 3NP. 
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Paradoxically, the ∆icl1 mutant was found to be unable to grow on valerate in the presence of 
vitamin B12 (results not shown). The ICL enzyme may have some regulatory role on longer 
chain fatty acids which is important for isocitrate homeostasis at the ICL/ICD branchpoint, 
which had been disrupted in ∆ic1l.  
 
4.10.3 Growth on heptadecanoate 
 
Growth of H37Rv and the prpDC mutant was then assessed on the longer chain fatty acid, 
heptadecanoate (C17), the oxidation of which produces seven molecules of acetyl-CoA for 
each molecule of propionyl-CoA (7:1 ratio). In contrast to the findings on valerate, growth of 
H37Rv in the absence or presence of vitamin B12 was indistinguishable (Fig. 23). 
Furthermore, unlike growth on propionate (Fig. 11) and valerate (Fig. 19a), the ∆prpDC grew 
on heptadecanoate in the absence of vitamin B12 (Fig. 23), although initially, at a slightly 
slower rate than wild type. Vitamin B12 supplementation augmented growth of ∆prpDC on 
heptadecanoate. This implied that in the presence of a functional methylmalonyl pathway, 
propionyl-CoA may be predominantly catabolised through this route, as seemed to be the 
trend in cultures grown in propionate and valerate with vitamin B12 supplement. This would 
suggest that even though a functional methylmalonyl pathway appears dispensable for optimal 
growth on this carbon source as no visible growth advantage was afforded by vitamin B12 for 
H37Rv as seen on propionate (Fig. 5b. ii and iii) and valerate (Fig. 19a), the flux distribution 
through these central networks may differ in vitamin B12-supplemented vs. non-supplemented 
cultures. The anaplerotic contribution by a functional methylmalonyl pathway was not 
assessed, although it is probable that with increasing molar ratio of acetyl-CoA to propionyl-
CoA, anaplerosis by the methylmalonyl pathway progressively declines consistent with the 
dispensability of this pathway for growth of ∆prpDC on longer odd-chain fatty acids.  
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Fig. 23 Growth of MTB on heptadecanoate (C17)   
Growth of H37Rv with () or without () vitamin B12;  growth of ∆prpDC on heptadecanoate 
(C17) both with () and without () vitamin B12. 
 
 
 
It was considered that intracellular propionyl-CoA generated by the catabolism of 
heptadecanoate may be incorporated in methyl-branched lipids in ∆prpDC grown without 
vitamin B12. By extension, H37Rv grown on valerate may similarly divert propionyl-CoA into 
methyl-branched fatty acids. The activated methylmalonyl-CoA derivative from propionyl-
CoA was shown to be used as a substrate by M.  tuberculosis var. bovis cell extract to 
generate methyl-branched mycocerosic acids, providing direct evidence for elongation of  
preformed n- fatty acid primers with methylmalonyl-CoA (Rainwater and Kolattukudy, 1983). 
Each molecule of PDIM synthesised abstracts ten molecules of methylmalonyl-CoA from the 
intracellular  metabolite pool (Trivedi et al., 2005). Growth on valerate was thus compared 
between isolates of H37Rv producing either negligible amounts of PDIM (the standard 
laboratory strain employed in the MMRU (Kana et al., 2008)) or significant amounts of this 
lipid (H37Rv strain received as a kind gift from Prof. C. Sassetti. University of 
Massachusetts). The rationale for this comparison was that if the latter strain could incorporate 
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greater amounts of propionyl-CoA levels into this methyl-branched virulence lipid than the 
former, this would translate into improved growth on valerate without vitamin B12.  The 
results demonstrated that the high PDIM-producing isolate of H37Rv showed markedly 
improved growth on valerate that is independent of the requirement for vitamin B12 on this 
carbon source, compared to the poor PDIM producer strain employed in this study (Fig. 24).  
Growth of the two H37Rv strains on glycerol as a carbon source is identical. These results 
suggests that PDIM production may act to detoxify intracellular propionyl-CoA in MTB.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 24 Growth comparison on valerate between two variable PDIM-producing strains of 
H37Rv  
Differential growth of H37Rv producing lower () and higher () levels of PDIM. 
 
 
4.11 Growth of MTB on acetate with vitamin B12 
Growth of MTB on acetate requires the glyoxylate shunt (McKinney et al., 2000; Muñoz-
Elias and McKinney, 2005). Alternate acetate assimilation pathways have been described, and 
a common denominator is that all such characterised pathways require MCM activity (Alber et 
al., 2006; Erb et al., 2007; Erb et al., 2008; Ivanovsky et al., 1997; Korotkova et al., 2002; 
Korotkova et al., 2005). Assessing the MTB genome for alternative acetate assimilation 
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pathways using bioinformatics is complicated as the enzyme activities for all of the steps in 
these pathways have yet to be resolved. The possibility that MTB could utilise acetate in the 
absence of the glyoxylate shunt was therefore investigated experimentally. Acetate 
supplemented with vitamin B12 (to enable MCM) and 3NP (to inhibit ICL) did not support 
growth of MTB (Table 2). The results in Table 2 suggest that alternate acetate assimilation 
pathways are either not expressed or are not functional in MTB under standard growth 
conditions.  
 
 
 
 
Table 2. Growth on MTB on acetate supplemented with 3NP and vitamin B12. 
MTB grew on acetate media (+), but failed to grow in the presence of 3NP (-) regardless of 
vitamin B12 supplementation.   
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5 DISCUSSION  
 
In this work, mutants of MTB H37Rv impairing one or both of the recognised pathways for 
propionate oxidation were generated by allelic exchange mutagenesis. Flux through either 
pathway enabled growth of the mycobacterium on propionate, suggesting a redundancy of 
function for growth on propionate. Inhibition of both pathways abrogated growth on 
propionate, suggesting the presence of only these two functional pathway alternatives for 
propionyl-CoA catabolism in vitro (Fig. 2). 
 
5.1 The MTB gene complement for propionate oxidation 
In silico interrogation of the whole genome sequence of MTB indicated that this organism 
possesses two possible routes for the catabolism of propionyl-CoA, namely the methylcitrate 
cycle and the methylmalonyl pathway. All putative components of the methylmalonyl 
pathway were readily identified as being intact by homology searches suggesting a complete 
and functional pathway. Conversely, the methylcitrate cycle appeared incomplete as it lacked 
a homologue of prpB, which encodes MCL. MTB does not have the characteristic prpDBC 
gene cluster present in other actinomycetes such as C. glutamicum (Claes et al., 2002) and  
MSM  (Upton and McKinney, 2007) and appears to have undergone a probable deletion of 
prpB in this region. M. leprae, on the other hand, has lost the entire prpDBC operon but 
retains a complete MCM pathway (Cole et al., 2001). Potentially contributing to the apparent 
loss of prpB in MTB would be the presence of another protein having MCL function. A 
bifunctional ICL possessing MCL/ICL activity was considered as one possibility, as reported 
for several organisms (Brock, 2005; Horswill and Escalante-Semerena, 1999; Luttik et al., 
2000; McFadden et al., 1972; Pronk et al., 1994; Upton and McKinney, 2007). Another 
possibility was that PrpB activity in MTB is provided by Rv1998c which was identified as a 
member of the group of proteins included in COG2513. This group of proteins is part of the 
ICL/PEPM enzyme superfamily. Significantly, a member of COG2513 is E. coli PrpB, which 
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was the template with highest homology to Rv1998c selected by the Robetta server for 
modeling the tertiary structure of this CHP. On the basis of these findings, Rv1998c was 
hypothesized to provide non-orthologous MCL activity in MTB.  
5.2 MCM is not essential for propionate metabolism in MTB 
To assess the role of the methylmalonyl pathway in MTB H37Rv, the MCM-encoding mutAB 
genes were functionally inactivated and the mutant was assessed for growth on propionate. 
Surprisingly, no difference in propionate metabolism was observed between the parental and 
∆mutAB strains, indicating that the methylmalonyl pathway is dispensable for growth on 
propionate (Fig. 5) and confirming the existence of an alternate pathway(s) for propionate 
metabolism, specifically, the methylcitrate cycle (see section 5.5).   This finding contrasts with 
the situation in the actinomycetes Nocardia corallina, Aeromicrobium erythreum and S. 
cinnamonensis, where disruption of mutB abolished growth on propionate (Reeves et al., 
2004; Valentin and Dennis, 1996; Vrijbloed et al., 1999), indicating that, unlike MTB, these 
actinomycetes do not possess alternative pathways for propionate metabolism or that these 
pathways are negatively regulated by vitamin B12.  
5.3 Vitamin B12 supplementation facilitates operation of the 
methylmalonyl pathway 
Despite reports that MTB has a complete gene complement for coenzyme B12 biosynthesis 
(Rodionov et al., 2003), the results of a related study suggested that MTB does not synthesise 
the cobalamin cofactor in vitro (outside the living host). In that study, vitamin B12 
supplementation was shown to be required to support the function of the vitamin B12-
dependent methionine synthase, MetH (Warner et al., 2007). As vitamin B12 is also required 
as a cofactor for MCM, cyanocobalamin was included as a supplement in the growth medium 
and was found to stimulate growth of MTB on propionate (Fig. 5b. ii and iii). It was evident 
that increasing concentrations of propionate were metabolised less efficiently by the 
methylcitrate cycle in the absence of vitamin B12 supplement. Two possible explanations are 
proposed. (i) Higher concentrations of propionate require the synthesis of TCA cycle 
intermediates via induction of glyoxylate cycle enzymes in addition to the reliance on 
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anaplerotic enzymes such as malic enzyme or PCA (Muñoz-Elias et al., 2006) (ii) Should 
oxidation of propionyl-CoA via the methylcitrate cycle proceed to acetyl-CoA via the 
pyruvate dehydrogenase complex, inhibition of this enzyme complex by elevated levels of 
propionyl-CoA (Brock and Buckel, 2004; Maerker et al., 2005; Maruyama and Kitamura, 
1985) may explain the poor initial growth on 0.2% propionate, as activation and turnover of 
propionate needs to be balanced  (Brock and Buckel, 2004).  Supplementation with vitamin 
B12 eliminates this lag, consistent with the elimination, by supplementation with succinate, of 
an extended lag phase similarly displayed in E. coli cultures grown on propionate (Wegener et 
al., 1968a). 
The impaired growth of ∆mutAB on 0.1 and 0.2% propionate supplemented with vitamin B12 
relative to H37Rv indicated that the improved growth was mediated by MCM (Fig. 5b. ii and 
iii) and provided the first evidence that all of the reactions required for a complete 
methylmalonyl pathway are functional in MTB. Further, the identical growth of ∆mutAB on 
propionate in the presence of vitamin B12 to H37Rv grown on propionate in the absence of 
vitamin B12 (Fig. 5b. ii) indicates that the alternate pathway(s) for propionate assimilation are 
not negatively regulated by vitamin B12. However, although the independent operation of 
either propionate oxidation pathway in MTB is considered unlikely, from these observations 
alone it is not possible to determine whether the enhanced growth of H37Rv on vitamin B12-
supplemented propionate reflects operation of solely the MCM pathway, or a combination of 
pathways. Thus, further investigation of the methylmalonyl pathway in MTB was dependent 
on a concomitant investigation of the operation of the methylcitrate cycle. This study therefore 
probed the possible contribution of Rv1998c activity to propionate metabolism in MTB in 
parallel with studies on the methylmalonyl pathway.  
5.4 The unresolved function of Rv1998c in MTB  
Growth of the ∆mutAB mutant on propionate (Fig. 5) provided the first evidence that the 
putative methylcitrate cycle identified using bioinformatic analysis (section 4.4) was 
responsible for growth on this substrate in the absence of a functional methylmalonyl 
pathway.   
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Early reports that ICL1 and, to a lesser extent, ICL2 are required for growth on propionate in 
MTB (Muñoz-Elias and McKinney, 2005) could be interpreted in two ways. The first 
implicates a role for these enzymes as MCLs even though it had been reported that ICL cannot 
substitute for MCL for growth on propionate in other organisms (Bramer and Steinbuchel, 
2001; Brock, 2005; Claes et al., 2002; Horswill and Escalante-Semerena, 1999). The second is 
that the operation of the methylcitrate and glyoxylate cycles together are required for growth 
on propionate (Textor et al., 1997; Wang et al., 2003; Wegener et al., 1969) and that MCL 
activity is not provided by ICL. Rv1998c was identified as a potential candidate for providing 
MCL activity in MTB (Fig. 6 and Fig. 7). Studies reported during the course of this work 
subsequently revealed that ICL1 from MTB Erdman does indeed have dual ICL and MCL 
activity (Gould et al., 2006; Muñoz-Elias et al., 2006) although recombinant ICL2 had no 
MCL activity. Therefore, the poor growth of an ∆icl1 mutant on propionate could be as a 
result of another uncharacterised enzyme functioning as a MCL in the methylcitrate cycle with 
the further requirement for ICL2 exclusively in the glyoxylate cycle, supporting the notion 
forwarded above (Muñoz-Elias and McKinney, 2005).  
Rv1998c was initially over-expressed as a His-tag protein in E. coli and found to be insoluble 
under all conditions tested, in contrast to recombinant E. coli PrpB which was over-expressed 
in parallel as a soluble protein. The production of insoluble inclusion bodies when over-
expressing recombinant protein in E. coli is particularly pronounced with MTB proteins 
(www.webtb.org).  Further studies therefore focused on expression of Rv1998c in MTB under 
the control of a Tet-inducible promoter. Although RT-PCR analysis confirmed Tet-regulated 
over-expression of Rv1998c transcript in MTB, no MCL activity was detected in the crude cell 
extracts (Table 1). As expected, MCL activity was induced by growth of wild type MTB on 
propionate (Table 1; (Muñoz-Elias et al., 2006) thus validating the biochemical assay for 
MCL activity. The lack of activity could be due to inefficient translation of the Rv1998c 
transcript resulting in low protein levels. Alternatively, it is possible that Rv1998c protein was 
over-produced but has no MCL activity.  
A genetic approach was thus adopted to further investigate whether Rv1998c possesses MCL 
activity. Growth on the reduced carbon source, palmitate, results in up-regulation of the DosR 
regulon in MTB (Boshoff et al., 2004). As a member of the DosR regulon (Voskuil et al., 
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2003), induction of Rv1998c on propionate may account for the residual MCL activity 
observed in cell extracts from ∆icl1 Erdman (Muñoz-Elias et al., 2006). It was postulated, 
therefore, that the poor growth of ∆icl1 Erdman observed on propionate (Muñoz-Elias and 
McKinney, 2005) would be eliminated by loss of Rv1998c gene function . However, whereas 
H37Rv was readily transformed with the Rv1998c knockout construct to yield single 
crossover recombinants, no single crossovers were obtained in the ∆icl1 mutant of Erdman 
consistent with the markedly reduced frequency of homologous recombination in the Erdman 
strain of MTB compared to the H37Rv strain employed in this study (G. Abrahams, 
unpublished; J. McKinney, personal communication).  
An alternate hypothesis is that Rv1998c may play a role in propionate metabolism as part of a 
putative citramalate pathway in MTB. 2-Methylmalate is a metabolite in the citramalate 
pathway implicated in propionate oxidation (Textor et al., 1997), acetate assimilation 
(Ivanovsky et al., 1997) and autotrophic CO2 fixation (Herter et al., 2002b) (Fig. 25).  
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Fig. 25: Citramalate cycle adapted from Ivanovsky et al (2002) and Textor et al (1997).  
The scheme shows the citramalate cycle for acetate assimilation (right to left in blue) where 
acetate and pyruvate are condensed to citramalate by Cms; citramalate synthase (Ivanovsky et 
al., 1997; Meister et al., 2005; Xu et al., 2004). Cms from Leptospira interrogans has highest 
homology  (31% identity, 52% similarity) to hsaF (in the KstR regulon (Kendall et al., 2007b; 
Van der Geize et al., 2007) of MTB. Further the scheme shows the citramalte cycle for 
propionate oxidation (left to right in red) (Friedmann et al., 2007; Herter et al., 2002a; Textor 
et al., 1997) where propionyl CoA and glyoxylate are condensed to  β-methylmalyl-CoA by 
Mcl; L-malyl-CoA lyase/β-methylmalyl-CoA (Meister et al., 2005). Mcl from R. capsulatus 
has highest homology (31% identity, 44% similarity) to the CHP Rv3075c of  MTB. 
Following dehydration/hydration of β-methylmalyl-CoA by unknown enzymes to 2-
methylmalate, cleavage to acetate and pyruvate is postulated by Rv1998c.   
 
2-Methylmalate was identified as a substrate for PDP, a member of the ICL/PEPM enzyme 
superfamily whose broad substrate activity also includes 2-methylisocitrate, as mentioned 
previously. If Rv1998c displays similar diversity of function, it is possible MTB possesses a 
citramalate pathway that may function in propionate oxidation in MTB. To test this 
hypothesis, growth of the ∆prpDC mutant expressing Rv1998c under the control of a Tet-
regulated promoter was assessed in propionate media. Tet-induced expression of Rv1998c 
was unable to facilitate growth of this mutant on propionate (results no shown) suggesting that 
further biochemical studies would be required to establish whether a citramalate pathway for 
propionate oxidation, having Rv1998c perform as a putative citramalate lyase, exists in MTB. 
Conceivably, genes of the citramalate pathway may be induced only under certain in vivo 
conditions.  
5.5 Conditional essentiality of ∆prpDC for growth on propionate  
During the course of this study, elegant work by others (Muñoz-Elias et al., 2006) 
demonstrated the essentiality of the methylcitrate cycle for growth of MTB Erdman on 
propionate. The contribution of the methylcitrate cycle to propionate metabolism in H37Rv 
MTB was therefore investigated by the construction of a mutant strain lacking the prpDC 
genes, which encode the first two enzymes of the cycle (Fig. 2). As observed in Erdman 
(Muñoz-Elias et al., 2006), loss of prpDC also abolished growth of H37Rv MTB on 
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propionate (Fig. 11). However, the conditional essentiality of the methylcitrate cycle in vitro 
(Fig. 11) was shown to be due to the vitamin B12 auxotrophy of MTB, as growth of ∆prpDC 
on propionate was observed provided the media was supplemented with vitamin B12 (Fig. 12). 
The fact that growth of ∆prpDC on propionate with vitamin B12 supplement was abrogated by 
loss of mutAB function (Fig. 13) confirmed the essential role of the vitamin B12-dependent 
activity of MCM in growth of the ∆prpDC mutant on propionate. Furthermore, the finding 
that supplementation with exogenous cyanocobalamin (vitamin B12) is able to support the 
activity of MCM (Fig. 12 and Fig. 13)  confirms that MTB can not only assimilate vitamin B12 
from the environment, but also has a functional ATR system for enzymatic conversion of 
vitamin B12 to the active form of the cofactor. Together, these observations establish 
unambiguously the existence of a functional methylmalonyl pathway in MTB.  
 
5.5.1 A  functional methylmalonyl pathway in MTB  
 
Propionate incorporation into resting cells of MTB (Yano and Kusunose, 1966) contributed to 
earlier evidence supporting the activity of PCC in mycobacteria. Subsequently, variable PCC 
activity was reported in MSM cultured under different conditions (Wheeler et al., 1992), for 
which the quaternary structure of the PCC complex was available (Haase et al., 1982). The 
main role of the recently characterised αAccA3-βAccD5-εAccE5 biotin-dependent PCC 
complex of MTB is proposed to be the synthesis of methylmalonyl-CoA (Gago et al., 2006; 
Oh et al., 2006). In MSM, the AccD5 orthologue, together with AccA3 and AccD4, comprise 
the subunits of the ACC involved in mycolic acid biosynthesis (Portevin et al., 2005), 
suggesting a broader role for the AccD5 carboxytransferase β-subunit in MTB. In C. 
glutamicum, linear chain ketoacyl derivatives are substrates for carboxylase complexes 
essential for mycolic acid synthesis (Gande et al., 2004; Gande et al., 2007); specifically, 
AccD2 and AccD3 constitute the β subunits of the carboxylase involved in mycolic acid 
synthesis (Gande et al., 2004; Gande et al., 2007). Supporting a broader role for AccD5 in 
mycolic acid biosynthesis, an accD2 mutant of C. glutamicum, the orthologue of accD5 in 
MTB (Gande et al., 2007) is deficient in mycolic acid production (Gande et al., 2004). Efforts 
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are been made to design inhibitors against the PCC of MTB (Lin et al., 2006b) using the 
crystal structure of AccD5 (Holton et al., 2006; Lin et al., 2006b), given the essentiality of the 
subunit components in vitro (Holton et al., 2006; Sassetti et al., 2003).  
MCM requires the (R)-epimer of methylmalonyl-CoA as a substrate. The putative epimerase 
responsible for the conversion to this stereoisomer was identified as Rv1322A. However, the 
promiscuous α-methylacyl CoA racemase (MCR ; Rv1143) which is intimately involved in 
the β-oxidation of methylbranched fatty acids originating from isoprenoids, has reported 
racemization activity with methylmalonyl-CoA thioester and might provide redundant 
activity. Its wide range of substrates includes pristanic acid. MCR is essential in mycobacteria  
for the oxidation of this carboxylic acid (Sakai et al., 2004). Conceivably, the propionyl-CoA 
liberated during β-oxidation is carboxylated to (S)-methylmalonyl-CoA, which is further 
dependent on this MCR for conversion to the corresponding (R)-methyl enantiomer in a 
reaction that is cobalt dependent, interestingly so, given the cobalt requirement for the B12 
coenzyme (Bhaumik et al., 2007).  Should growth on vitamin B12-supplemented propionate be 
abolished in a strain where both prpDC and Rv1322A have been deleted, redundant epimerase 
activity by MCR could be excluded.  
 
Vitamin B12 was titrated to establish the optimal concentration of this supplement for growth 
of the ∆prpDC mutant on propionate (Fig. 14). However growth of ∆prpDC equivalent to that 
of wildtype (with or without vitamin B12) could not be obtained, even with saturating 
concentrations of vitamin B12 (>7.5 µg/ml). The following possibilities were considered: 
i. Propionate oxidation via the methylmalonyl pathway may not be as efficient as via the 
methylcitrate cycle as growth of ∆prpDC with vitamin B12  (Fig. 12) was poorer than 
wild type without vitamin B12 (Fig. 11). However, this is unlikely in organisms where 
close co-operation of the methylcitrate and glyoxylate cycles exists (Textor et al., 
1997; Wang et al., 2003; Wegener et al., 1969) as it undermines the rate of energy 
flow by circumventing two NADH-generating reactions of the TCA cycle, and also 
fails to harness the ATP-generating potential of the propionyl-CoA metabolite from 
substrate level phosphorylation at the succinyl-CoA synthase junction common to the 
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methylmalonyl pathway and TCA cycle (Hamblin et al., 2008). The methylmalonyl-
CoA pathway therefore appears the more efficient route for propionate metabolism.  
ii. The operation of the methylmalonyl pathway is constrained either by inefficient uptake 
or adenosylation of vitamin B12 which leads to insufficient coenzyme. However, a 
metE mutant grows as well as wild type suggesting efficient transport of vitamin B12 
(Warner et al., 2007) despite the  apparent absence of a specific high affinity 
transporter system (Rodionov et al., 2003). The B12-dependent MetH and MCM 
enzymes require a different form of cofactor for activity, namely, methylcobalamin vs. 
adenosylcobalamin. Therefore, processing of exogenous vitamin B12 to the active 
coenzyme subsequent to uptake may rather be the rate-limiting step.  
iii. Insufficiency in other aspects of the methylmalonyl pathway such as CO2 for 
carboxylation of propionate or constitutively low levels of MCM itself (see section 
5.6) is a further possibility. Growth on propionate may be enhanced by the addition of 
biotin or sodium bicarbonate by stimulating PCC activity, as has been reported in 
mycobacteria (Wheeler et al., 1992) and other organisms (Evans et al., 1993; 
Maruyama and Kitamura, 1985). Preliminary examinations of ∆prpDC grown in 
propionate with vitamin B12 in a 5% CO2 humidified incubator surprisingly revealed 
no growth for ∆prpDC, although wild type cultured under identical conditions grew 
well (data not shown), consistent with the reported stimulatory effects of 5% CO2 on 
growth of MTB
  
(Schaefer et al., 1955)
. 
A plausible explanation for these observations 
is that rate-limiting enzymes downstream of PCC may result in buildup of 
methylmalonyl-CoA as a result of the increased flux through this pathway. In 
Caenorhabditis elegans, accumulation of this metabolite produced increased amounts 
of growth inhibitory methylmalonic acid in the culture media (Chandler et al., 2006). 
iv. Propionyl-CoA may, in the absence of prpC, competitively inhibit citrate synthase 
(Horswill et al., 2001; Man et al., 1995) counteracting the growth stimulatory effects 
of an active methylmalonyl pathway. Should this be the case, it is clear that the citrate 
synthase cannot be that proficient in making 2-methylcitrate as the low levels 
produced are not enough to arrest cell growth in the presence of vitamin B12.  
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The poorer growth on propionate supplemented with vitamin B12 of both ∆prpDC (Fig. 12) 
and ∆mutAB mutants (Fig. 5b. ii) relative to the wild type strain (Fig. 5b. ii) reinforced the 
notion that the additive effects of two propionate oxidizing pathways are required for optimal 
growth on this fatty acid carbon source. If the methylmalonyl pathway alone was responsible 
for improved growth on propionate supplemented with vitamin B12 (Fig. 5b. ii and iii) and if 
the methylcitrate pathway is negatively regulated by vitamin B12, then growth of the ∆prpDC 
would be identical to that of the wild type with vitamin B12 supplement and the ∆mutAB 
mutant would not be expected to grow. In the case of the two methionine synthases, MetE and 
MetH, their activity  is mutually exclusive as exogenous vitamin B12 represses transcription of 
metE by binding to the upstream B12-riboswitch motif present in  the promoter region of this 
gene (Warner et al., 2007).  Since only two B12-riboswitch motifs have been identified in the 
MTB genome, the other located immediately upstream of PPE2 (Rodionov et al., 2003; 
Vitreschak et al., 2003), the methylcitrate cycle in MTB is not subject to this regulatory 
mechanism (∆mutAB grows in the presence of vitamin B12, unlike ∆metH (Warner et al., 
2007)). Thus the observations in this study suggested a synergistic interaction between the 
vitamin B12-dependent methylmalonyl pathway and vitamin B12-independent methylcitrate 
cycle. To further investigate this relationship, their regulation was therefore probed by gene 
expression analysis.  
 
5.6 Transcriptional analysis of prpD, icl and mutB 
Global regulation of gene expression by transcription factors (Martinez-Antonio and Collado-
Vides, 2003) or bifunctional proteins active in both metabolism and control of gene 
expression, (known as trigger enzymes; (Commichau and Stulke, 2008)), is generally the 
mainstream control of flux distribution. In this study, the levels of transcript for selected genes 
in the methylmalonyl pathway and methylcitrate cycle were investigated as an indicator of 
intracellular flux distribution through the pathways. In other organisms, a correlation between 
gene expression and metabolic activity  on propionate has generally been observed for the 
methylcitrate cycle (Claes et al., 2002; Huser et al., 2003; Plassmeier et al., 2007). In MTB, 
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the genes of the methylcitrate cycle (prpD and icl) were found to be significantly upregulated 
in propionate compared to propionate supplemented with vitamin B12  (Fig. 15). The reduced 
levels of prpD and icl transcript implied that the improved growth on B12-supplemented 
propionate (Fig. 5b. ii and iii) may be largely due to the activity of the methylmalonyl 
pathway rather than upregulation of both pathways simultaneously. Paradoxically, however, 
growth of ∆prpDC (Fig. 12) is significantly poorer than wild type (Fig. 5b. ii and iii) on 
propionate media supplemented with vitamin B12.  
The downregulation of prpD and icl in response to vitamin B12 supplementation is interesting 
given the lack of an identifiable upstream B12-riboswitch in the promoter regions of these 
genes.  Instead, this transcriptional responsiveness is probably regulated by propionyl-CoA 
and derivative metabolite levels rather than by vitamin B12, since ∆mutAB grows similarly on 
propionate in the presence and absence of this supplement (Fig. 5b. ii). If vitamin B12 was 
directly responsible for influencing a reduction in prpD and icl transcript, a reduced growth 
rate for ∆mutAB on B12-supplemented propionate relative to propionate would be expected. 
Presumably, vitamin B12 facilitates propionate regulation indirectly by enabling MCM 
activity, which influences the intracellular metabolite profile.  
However, it is recognised that induction at the transcriptional level does not always reflect the 
level of flux or enzyme activity in these pathways. This is exemplified by the fact that there 
was virtually no induction of mutB in B12-supplemented propionate cultures (Fig. 15) despite 
the modest contribution to growth by this pathway, as evidenced by growth of ∆prpDC in 
propionate with vitamin B12 (Fig. 12). This is contrary to the observed B12-riboswitch located 
upstream of mutA in P. shermanii (Vitreschak et al., 2003), which suggests that in this 
actinomycete, MCM would be transcriptionally responsive to vitamin B12. In MTB, the 
absence of induction may suggest that given the remarkably accelerated reaction rate of this 
enzyme (Chowdhury and Banerjee, 2000; Doll and Finke, 2003) constitutive levels of MCM 
suffice, which are able to support any measurable flux through the pathway. Furthermore, 
given the very low rate of generation of inactive mutases (Padovani and Banerjee, 2006; 
Vlasie and Banerjee, 2004; Yamanishi et al., 2005), a low, steady-state turnover of the protein 
is maintained. Consistent with the findings of this study, it is worth noting that numerous 
studies profiling the global transcription of MTB genes under different conditions have not 
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found mutAB to be highly responsive. Insertion of the mazEF-type TA module inserted 
between mutAB and the putative meaB of MTB may have selected for constitutive low 
expression of this operon, since fluctuations in mazEF transcript levels could conceivably 
result in an excess of the stable toxin over the unstable antitoxin with negative consequences 
for the bacterium. Tight regulation of mutAB might therefore account for the poorer growth of 
∆prpDC relative to wildtype on vitamin B12-supplemented propionate.   
In future studies, metabolic analysis using 1,2-[13C]-propionate could be done to distinguish 
the partitioning between these two pathways. Specifically, the  coupling interaction of 13C-
13C-12C of the propionate carbon skeleton would be preserved with flux through the 
methylcitrate cycle as it is converted to pyruvate, where it is lost in the randomizing 
methylmalonyl pathway, as demonstrated in E. coli (London et al., 1999). The relative 
contribution of these pathways to the formation of alanine (or its pyruvate precursor) could be 
calculated from the abundance of the different mass isotopes. Developments made in 
extraction protocols for metabolome analysis in mycobacteria make such future studies 
feasible (Jaki et al., 2006).  
 
 
5.7 Bypassing the requirement for the glyoxylate cycle for growth on 
propionate by the methylmalonyl pathway 
In this study, carbon anaplerosis by the methylmalonyl pathway independent of the glyoxylate 
cycle on the fatty acids, propionate and valerate (see section 5.9), was demonstrated. Growth 
on odd-chain fatty acids has been noted in the absence of virtually any glyoxylate cycle 
activity (Blevins and Perry, 1972; Evans et al., 1993) or in mutants defective for the 
glyoxylate cycle (Horswill and Escalante-Semerena, 1999; Nieder and Shapiro, 1975; Sakai et 
al., 2004; Upton and McKinney, 2007). These observations suggested that in some organisms, 
propionate metabolism is divorced from the glyoxylate cycle. In the absence of carbon 
anaplerosis through this pathway, other candidate anaplerotic enzymes were obviously 
supporting growth on this fatty acid although no studies have been done to elucidate which 
may have been responsible. By deduction, if propionate is metabolised to pyruvate through 
one of several previously described routes, malic enzyme, pyruvate carboxylase, or PEP 
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synthase and PEP carboxylase would be individually or collectively responsible for ‘topping 
up’ of TCA cycle intermediates (Fig. 1).  
In this study, an icl1 mutant of MTB was shown to be able to grow on B12-supplemented 
propionate in the absence of both the methycitrate and glyoxylate cycles (Fig. 16). Similarly, 
inhibition of ICL with 3NP allowed for growth of MTB on propionate subject to 
supplementation with vitamin B12 (Fig. 17a). This growth was shown to be mediated by 
mutAB (Fig. 17b). There are two known pathways which form C4 acids directly from 
propionate. For the first pathway, Reeves and Ajl (1962) reported the synthesis of α-
hydroxyglutarate from propionyl-CoA and glyoxylate catalyzed by cell-free extracts from E. 
coli grown on propionate. α-Hydroxyglutarate is metabolised to succinate although no attempt 
was made to purify the enzyme and to elucidate its mechanism of action (Reeves and Ajl, 
1962; Wegener et al., 1968b). α-Hydroxyglutarate synthase is not expected to function in the 
absence of ICL (Wegener et al., 1968a; Wegener et al., 1969). The second is the anaplerotic 
methylmalonyl pathway.  
Despite the significantly reduced levels of prpD in propionate with vitamin B12 relative to 
propionate alone (Fig. 15), the methylcitrate cycle was still partially active as evidenced by 
the growth delays of ∆icl1 in propionate with vitamin B12 and H37Rv in propionate with 
vitamin B12 and 3NP when compared to ∆prpDC, confirming that the growth delay was a 
result of the build-up of toxic 2-methylcitrate/2-methylisocitrate metabolites (Brock, 2005; 
Cheema-Dhadli et al., 1975; Horswill et al., 2001; Plaut et al., 1975). Similar toxic 
intermediate buildup has been reported by function impairment of the methylcitrate cycle in 
Ralstonia eutropha (Bramer and Steinbuchel, 2001), MSM (Upton and McKinney, 2007) and 
C. glutamicum (Plassmeier et al., 2007). However, this does not necessarily detract from the 
ability of the methylmalonyl pathway to support growth independently of ICL. Together, 
these observations provide conclusive evidence that the methylmalonyl pathway bypasses the 
need for anaplerosis via the glyoxylate cycle and is sufficient for the growth of MTB on 
propionate as the sole carbon source, provided that the vitamin B12 cofactor requirement for 
MCM activity are met.   
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Unlike MTB, MSM produces vitamin B12 in vitro  (Karasseva et al., 1977)(S. Dawes, personal 
communication). In MSM the growth of ∆ic1l∆icl2, ∆prpDBC and ∆prpDBC∆ic1l∆icl2 
mutants on propionate (Upton and McKinney, 2007) could therefore be attributed to a putative 
methylmalonyl-CoA pathway (Stjernholm et al., 1962; Wheeler et al., 1992). A 
∆prpDC∆mutAB mutant would confirm if the methylmalonyl pathway is functional and/or if 
another propionate oxidizing pathway is present in MSM. This is the focus of ongoing studies 
in the MMRU. Notably, 3NP inhibits growth of MSM on acetate (Muñoz-Elías, 2005). 
However, preliminary findings suggested that 3NP does not inhibit growth of a ∆mutAB 
mutant of MSM on propionate (data not shown) in contrast to the 3NP-mediated inhibition of 
MTB grown on this carbon source (Fig. 17). Assuming that propionate oxidation in MSM 
occurs only via the methylmalonyl pathway and methylcitrate cycle, these observation suggest 
that 3NP specifically inhibits ICL and not the MCL of MSM and that MSM is able to oxidise 
propionate in the absence of carbon anaplerosis by the glyoxylate cycle or methylmalonyl 
pathway. In this case, anaplerosis is presumably orchestrated by pca (Fig. 1) which, in MSM, 
is transcribed as part of the  methylcitrate cycle gene operon (Mukhopadhyay and Purwantini, 
2000). These findings contrast with the essential requirement of the glyoxylate cycle by some 
microorganisms during growth on propionate (Textor et al., 1997; Wang et al., 2003; 
Wegener et al., 1969).  
5.8 Genotypic adaptation of ∆icl1 to growth on B12-supplemented 
propionate  
As described above, toxic metabolite buildup could account for the retarded growth of ∆icl1 
on propionate with vitamin B12 (Fig. 16), H37Rv with 3NP on propionate with vitamin B12 
(Fig. 17a) and also, of H37Rv on valerate without vitamin B12 (see section 5.9 below). 
Positive feedback by 2-methylcitrate is regulated by the transcriptional activator, PrpR, in S.  
enterica (Palacios and Escalante-Semerena, 2004). The genes for propionate oxidation in S. 
enterica are located in two adjacent divergently transcribed units, prpR and prpBCDE 
(Horswill and Escalante-Semerena, 1997). Closer examination of the prpDC locus in MTB 
displays a similar gene arrangement, having a 20bp intergenic region between prpDC and a 
putative transcriptional regulatory protein (Rv1129c) transcribed in the reverse orientation. 
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Rv1129c is induced (17-fold) with prpDC in activated macrophages (Schnappinger et al., 
2003). A similar feedback mechanism may occur in MTB through buildup of 2-
methylcitrate/2-methylisocitrate in the absence of ICL (Palacios and Escalante-Semerena, 
2004). This may be particularly relevant to the attenuated phenotype observed for an ICL 
mutant in vivo (Muñoz-Elias and McKinney, 2005), and reinforces the importance of 
investigating the regulation of the methylcitrate cycle in MTB. As a result, ICL may be 
essential for its MCL activity rather than for its role in the glyoxylate or PEP-glyoxylate 
cycles. Supporting this possibility is the following: (i) unlike icl, glcB encoding MLS is not 
upregulated in the lungs of chronically infected mice (Timm et al., 2003); and (ii) the apparent 
attenuation of a ∆prpD but not a ∆prpDC in mice (Mattow et al., 2006). However, if this were 
the case, one would expect that an icl1 mutant would be as severely attenuated as ∆icl1∆icl2 
(McKinney et al., 2000; Muñoz-Elias and McKinney, 2005) assuming that no MCL activity is 
afforded by ICL2. Should another enzyme function as a MCL (accounting for the growth of 
the ∆icl1 on propionate), then the suggestion that ICL is essential by virtue of its role as a 
MCL would be invalidated.   
Genetic adaptation, presumably in response to metabolite stress, was revealed by isolating 
suppressor mutants from H37Rv grown in propionate with vitamin B12 and 3NP (Fig. 17) as 
well as from ∆icl1 grown in propionate with vitamin B12 (Fig. 16). The prpDC locus was 
sequenced for any mutations that might abrogate the activity of the enzymes responsible for 2-
methylcitrate / 2-methylisocitrate buildup. However, no mutations were detected at this locus 
in two independent suppressor mutants. The  5' coding region of Rv1129c was also sequenced 
as lesions which altered prpR activity had found to map to the N-terminal domain of the 
protein in S. enterica (Palacios and Escalante-Semerena, 2004), but no mutations were 
uncovered. CobB, an enzyme of the cobalamin biosynthetic pathway is a co-regulator of the 
of prpBCDE operon  in S. typhimurium (Tsang et al., 1998). Therfore cobB in MTB will be 
examined for lesions in ongoing studies.  
Preliminary investigations found that the specialised polymerases DnaE2 and DinB1/DinB2  
were not involved in the emergence of suppressor mutants under conditions of metabolite 
stress investigated in this study (Fig. 18). Interestingly, PolI mutants in S. typhimurium are 
unable to grow on propionate as a carbon source (Rondon et al., 1995) owing to the 
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production of reactive intermediates during propionate catabolism by the methylcitrate cycle 
which exert damaging effects on DNA that require PolI editing function during DNA 
replication. Therefore, in the presence of an alternate propionate oxidizing pathway, selection 
for mutations which inactivate the methylcitrate cycle is likely to be strong. It has yet to be 
established whether stress-induced mutagenesis plays any role in facilitating the emergence of 
suppressor mutants under these conditions.   
5.9 Growth on valerate as a carbon source 
In this study H37Rv MTB was found to grow poorly on valerate, a C5 substrate which yields 
acetyl-CoA and propionyl-CoA subunits in equal proportion. ICL has a considerably  higher 
affinity for isocitrate (Km =180 µM) than 2-methylisocitrate (Km = 718 µM) (Gould et al., 
2006). Very low levels of 2-methylcitrate / 2-methylisocitrate are considered sufficient to 
arrest growth (Brock, 2005; Horswill et al., 2001) which raises the question as to whether 
efficient clearance of these metabolites would occur if ICL catabolises propionate (through the 
methylcitrate cycle) and acetate (through the glyoxylate cycle) simultaneously. The poor 
growth of H37Rv on valerate (Fig. 19a) is therefore thought to be due to the potentially 
crippling effects of methylcitrate cycle intermediate buildup, analogous with the delayed 
growth of ∆icl1 in vitamin B12 supplemented propionate (Fig. 16) The compromised growth 
of H37Rv on valerate raises question as to the physiological relevance of ICL as an MCL 
given its apparently limited capacity to catalyse both reactions simultaneously. However 
should MTB encounter only longer chain fatty acids (see section 5.10)  and/or cholesterol 
(Pandey and Sassetti, 2008) in vivo low levels of MCL activity may be sufficient.   
The findings on propionate established that the methylmalonyl-CoA pathway can metabolise 
propionate independently of the methylcitrate and glyoxylate cycles. However, the dual 
operation of the methylmalonyl pathway and the glyoxylate cycle may be required for optimal 
growth on valerate. Indeed, the markedly improved growth on valerate in the presence of 
vitamin B12 suggested the regulated partitioning of propionyl-CoA into the methylmalonyl 
pathway and acetyl-CoA into the TCA cycle.  
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The transcriptional data for growth on valerate  are consistent with propionate oxidation 
primarily through the methylmalonyl pathway (Fig. 20). Further downregulation of prpD and 
icl expression on valerate with vitamin B12 relative to propionate with vitamin B12 suggests 
that flux through the methylcitrate and glyoxylate cycle is minimal. This is also consistent 
with metabolite rather than vitamin B12-mediated regulation of transcription.  
The key finding that no differential phenotype could be detected in theH37Rv vs. ∆prpDC for 
growth on valerate in the presence of 3NP and vitamin B12 (Fig. 21a) reinforced the notion 
that methylmalonyl pathway  is the default route for propionyl-CoA oxidation in the presence 
of vitamin B12 and acetyl-CoA (derived from valerate). On valerate with vitamin B12, 
chemical inhibition of ICL with 3NP (Fig. 21a) did not result in the 2-methylcitrate / 2-
methylisocitrate-mediated growth inhibitory effects observed on propionate with vitamin B12 
(Fig. 17a), consistent with the 2.6-fold lower level of prpD expression in vitamin B12-
supplemented valerate compared to propionate. (Fig. 20). Furthermore, the expression data 
suggested an absence of any significant prpD induction in valerate with vitamin B12 relative to 
7H9 (Fig. 20). Therefore, these findings suggest that in the presence of an active 
methylmalonyl pathway, the flux through the methylcitrate cycle is substantially reduced in 
cultures grown on valerate. This reflects an important facet of propionate regulation at the 
PCC/MCS junction. The marked upregulation of prpDC genes (Schnappinger et al., 2003) in 
macrophages may be an indication that vitamin B12 is unavailable ex vivo, and may explain 
the requirement of prpDC for MTB replication in macrophages (Muñoz-Elias et al., 2006).  
5.9.1 Anaplerotic role for the methylmalonyl pathway on valerate 
  
Growth of H37Rv on valerate with vitamin B12 was unaffected by the presence of 3NP (Fig. 
21a). This demonstrates the anaplerotic contribution of the methylmalonyl pathway, as growth 
on a theoretical mixture of propionate and acetate is supported in the absence of a glyoxylate 
cycle. The robust growth on valerate with 3NP in the presence of vitamin B12 confirms that 
the generation of energy equivalents by the active TCA cycle satisfies the demand for 
gluconeogenesis on this fatty acid carbon source. Therefore, the expression data, the absence 
of putative toxic methylcitrate cycle intermediate accumulation (Fig. 21a) and the 
dispensability  of glyoxylate cycle (Fig. 22) together substantiates the methylmalonyl pathway 
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as the preferred route for propionate metabolism and establishes the fundamental role of the 
methylmalonyl pathway in anaplerosis. 
The finding that the ∆icl1 mutant was unable to grow on valerate despite vitamin B12 
supplementation was unexpected as it was not consistent with the robust growth observed for 
H37Rv on vitamin B12-supplemented valerate in the presence of 3-NP. Singh and Ghosh 
predicted approximately 24% flux through the glyoxylate cycle in the presence of 0.1mM 3NP 
(Singh and Ghosh, 2006). Therefore, one possible explanation for the lack of growth of the 
∆icl1mutant on vitamin B12-supplemented valerate is that some minimal threshold activity 
regulates metabolite flow at the ICL/ICD (glyoxylate cycle/TCA) branch point preventing the 
buildup of derivative acetyl-CoA. Acetate inhibition of growth has been shown to arise from 
the depletion of intracellular methionine pools with the concomitant accumulation of the toxic 
intermediate, homocysteine (Roe et al., 2002a). Alternatively, some baseline activity of ICL 
(~24%), while not sufficient to support growth on valerate with 3NP (Fig. 21a), may be 
adequate to prevent 2-methylcitrate/2-methylisocitrate buildup from propionyl-CoA that 
potentially ‘overflows’ into the methylcitrate cycle on vitamin B12 supplemented valerate with 
3NP.  Three independent lines of evidence support this notion. (1) No anaplerosis by the 
glyoxylate cycle is necessary on valerate with vitamin B12 when the methylmalonyl pathway 
predominates (Fig. 22). Growth on valerate with vitamin B12 is orchestrated by the 
methylmalonyl pathway in conjunction with the TCA cycle. (2) Extremely low levels of 2-
methylisocitrate are sufficient to inhibit ICD (Brock, 2005; Horswill et al., 2001) and, has 
been shown that in response to such inhibition, the specific activity of ICD is increased 
(Brock, 2005). (3) ICL and ICD compete for a common substrate (Walsh and Koshland, 
1985), so given the rather low affinity of ICL for isocitrate relative to ICD (Holms, 1987), the 
residual ICL may, by default, fulfill a dedicated MCL function. Therefore, given the evidence 
that there is little requirement for the role of ICL in the glyoxylate cycle and the compensatory 
action of ICD to 2-methylcitrate/2-methylisocitrate inhibition, ICL may perform exclusively 
as a MCL during on valerate supplemented with vitamin B12. 
In an ICL-deficient mutant, clearance of methylcitrate cycle intermediates would be entirely 
abrogated. For the reasons outlined above, the resultant flow of isocitrate at the ICL / ICD 
junction would be potentially severed. Additionally, in this background, increasing levels of 2-
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methylcitrate would target aconitase and citrate synthase (Cheema-Dhadli et al., 1975), 
manifesting in acetyl-CoA buildup which would further thwart efforts by ICD to maintain 
isocitrate homeostasis in the absence of ICL function. Moreover, decreasing the generation of 
energy equivalents in this way would exacerbate energy loss due to uncoupling of the 
membrane potential by acetate buildup (Baronofsky et al., 1984). This reasoning is supported 
by the growth on similar fatty acids of other mycobacteria which lack the glyoxylate cycle but 
maintain an intact methylcitrate cycle by virtue of having a dedicated MCL. For example, a 
MLS mutant of Mycobacterium sp. strain P101 is able to grow on pristanic acid, which is also 
oxidised to a propionyl-CoA:acetyl-CoA ratio of 1:1 (Sakai et al., 2004).  An ∆icl1∆icl2 
mutant of MSM is also able to grow on valerate (Muñoz Elías, 2005). Here, the ability of ICL-
deficient mycobacterial strains to grow on these fatty acids may be largely due to detoxifying 
MCL (prpB) activity, which is entirely absent in MTB ∆icl1. In keeping with this hypothesis, 
a ∆prpDC∆icl1 double mutant would be expected to grow in valerate supplemented with 
vitamin B12.  
Finally, understanding the disparity between genetic (knockout) and chemical (3-NP) loss of 
ICL function is of considerable importance in terms of drug targeting against ICL. By analogy 
with the relatively invulnerable mycobacterial DNA ligase, whose activity can be reduced by 
90% without any effect on survival (Korycka-Machala et al., 2007), it is possible that 
(incomplete) chemical inhibition of ICL may have little effect on mycobacterial cell viability.  
5.10 Growth on heptadecanoate as a carbon source 
Markedly improved growth of H37Rv was observed on heptadecanoate  (Fig. 23) relative to 
valerate  (Fig. 19a). In this case, oxidation of the propionyl-CoA moiety released from 
oxidation of the C17 substrate did not appear to cause sufficient buildup of toxic, methylcitrate 
cycle intermediates believed to account for the retarded growth on valerate.  Furthermore, the 
methylcitrate cycle is dispensable for growth on this odd-chain fatty acid  (Fig. 23), contrary 
to the failure of ∆prpDC to grow on propionate (Fig. 11) and valerate (Fig. 19). Subculturing 
of ∆prpDC revealed no detectable growth inhibitory effects, which would have suggested 
propionyl-CoA accumulation over time. Furthermore, growth of ∆prpDC was restored to that 
of wildtype on the second passage (data not shown). This adaptation suggests that derivative 
 107 
propionyl-CoA not able to be oxidized as a carbon and energy source, may instead be 
accommodated into cellular lipids during derivative acetyl-CoA-dependent growth. Here 
endogenous propionyl-CoA is carboxylated by PCC to methylmalonyl-CoA extender subunits 
required for methyl-branched fatty acid synthesis (see section 5.11), consistent with the 
essentiality of  AccD5 (Holton et al., 2006), accA3 and accE5 (Sassetti et al., 2003). However, 
given the poor growth of H37Rv on valerate (Fig. 19a), the amount of intracellular propionyl-
CoA diverted into this alternate route appears to be restricted, although variable and subject to 
differences between strains , as discussed in section 5.11.  
Valerate media may be approximated  to a carbon mixture of 50% acetate and 50% propionate 
(1:1) (bearing in mind the addition of 0.05% Tween-80 in the media). Consistent with this, a 
∆prpDC mutant of MTB Erdman is unable to grow in media containing either a mixture of 
50% acetate and 50% propionate or valerate as the carbon source (Muñoz-Elias et al., 2006). 
This is contrary to ∆prpC2 of C. glutamicum which is able to grow in media comprising a 
carbon mixture of 50% propionate and 50% acetate (Plassmeier et al., 2007), despite being 
unable to grow solely on propionate (Claes et al., 2002).  Varying carbon balances in media 
with decreasing concentrations of propionate has been shown to relieve growth inhibition 
(Brock and Buckel, 2004). In this study growth of ∆prpDC on heptadecanoate (Fig. 23), 
which compares to a carbon mixture of 85% acetate and 15% propionate (7:1), but not on 
valerate (Fig. 19a) indicates that MTB in the absence of propionate oxidizing pathways is able 
to grow on longer odd-chain fatty acids provided propionate is sufficiently diluted relative to 
acetate. Growth on heptadecanoate in the absence of any propionate oxidizing pathways has 
also been reported for the actinomycete A. erythreum (Reeves et al., 2004).  Should growth on 
heptadecanoate most accurately reflect the in vivo environment  it may explain the 
dispensability of prpDC in vivo (Muñoz-Elias et al., 2006).   
In A. fumigatus a ratio between acetyl-CoA and propionyl-CoA greater than 4 (specifically 
4.8:1) has no adverse effect on growth of wild type or mutant strains unable to oxidise 
propionate (Ibrahim-Granet et al., 2008). Similarly, this study established that for a ratio of 
7:1 acetate to propionate (for C17), MTB experiences no apparent propionyl-CoA toxicity. 
From this it may be may assumed that  the endogenous ratio of acetyl-CoA:propionyl-CoA 
generated by the oxidation of odd-chain amino acid and/or fatty acid turnover is ≥ 7 given that 
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a ∆prpDC mutant of MTB shows no growth deficit on 7H9 media, as is the case for C. 
glutamicum where the methycitrate cycle has a nominated ‘housekeeping function’(Plassmeier 
et al., 2007).  
The anaplerotic role of the methylmalonyl pathway in MTB on odd-chain fatty acids longer 
than valerate has yet to be demonstrated. Interestingly, growth is possible on nonanoic acid in 
Pseudomonas putida lacking isocitrate lyase (Nieder and Shapiro, 1975). Growth on this odd-
chain fatty acid was ascribed to the organism’s ability to form and incorporate propionyl-CoA, 
although no pathway was implicated. In C. glutamicum the activity of the glyoxylate cycle 
significantly diminishes on addition of propionate to acetate media which has been speculated 
to be due to the anaplerotic reaction catalysed by PCA which uses the pyruvate produced by 
the methylcitrate cycle. In MTB, the findings from this study suggest that as the ratio of 
derivative propionyl-CoA decreases relative to acetyl-CoA, the anaplerotic contribution of an 
active methylmalonyl pathway would diminish, as would its ability to support growth on odd-
chain fatty acids of increasing length in the absence of a functional glyoxylate cycle  (Fig. 26).  
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Fig. 26  Proposed model detailing the variable anaplerotic contribution of the 
methylmalonyl pathway relative to the glyoxylate cycle on odd-chain fatty acids.  
As the relative ratio of propionate (C3) to acetate (C2) increases along the gradient of 
decreasing length odd-chain fatty acids, the anaplerotic contribution of the methylmalonyl 
pathway is proposed to become more pronounced, provided the vitamin B12-derived cofactor 
requirements are met. In the absence of relatively high concentrations of propionate relative to 
acetate, the glyoxylate cycle may predominate. The direction of decreasing magnitude is 
illustrated by the narrowing triangular neck. 
 
In accordance with this model, two possible explanations for the attenuated phenotype of 
MTB infecting macrophages with added 3NP (Muñoz-Elias and McKinney, 2005) are offered. 
Either vitamin B12 supplies may be limiting ex vivo or alternately insufficient propionyl-CoA 
is metabolised through the anaplerotic methylmalonyl pathway to afford growth in the 
absence of the glyoxylate cycle.  
Altering intracellular pathway fluxes by vitamin B12 supplementation may also increase 
resistance to ICL inhibitors, as observed for 3NP in valerate with vitamin B12. The action of 
the methylmalonyl pathway may also alter MTB susceptibility to other classes of antibiotics. 
It has been recently shown that several antibiotics exert a bactericidal effect through the 
common induction of oxidative stress independent of drug-target interaction (Dwyer et al., 
2007; Kohanski et al., 2007).  This oxidative damage pathway resulting in cellular death is 
triggered by NADH depletion and superoxide formation by hyperactivation of the electron 
transport chain. These events promote destabilization of iron-sulfur clusters, stimulation of the 
Fenton reaction and cell death. Diminution of the TCA cycle decreases NADH production and 
consequently decreases superoxide generation. Modulation of the cellular redox environment 
by the TCA cycle and its established link with ROS homeostasis (Mailloux et al., 2007; 
Ogasawara et al., 2007) can be exploited by organisms for increased resistance to oxidative 
stress (Husain et al., 2008; Mailloux et al., 2007) or such bactericidal antibiotics (Kohanski et 
al., 2007). Therefore, the MICs of anti-tubercular drugs may vary as the available pool of 
NADH generated during the TCA cycle is increased when the methylmalonyl pathway is the 
major propionate oxidizing route. This is consistent with carbon source utilization influencing 
the intracellular redox state (Singh et al., 2007a). Accordingly, susceptibility to oxidative 
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stress in cultures grown on odd- and even-chain carbon sources with and without vitamin B12 
should be evaluated.  
5.11 Propionyl-CoA incorporation into virulence lipids relieves toxicity on 
valerate 
 
The ability of MTB to grow on valerate appears to be subject to inter-strain variation. Unlike 
the data reported from other studies, the strain of H37Rv used in this study grew relatively 
poorly on valerate (Chang et al., 2007; Muñoz-Elias et al., 2006). Furthermore, Muñoz-Elías 
showed that ICL1-dependent growth of the ∆icl2 mutant of MTB Erdman on valerate does not 
phenocopy the H37Rv strain employed in this study, despite possessing only a single 
functional ICL (Muñoz Elías, 2005). Instead, growth on valerate was similar to the parental 
Erdman strain (Muñoz-Elias et al., 2006).  
This perplexing observation suggested the possibility of an alternate route for ‘diffusion’ of 
propionyl-CoA, evident in Erdman ∆icl2 on valerate and, to a lesser, extent in H37Rv on 
heptadecanoate. If one reconciles this notion with the observation that in the absence of a 
methylcitrate cycle, H37Rv fails to grow on valerate but not on heptadecanoate, the siphoning 
of propionyl-CoA into methylmalonyl-CoA -and hence into lipid synthesis, in a concentration 
dependent manner -emerges as a likely explanation for the differences observed. The H37Rv 
strain used in this study is a poor producer of PDIM  (Kana et al., 2008) unlike the Erdman 
strain, which produces high quantities of this lipid  (Prof. J. McKinney, personal comm.). 
Therefore, production of PDIM can drain the methylmalonyl-CoA pool and hence, provide a 
sink for intracellular propionyl-CoA. Significant shedding of PDIM into culture media 
containing  0.05% Tween (Camacho et al., 2001) supports the notion of a propionyl-CoA 
‘sink’. Jain et al. observed a significant  increase in PDIM for MTB grown in propionate and 
valerate (Jain et al., 2007) and proposed that this phenotype was the direct result of increasing 
intracellular levels of the biosynthetic precursor of polyketide lipids, namely, methylmalonyl-
CoA. Furthermore, propionyl-CoA released from oxidation of the cholesterol side chain is 
assimilated into PDIM in activated macrophages (Pandey and Sassetti, 2008).  Consistent with 
the observations is the finding that accD5 is  strongly upregulated in MTB grown in IFN-γ 
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activated macrophages vs. resting macrophages (Rachman et al., 2006a) which may explain 
why the ∆prpDC mutant of MTB Erdman is severely impaired in resting vs. activated 
macrophages (Muñoz-Elias et al., 2006). In this respect, the virulence attributes of PDIM 
extend beyond its antigenic properties to encompass a broader role in propionate metabolism. 
The markedly improved growth on valerate of a PDIM-producing isolate of H37Rv compared 
to the isolate employed in this study (Fig. 24) was consistent with this notion. However, this 
may be an over-simplified explanation as excess methylmalonyl-CoA has been shown to be 
diverted into hydroxyacids and further incorporated into sulpholipids in a PDIM mutant 
(Sirakova et al., 2003). Pks2 incorporation of methylbranches (using methylmalonyl-CoA) 
into virulence lipid SL-1 (Sirakova et al., 2001) was also shown to increase dramatically with 
increasing concentrations of propionate resulting in a greater abundance and mass of SL-1 
(Jain et al., 2007). Perturbations in the methylmalonyl-CoA supply would likely have 
pleiotropic effects as this substrate is necessary for the biosynthesis of multiple methyl- 
branched fatty acids including phthioceranic, hydroxyphthioceranic, mycosanoic, and 
mycolipenic acids, which form glycolipids PDIM, SL-1, diacyl trehaloses (DAT), and 
pentaacyl trehalose (PAT) (Jackson et al., 2007; Minnikin et al., 2002).   
This raises the question as to what extent cell envelope remodeling may occur in the H37Rv 
strain employed in this study to accommodate a propionyl-CoA sink when grown on valerate 
and heptadecanoate. Clearly, the complex regulation of methyl- branched fatty acids is subject 
to strain variation and is not simply dictated by the availability of methylmalonyl-CoA. 
Further insight will be gained from ongoing investigations into the role of MCM in secondary 
metabolism of polyketide synthesis.   
Diverting propionyl-CoA metabolites into virulence lipids this way may regulate flux 
primarily through the methylmalonyl pathway. This study has  shown that an active MCM 
enzyme (and not vitamin B12 per se) decreases flux through the methylcitrate cycle. It is 
possible, therefore, that an active MCM would reduce the methylmalonyl-CoA metabolite 
pool, in response to which flux through the methylcitrate cycle may be ‘turned-down’ to 
compensate for flow through the methylmalonyl branch to sustain methylmalonyl-CoA 
homeostasis. This proposal is substantiated by recent studies which linked mutAB 
overexpression in cultures grown in 7H9 to a 30% and 80% drop in PDIM and SL-1 
 112 
production respectively (Jain et al., 2007), suggesting methylmalonyl-CoA sequestration by 
MCM despite the absence of vitamin B12 in the 7H9 growth media. Such a proposed 
coherence of reaction fluxes in the network is described for metabolites with a low degree of 
connectivity, such as methylmalonyl-CoA (Samal et al., 2006).  
5.11.1 Maintaining methylmalonyl-CoA homeostasis in MTB  
 
Propionyl-CoA as the terminal product of β-oxidation and as a precursor for polyketide lipid 
biosynthesis, including SL-1 and PDIM, provides an intimate link between central carbon 
catabolism and virulence (Brown et al., 2008). Mutants deficient in multimethyl-branched 
fatty acids such as PDIMs  (Cox et al., 1999; Sirakova et al., 2003), related but structurally 
distinct phenolic glycolipids (Reed et al., 2004) and SL-1 (Converse et al., 2003), are 
attenuated in mice although the mechanism by which the absence of these virulence lipids 
causes attenuation is unclear. Presumably, they are involved in immune modulation as they 
form a significant portion of the noncovalently linked lipids in the mycobacterial outer 
membrane leaflet (Zuber et al., 2008). However, another mode of action of this family of 
virulence factors may be in maintaining the physical properties of the cell wall such as 
reducing cell wall permeability (Camacho et al., 2001) and protecting against bacteriocidal 
activity of reactive nitrogen intermediates released by activated macrophages (Rousseau et al., 
2004). MTB may have adopted specific mechanisms to ensure that a biosynthetic deficiency 
of such virulence lipids is limited.   
An increase in PDIM synthesis is reported for bacteria growing within host tissue (Jain et al., 
2007). Significantly, Jain et al. (2007) concluded that such virulence polyketide anabolism is 
directly regulated by a metabolic shift to growth on odd-chain fatty acids in vivo, given that 
PDIM and SL-1 production was stimulated during growth on propionate and valerate, but not 
on acetate. However the possibility that bacteria exploit the reverse succinyl-CoA 
→methylmalonyl-CoA mutase reaction as an adaptive response to insufficient propionyl-CoA 
precursor in vivo cannot be excluded and requires further investigation. Consistent with such a 
proposal,  methylmalonyl-CoA production for PDIM synthesis  may have increased as a result 
of MCM activity in host tissue, assuming the B12-cofactor is accessible in vivo. Similarly, 
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should vitamin B12 be supplied to acetate grown cultures, a similar increase in PDIM synthesis 
may occur by virtue of raised levels of intracellular glyoxylate cycle-derived succinate 
diverted to methylmalonyl-CoA through MCM. Comparisons of lipid profiles on acetate or 
butyrate with and without vitamin B12 would offer insight into the contributing role of MCM 
on even-chain fatty acids.  
In vitro (outside the living host), the carboxylation of propionyl-CoA by PCCase 
(accD5/accA3/accE5) is an essential reaction (Holton et al., 2006; Sassetti et al., 2003) 
supporting the notion that under standard culturing conditions, only this pathway contributes 
to the generation of methylmalonyl-CoA. However this reaction may be conditionally 
essential subject to the availability of vitamin B12 on succinate and/or acetate. In this instance, 
an accD5 mutant of MTB might be viable for growth on succinate and /or acetate media 
supplemented with vitamin B12, as demonstrated in this study for ∆prpDC on propionate 
supplemented with vitamin B12.  Conversely, a mutAB mutant may be attenuated for growth in 
vivo should methylmalonyl-CoA be generated via this route in the human host.  
Targeting virulence has been proposed as a new approach in antimicrobial development 
(Clatworthy et al., 2007). The increased pathology of MTB clinical isolates has been 
attributed to differences in the surface exposed lipids (Manca et al., 2001). In this context, 
targeting genes which perturb methylmalonyl-CoA pools presents an attractive option. 
5.12 A role for MCM in acetate assimilation 
Aside from the glyoxylate cycle MCM plays a role in all other described alternate pathways 
for acetate assimilation. Notably these alternate pathways require complex carbon skeletal 
rearrangements involving cobalamin as a cofactor. These are the glyoxylate regeneration cycle 
for M. extorquens (Korotkova et al., 2002; Korotkova et al., 2005), the citramalate cycle (see  
Fig. 25) in Rhodospirillum rubrum (Ivanovsky et al., 1997) and the ethylmalonyl-CoA 
pathway of R. sphaeroides (Alber et al., 2006; Erb et al., 2007; Erb et al., 2008). These 
alternate anaplerotic reactions are not restricted to ICL-deficient bacteria. Alternate acetyl-
CoA assimilation has been shown to operate independently of the glyoxylate cycle in 
Streptomyces collinus grown on acetate without Tween (Han and Reynolds, 1997). As 
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mentioned above, interrogation of the MTB genome for alternative acetate assimilation 
pathways is complicated as the enzyme activities for all the steps in these pathways have yet 
to be resolved. Both the ethylmalonyl-CoA pathway and the proposed citramalate cycle in 
MTB (Fig. 25) involve a complex series of carboxylation and rearrangement reactions 
involving the newly discovered enzyme L-malyl-CoA lyase/β-methylmalyl-CoA lyase (see 
Fig. 25) (Meister et al., 2005), as well as enzymes of propionate metabolism (MCM) to yield 
succinate. However, preliminary investigations revealed that chemical inhibition of ICL using 
3NP resulted in no growth of MTB on acetate supplemented with vitamin B12. Similarly, 
MSM, which is capable of producing sufficient vitamin B12 to support its vitamin B12-
dependent enzymes (Karasseva et al., 1977) (D. Warner & S. Dawes, unpublished 
observations) cannot grow on acetate in the absence of ICL (Muñoz Elías, 2005).  
Therefore, in MTB, the glyoxylate cycle seems to be the only pathway for assimilating acetate 
in vitro. However the possible upregulation of alternate acetate pathway genes in vivo cannot 
be excluded.  It may therefore be argued that the in vivo essentiality of ICL in mice might be 
attributed, at least in part, to insufficient B12-coenzyme. 
The carbon rearrangement of methylmalonyl-CoA to succinyl-CoA by coenzyme vitamin B12 
dependent MCM is also an integral part of autotrophic carbon dioxide assimilation routes 
(Berg et al., 2007; Herter et al., 2002a). In the described 3-hydroxypropionate/4-
hydroxybutyrate autotrophic carbon dioxide assimilation pathway (Berg et al., 2007; Strauss 
and Fuchs, 1993), CO2 fixation by the methylmalonyl pathway enzyme, PCC and acetate 
assimilation cycles are intimately linked through a series of common enzymes, with both 
pathways requiring MCM. This raises the intriguing question as to whether similar cycles may 
be operational in MTB, provided the cofactor requirements are met. An alternate strategy for 
C2 assimilation may afford some advantage to MTB under nitrosative stress where enzymes of 
the glyoxylate cycle, aconitase and MLS are inhibited (Rhee et al., 2005). The possibility that 
the MCM reaction may be involved in such other metabolic pathways in MTB remains to be 
addressed. 
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6 CONCLUDING REMARKS 
 
 
MTB as an obligate pathogen needs to survive in an increasingly complex and heterogeneous 
environment in the human lung as disease progresses. This requirement is illustrated by the 
rich and diverse set of genes (Cole et al., 1998) which this organism possesses to optimise 
survival in the numerous cellular niches serving as potential habitats within the human host 
(Hernandez-Pando et al., 2000; Neyrolles et al., 2006; van der Wel et al., 2007). The 
metabolic adaptability of this organism is a key component of virulence.  
Given the central role occupied by propionyl-CoA in cellular metabolism as both a terminal 
product of β-oxidation of odd- and branched-chain fatty acids and a precursor in several lipid 
biosynthetic pathways (Kolattukudy et al., 1997), this study has focused on characterizing the 
pathways for propionate metabolism as an important facet of MTB physiology. Host 
cholesterol is avidly exploited as a carbon source by this organism (Mohn et al., 2008; Pandey 
and Sassetti, 2008; Senaratne et al., 2008; Van der Geize et al., 2007) potentially releasing 
copious amounts of derivative propionyl-CoA during oxidation of this sterol. MTB possesses 
alternate pathways for oxidizing this high-energy metabolite owing to the toxic side-effects of 
derivative propionyl-CoA accumulation(Brock and Buckel, 2004).  
Marked up- regulation of prpC and prpD in the macrophage (Schnappinger et al., 2003) 
revealed a methylcitrate cycle in MTB, and is consistent with the propionate-induced activity 
of MCS in vitro (Muñoz-Elias et al., 2006). However, a prpDC-deficient of MTB is not 
attenuated for growth in vivo (Muñoz-Elias et al., 2006) which signifies the presence of 
alternate buffering  pathway(s). As methylmalonyl-CoA is a precursor of essential methyl-
branched lipids (Camacho et al., 2001; Minnikin et al., 2002; Rainwater and Kolattukudy, 
1983), propionyl-CoA may be diverted into anabolic pathways for cell wall synthesis and 
maintenance in vivo. This is consistent with the growth on a C17 fatty acid of the ∆prpDC 
mutant of the H37Rv strain of MTB observed in this study. Alternatively, propionyl-CoA may 
be oxidised to succinyl-CoA by the vitamin B12-dependent methylmalonyl pathway. In this 
study, the functionality of this anaplerotic pathway subject to supplementation of media with 
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vitamin B12 was demonstrated, reinforcing the potential importance of vitamin B12 in 
mycobacterial pathogenesis.  
Pathway(s) preference by MTB for propionate oxidation in vivo is likely to be balanced by the 
availability of vitamin B12 and the demands for TCA cycle intermediates and methyl-branched 
lipids as a function of stage of infection and microenvironment encountered by the pathogen 
within the host. For example, although ICL is essential during acute infection (Muñoz-Elias 
and McKinney, 2005), it is downregulated in end-stage granulomas concomitant with the 
upregulation of meaB (Rachman et al., 2006b). Therefore, the role of the MCM pathway in 
vivo has been prioritized for ongoing and future investigation. Important areas for further 
study include characterising different MTB strains by their ability to synthesize methyl-
branched polyketides as a means of detoxifying derivative propionyl-CoA by monitoring  
growth of  ∆prpDC on odd-chain fatty acids of chain length between the two extremes 
employed in this study (i.e. >5 and <17). Furthermore, validation of the model proposed in 
this study (Fig. 26) requires that anaplerosis by the methylmalonyl pathway on odd-chain fatty 
acids of chain length greater than five be assessed as a function of growth independent of the 
glyoxylate cycle.  Future work will also focus on the construction of  ∆mutAB∆prpDC  and 
∆prpDC∆icl1∆icl2 mutants of MTB Erdman and assessment of their ability to grow and 
persist in macrophages and in mice to establish the relevance of propionate metabolism in 
MTB pathogenesis. A possible essential role for MCM in propionate and/or acetate 
metabolism and/or polyketide synthesis during the chronic stage infection will be investigated 
in parallel by assessing the virulence of a mutAB mutant of MTB Erdman. Such studies should 
provide key insights into the availability of vitamin B12 cofactor in vivo.  
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7 APPENDICES 
7.1 Appendix 1: List of Abbreveations 
 
Abbreviation    Abbreveated term/phrase 
___________________________________________________________________________ 
 
ACC   Acyl-CoA carboxylase 
ACN   Aconitase   
AdoCba   Adenosylcobinamide 
AdoCbl   Adenosylcobalamin 
AHTc   Anhydrotetracycline 
Amp   Ampicillin 
aph   Gene encoding aminoglycoside phosphotransferase 
ATCC   American Type Culture Collection 
ATR   Adenosyl transferase 
BCAA   Branched chain amino acids 
BCG   Bacilli Calmette-Guérin 
bp   Base pair(s) 
CFU   Colony forming unit 
CIT   Citrate synthase 
CMS   Citramalate synthase 
CNCbl   Cyanocobalamin (vitamin B12) 
CO   Carbon monoxide 
CRP   cAMP receptor protein 
DAG   Diacylglycerol 
DMB   Dimethylbenzimidazole 
DMSO   Dimethylsulphoxide 
DNA   Deoxyribonucleic acid 
dNTP   Deoxyribonucleotide triphosphate 
DOTS   Directly observed therapy, short-course 
EHR   Enduring Hypoxic Response 
EMB   Ethambutanol 
ETC    Electron transport chain 
FNR   Fumurate-nitrate regulator 
FUM   Fumurase 
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HIV   Human immunodeficiency virus 
Hyg   Hygromycin B 
Hyg   Gene conferring resistance to hygromycinB 
ICD   Isocitrate dehydrogenase 
ICL   Isocitrate lyase 
IL   Interleukin 
INH   Isoniazid 
IPTG   Isopropyl thio-β-D-galactoside 
IRIS   Immune reconstitution inflammatory syndrome 
LTBI   Latent TB infection 
Kb   Kilobase 
2KG   α-Ketoglutarate 
KGD   α-Ketoglutarate decarboxylase 
Km   Kanamycin 
Km   Michaelis constant 
lacZ   Gene encoding β-galactosidase 
LB   Luria-Bertani broth 
LDH   Lactate dehydrogenase 
MCD   Methylcitrate dehydratase 
MCL   Methylcitrate lyase 
MCM   Methylmalonyl-CoA mutase 
MCR   α-Methylacyl-CoA racemase 
MCS   Methylcitrate synthase 
MDH   Malate dehydrogenase 
MDR   Multi-drug resistant 
MEZ   Malic enzyme 
MLS   Malate synthase 
MMEE   Methylmalonyl-CoA epimerase 
MQO   Malate:quinine oxidoreductase 
MSM   Mycobacterium smegmatis 
MTB   Mycobacterium tuberculosis 
NDH   NADH dehydrogenase 
Ni-NTA   Nickel-nitrilotriacetic acid 
NO   Nitric oxide 
3-NP   3-Nitropropionate 
OADC   Albumin-dextrose complex supplement with oleic acid for Middlebrook 7H9 
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OD600 Optical density at 600 nanometre wavelength 
ORF Open reading frame 
PAGE Polyacrylamide gel electrophoresis 
PCA Pyruvate carboxylase 
PCC Propionyl-CoA carboxylase 
PCK PEP carboxykinase 
PCR Polymerase chain reaction 
PDB Protein data bank 
PDHC Pyruvate dehydrogenase complex 
PDIM Pthiocerol dimycocerates 
PDP Petal death protein 
PEP  Phosphoenolpyruvate 
PEPM PEP mutase  
PKS Polyketide synthase 
PMF Proton motive force 
PPC PEP carboxylase 
PPS PEP synthase 
PYK Pyruvate kinase  
PZA Pyrazinamide 
RBS Ribosome binding site 
RIF Rifampicin 
RNA Ribonucleic acid 
RT Reverse transcription/transcriptase 
sacB Gene encoding levansucrase 
SCS  Succinate synthase 
SCFA Short chain fatty acids 
SDH Succinate dehydrogenase 
SDS Sodium dodecylsulphate 
SL Sulphlipids 
SSADH Succinic semialdehyde dehydrogenase 
TA Toxin-antitoxin 
TAG Triacylglycerol 
TB Tuberculosis 
TCA Trichloroacetic acid 
TNF Tumor necrosis factor 
Tween Polyoxyethylene sorbitan monooleate 
XDR Extreme drug resistance  
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7.2 Appendix 2: Culture Media 
 
All media was made up to a final volume of 1 litre deionised water, and sterilized by autoclaving at 121οC for 15 
minutes. 
 
 
Luria-Bertani broth (LB) 
10g tryptone powder; 5g yeast extract; 10g sodium chloride 
 
Middlebrook-OADC (7H9-OADC) 
4.7g Middlebrook 7H9 broth base; 2ml glycerol 
100ml OADC supplement  and 0.05% Tween 80 added after autoclaving. 
 
Middlebrook-OADC plates (7H10-OADC) 
19g Middlebrook 7H10 agar powder; 5ml glycerol 
100ml OADC supplement and 0.05% Tween 80 added after autoclaving. 
 
Propionate media 
4.7g Middlebrook 7H9 broth base 
0.5% Albumin 
0.085% NaCl 
0.05% Tween-80 
0.1% or 0.2% sodium propionate  
10 µg/ml vitamin B12  (optional) 
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Valerate media 
4.7g Middlebrook 7H9 broth base 
0.5% Albumin 
0.085% NaCl 
0.05% Tween-80 
0.1% Valeric acid 
pH of the valeric acid-containing medium was adjusted to 6.8 with 10M NaOH. 
10 µg/ml vitamin B12  (optional) 
 
Heptadecanoic acid 
4.7g Middlebrook 7H9 broth base 
0.5% Albumin 
0.085% NaCl 
0.05% Tween-80 
0.007% Heptadecanoic acid (from pre-warmed 0.2% stock solution) 
10 µg/ml vitamin B12  (optional) 
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Fig.S. 1 Vector Maps 
Maps of vectors used in this study i) mutAB with an internal deletion of 2342bp carried on the 
suicide vector p2∆mutAB17 (Parish and Stoker, 2000); ii) Full length mutAB used for 
complementation carried on the suicide vector p2mutAB17 (Parish and Stoker, 2000); iii)  
Rv1998c placed under the control of the tet-inducible promoter, Pmyc1tetO on the replicating 
vector pSE100::Rv1998c (Guo et al., 2007); iv) Pmyc1tetO ::Rv1998c and the tet-repressor, 
Pimyc::tetR expressed together on the integrating vector pMC1::Pmyc1tetORv1998c (Kaps et al., 
2001). 
i. ii.
iii. iv.
p2∆mutAB17  
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Fig.S. 2 Southern blots  
A. Southern blot for prpDC allele.   
For the Southern blot analysis (right), genomic DNA from the wild type, ∆prpDC, 
∆mutA∆prpDC, ∆mutAB:: mutAB∆prpDC and ∆icl1::hyg was digested with BglII which cuts 
on either side of the deleted region to produce a 5309-bp fragment from H37Rv and ∆icl::hyg 
and a 2649-bp fragment from ∆prpDC, ∆mutA∆prpDC and ∆mutAB:: mutAB∆prpDC which 
were detected using a 1073bp PCR-generated probe
B. Southern blot for icl1 allele 
For the Southern blot analysis (left), genomic DNA from the wild type and ∆ic1l::hyg was 
digested with SalI which cuts on either side of the deleted region to produce a 1072-bp 
fragment from H37Rv and a 1770-bp fragment from ∆ic1l::hyg which were detected using a 
787bp PCR-generated probe.
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 Table S. 1 Strains and plasmids used in this study 
Name Description Reference/source 
Strains   
H37Rv Virulent reference laboratory strain; ATCC 25618 London School of Hygiene and 
Tropical Medicine 
∆mutAB mutAB deletion mutant of H37Rv, lacking 2342 bp internal AscI / BglII fragment This study 
∆prpDC prpDC deletion mutant of H37Rv, lacking the 2660 bp region from the start codon of prpD to the stop 
codon of prpC (Munoz-Elias et al., 2006)  
This study 
∆mutAB::mutAB Reversion mutant of ∆mutAB in which the wild type mutAB allele was restored by knock-in mutagenesis This study 
∆prpDC::prpDC prpDC mutant carrying a 3115 bp gene region containing the prpDC locus in pPRPDC (Munoz-Elias et 
al., 2006) integrated at the attB locus; KmR 
This study 
∆mutAB ∆prpDC mutAB and  prpDC double deletion mutant This study 
∆mutAB::mutAB 
∆prpDC::prpDC 
Double mutant complemented  This study 
∆icl11::hyg Icl11 deletion mutant of H37Rv, carrying  ∆ic1l::hyg allele lacking codons for amino acids 65-290 of the 
428 amino acid ICL1 protein ; HygR     
This study 
∆icl1::hyg::icl1 icl1 mutant carrying a 1.6kb gene region containing the icl1 locus in pICL11(Muñoz-Elias and McKinney, 
2005) as an episomal vector;  HygR SmR 
This study 
H37Rv::Pmyc1tetO 
1998c ::pMC1s 
Wild type strain carrying episomal pSE100::Rv1998c plasmid and  pMC1s integrated  at attB locus This study 
∆icl11::hyg:: Pmyc1tetO 
1998c::pMC1m 
icl1 deletion mutant carrying  ∆icl1::hyg allele with vector pMC1m:: Pmyc1tetO Rv1998c integrated at attB 
locus 
This study 
H37Rv::pSE100 with 
pMC1s 
Wild type strain carrying episomal pSE100 plasmid and  pMC1s integrated  at attB locus. This study 
Plasmids   
pGEM3Z(+)f Cloning vector;  AmpR Promega 
p2NIL Cloning vector; KmR (Parish and Stoker, 2000) 
pGOAL17 Plasmid carrying lacZ and sacB genes as a PacI cassette; AmpR (Parish and Stoker, 2000) 
p2mutAB p2NIL carrying 7760 bp EcoRI fragment excised from the H37Rv cosmid Rv58 (Brosch et al., 1998) and 
containing the mutAB genes plus 1431 bp of 3’- and 2228 bp of 5’-flanking chromosomal sequence;  KmR 
This study 
p2∆mutAB p2NIL carrying ∆mutAB allele generated by digestion of p2mutAB with AscI and BglII and re-ligation to 
eliminate 2342 bp of sequence within the mutAB region; KmR 
This study 
p2∆mutAB17 ∆mutAB knockout vector – p2∆mutAB containing PacI cassette from pGOAL17;  KmR SucS This study 
p2mutAB17 mutAB knock-in vector – p2mutAB containing PacI cassette from pGOAL17;  KmR SucS This study 
pGEM1998c Derivative of  pGEM3Z(+)f carrying 3640bp SphI fragment excised from the H37Rv cosmid Rv175 
(Brosch et al., 1998) and containing the 777bp Rv1998c gene;  AmpR 
This study 
p2Rv1998c  Derivative of p2NIL carrying 3670bp BamHI-HindIII fragment excised from  pGEM1998c and containing 
Rv1998c; KmR   
This study 
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p2∆Rv1998c p2NIL carrying ∆Rv1998c allele generated by digestion of p2Rv1998c with NarI and re-ligation to 
eliminate 312 bp of sequence within the Rv1998c region; KmR 
This study 
p2∆Rv1998c17 ∆Rv1998c knockout vector – p2∆Rv1998c containing PacI cassette from pGOAL17;  KmR SucS This study 
pAU100 pJG1111 carrying ∆prpDC allele – fusion of 1kb PCR products  upstream and downstream of prpDC 
eliminating 2660bp prpDC coding sequence; KmR HygR 
(Munoz-Elias et al., 2006) 
pPRPDC pMV306 (Stover et al., 1991) carrying a 3115 bp EcoRI / NcoI fragment containing  prpDC; KmR   (Munoz-Elias et al., 2006) 
pJM056-1 pYUB631 (Pavelka and Jacobs, 1999)  carrying a 2.7kb BamHI-ClaI fragment containing icl1 had 685bp 
internal XhoI fragment deleted and replaced with hyg cassette (McKinney et al., 2000);  HygR KmR SucS 
(McKinney et al., 2000) 
pICL1 pEM2634 (Stover et al., 1991) carrying a 1.6kb SpeI fragment containing icl1;  SmR (Muñoz-Elias and 
McKinney, 2005) 
(Muñoz-Elias and McKinney, 
2005) 
pSE100 pMS2 derivative containing Pmyc1tetO (Guo et al., 2007) 
pMC1s pMV306Km derivative, Kmr, psmyc-tetR (Ehrt et al., 2005) 
pMC1m  pMV306Km derivative, Kmr, pimyc-tetR (Kaps et al., 2001) 
pSE100::Rv1998c Derivative of pMS2 with Rv1998c under the control of Pmyc1tetO This study 
pMC1m::Pmyc1tetO 
Rv1998c Derivative of pMS2 with Rv1998c under the control of Pmyc1tetO and tetR under the control of Pimyc 
This study 
pQE30xa Expression vector; AmpR Qiagen 
pQE30::prpB pQE30 carrying prpB from E. coli (Brock et al., 2001) 
pQE30xa::Rv1998c pQE30xa (Qiagen) carrying the 783bp BamHI / HindIII fragment containing Rv1998c fused in frame with 
a 6× His-tag under the control of PT5lacO;  AmpR 
This study 
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 Table S. 2 Oligonucleotides used in this study 
 
Name Sequence (5’-3’)a Application Properties 
Primers    
MutA-F GGGGTACCGAAGCAAGCCCAAGCA 
 
Forward primer used for PCR 
genotyping of mutAB and ∆mutAB 
alleles 
MutA-R GGACTAGTCAATGCCTTCCGGCGT 
 
Reverse primer used for PCR-based 
genotyping of the mutAB allele  
 
2084 bp amplicon generated 
from the wild type mutAB 
allele using MutA-F and 
MutA-R primers 
 
MutB-R GGAAGCTTGCAGGCGCTGGCGA 
 
Reverse primer used for PCR-based 
genotyping of the ∆mutAB allele 
1933 bp amplicon generated 
from the ∆mutAB allele 
using MutA-F and MutB-R 
primers 
MutAB-F  AGATCCGTACCATTTCCGGG 
MutAB-R  TTGTTGGAGACGATGAGCCA 
Forward and reverse primer pair used to 
generate the DNA probe used for 
genotypic confirmation of the ∆mutAB 
mutant by Southern blot analysis 
904 bp amplicon spanning 
from the 3’-end of mutB to 
within Rv1495 (see Fig. S1 
in the Supplementary 
Information) 
PrpDC-F GGGGGCTGCTCTGCGGCACGGTG 
 
PrpDC-R GGGGGATCTTGTAGGCCATGTGCTC 
 
Forward primer used for PCR-based 
genotyping of the prpDC and ∆prpDC 
alleles 
Reverse primer used for PCR 
genotyping of prpDC allele 
Forward and reverse primer pair used to 
generate the DNA probe used for 
genotypic confirmation of the ∆prpDC 
mutant by Southern blot analysis 
1073 bp amplicon generated 
from wild type prpDC allele 
using PrpDC-F and PrpDC-
R 
 
PrpDC-R2 GGGGGTACAACAGGATCTTGGCGAC 
 
Reverse primer used for PCR 
genotyping of ∆prpDC allele. 
1195bp amplicon from 
∆prpDC allele using PrpDC-
F and PrpDC-R2 
Icl1-F GGGGGACAACGCTCACATATGTGGTT 787bp amplicon generated 
from wild type icl1 allele 
using Icl1-F and Icl1-R 
 
Icl1-R GGGGGAGCCAGTTCTCCACCGAAGTA 
Forward and reverse primer pair used to 
generate the DNA probe used for 
genotypic confirmation of the ∆icl1 
mutant by Southern blot analysis 
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pSE100Rv1998c-F GGGGGGATCCTTACCAGGTCGGAACTAGCCA 
pSE100Rv1998-R GGGGGCATGCTCACACATACAATCAGGCCCAT 
Forward and reverse primer pair used to 
generate a full length copy of Rv1998c 
for expression study. 862bp PCR 
product restricted with SphI and BamHI 
and cloned into pSE100. Primers used 
to sequence PCR product. 
862bp amplicon generated 
from wildtype Rv1998c 
allele using pSE100 
Rv1998cF and 
pSE100Rv1998R 
UV15Tet-F GTCCTCCCTATCAGTGATAG 
Rv1998c-R 
(internal)  
ATGTCGACGCTGACGTAGCAT 
Primer pair used for PCR to confirm the  
presence of episomal pSE100::Rv1998c 
in  H37Rv::  pSE100::Rv1998c 
::pMC1s and pMC1m:: PmyctetO 
Rv1998c in ∆icl1::hyg :: 
pMC1m::PmyctetO::Rv1998c 
388bp amplicon 
attBT1-F ACCGGGTACGTAACGACTGC 
attL1-R CCGCGTATGCCCAGGTCAGA 
Primer pair used for PCR to confirm 
integration of  pMC1s, pMC1m and 
pMC1m:: PmyctetO Rv1998c at attB site 
in H37Rv::  pSE100::Rv1998c ::pMC1s 
and ∆icl1::hyg :: 
pMC1m::PmyctetO::Rv1998c 
857bp amplicon 
attL2-F CTTGGATCCTCCCGCTGCGC 
attBT2-R AGACACCTGGCCGTTGGTGC 
Primer pair used for PCR to confirm 
integration of  pMC1s, pMC1m and 
pMC1m:: PmyctetO Rv1998c at attB site 
in H37Rv::  pSE100::Rv1998c ::pMC1s 
and ∆icl1::hyg :: 
pMC1m::PmyctetO::Rv1998c 
1130bp amplicon 
Rv1998c-F CGCGCGCGCGCGAGGCCTATGAGTTTCCACGATCT 
Rv1998c-R GCGCGCGCGCGCAAGCTTTTACGTTGTACTCGTGCG 
Forward and reverse primer pair used 
for PCR to confirm the 312bp internal 
deletion in p2∆Rv1998c 
500bp amplicon 
1998c: pQE30xa-F    CCCCCGGATCCATGAGTTTCCACGATCTTCA 
 
1998c: pQE30xa-R   CCCCCAAGCTTTTACGTTGTACTCGTGCGGTT 
 
 
799bp PCR product digested with 
BamHI and HindIII for in-frame His-tag  
fusion in pQE30xa. 
Primers used to sequence PCR product. 
799bp amplicon 
 
 
Rv1998c-R2 GCTGTATCCGTCCTCGATGT sequencing primer Used to sequence upstream 
regions of Rv1998c in 
vectors pSE100::Rv1998c 
and pQE30xa::Rv1998c 
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RT primers  
1998c RT2-F GCTATCGGCACAACCAGTTT 
1998c RT2-R CGACAGTTGTGCGACGTAGT 
189bp amplicon to detect AHTc 
induced extrachromosomal 
expression of Rv1998c 
This study 
mutB  RT-F TATCGTTCTTCTGGGGCATC 
mutB  RT-R GCCACGTTGTTGAACACATC 
187bp amplicon This study 
PrpD RT(AS) ATCGCGTGGTAGATGGTCTC 
prpD RT (S) GGTCTGGTAACCGCCTATGA 
155bp amplicon This study 
icl1 RT-R ATACGCGCTCATCTGGTTCT 
icl1 RT-F ATGCTGGCCTACAACTGCTC 
195bp amplicon This study 
sigA-F1 TGCAGTCGGTGCTGGACAC 194bp amplicon 
sigA-R1 CGCGCAGGACCTGTGAGCGG  
(Dawes et al., 2003) 
Sequencing primers for Rv1129c and prpDC region 
Rv1129c-F AGCCACCGG TAAGACATTAC PCR and sequencing primer 
Rv1131-R TCATCGATTTCGTGGCAGCGA PCR and sequencing primer 
1679bp PCR product using 
Rv1129cF and Rv1131R from two 
isolated ∆icl1 suppressor mutants 
and sequenced 
Rv1130-F TGGACAAAGCGCCGGTGATT PCR and sequencing primer 
Rv1132-R ATTCGGCCAGGTCGATGTCG PCR and sequencing primer 
1276bp PCR product using Rv1130 
F and Rv1132 R from two isolated 
∆icl1 suppressor mutants and 
sequenced 
Rv1128c-F TGCTGAAACCACAGTAATAT PCR and sequencing primer 1684bp PCR product generated 
using Rv1128c and PrpDC-R from 
two isolated ∆icl1 suppressor 
mutants and sequenced 
Rv1130a -R ATCGCGTGGTAGATGGTCTCTT  sequencing primer Used to sequence Rv1130 
amplified from two isolated ∆icl1 
suppressor mutants 
Rv1130b -F TAACCGCCTATGAGATCCACAT  sequencing primer Used to sequence Rv1130 
amplified from two isolated ∆icl1 
suppressor mutants 
Rv1130c -F ATGTAGTGATCGGAACGGGAT  
 
sequencing primer Used to sequence Rv1130 
amplified from ∆icl1 1 and 2 
suppressor mutants 
 
Rv1131a -R TAGAGGATCATCGACTGCTCGAA  sequencing primer Used to sequence Rv1131 
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 amplified from two isolated ∆icl1 
suppressor mutants 
Rv1131b -F TTATGCGCAGAACTTCCTGCACA  sequencing primer Used to sequence Rv1131 
amplified from two isolated ∆icl1 
suppressor mutants 
Rv1131c -F AAGCTGCCGGACAACTGCCA  
 
sequencing primer Used to sequence Rv1131 
amplified from two isolated ∆icl1 
suppressor mutants 
Rv1131d -R AGGAAGGCGACCTGCTCGAAACT  sequencing primer Used to sequence Rv1131 
amplified from two isolated ∆icl1 
suppressor mutants 
a. GC-clamp sequences (non-H37Rv) are italicised. Restriction sites used for subsequent cloning of PCR fragments are underlined, and the relevant enzyme 
detailed under application.  
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All things are difficult before they are easy.  
Thomas Fuller, M.D. 
